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ROLE OF STAT3 IN HUMAN NK CELL FUNCTIONS
Prasad Vijaykumar Phatarpekar, Ph.D.*
Advisory Professor: Dean Anthony Lee, M.D, Ph.D.
Natural Killer (NK) cells are cytotoxic lymphocytes, which play a critical role
in the immune response against malignant cells and microbial infections, particularly
viral. NK cells are equipped with germline encoded activating receptors, which
upon detecting ligands expressed on stressed cells induce cytolytic activity of NK
cells. Stimulation of NK cell proliferation and priming of NK cytolytic capability are
accomplished by cytokines, which mediate their signals mainly through JAK -STAT
signaling pathway. We found that K562 cells genetically modified to express
membrane bound IL-21 (mbIL-21), which predominantly activates STAT3, induce
robust expansion and activation of human NK cells. Further investigations in the
lab, revealed role of STAT3 in the transcriptional regulation of NKG2D, a primary
activating NK receptor. Based on these findings, I hypothesized that STAT3
signaling plays a critical role in human cytolytic function and proliferation.
I analyzed NK cells from Job syndrome patients to test my hypothesis. Job
syndrome caused by dominant negative STAT3 mutations is a naturally occurring
STAT3 deficient genetic model. Assessment of cytolytic activity revealed impaired
cytolytic function in Job Syndrome patients’ NK cells. Investigations into the
probable underlying causes of impaired cytotoxicity showed deficient NKG2D
receptor expression and impaired polarization of cytolytic granules to the immune
synapse formed between Job syndrome patients’ NK cell and target cell. I validated
these finding in STAT3 knock-down primary human NK cells, which also displayed
impaired cytolytic function and impaired cytolytic granule polarization phenotype.
ix

Expansion of Job syndrome patients’ NK cells with mbIL21 stimulation restored
NKG2D expression to normal levels, corrected impaired cytolytic granule
polarization and enhanced cytolytic activity. As constitutively active STAT3 is
oncogenic, STAT3 is major drug target in cancer therapeutics. To assess a
probable side effect of pharmacological inhibition of STAT3, I assessed its effect on
human NK cell cytolytic function. Treatment of primary human NK cells with small
molecule STAT3 inhibitor S3I-201 suppressed NK cytolytic function.
I employed pharmacological and genetic models of STAT3 deficiency to
study the role of STAT3 in human NK cell proliferation. Treatment with STAT3
inhibitor S3I-201 reduced expansion of human NK cells stimulated not only with
mbIL21 that predominantly activates STAT3, but also the expansion stimulated with
membrane bound IL-15 (mbIL15), which predominantly activates STAT5 and
activates STAT3 only marginally. mbIL21 and mbIL15 induced expansion was also
found

to

be

deficient

in

Job

syndrome

patients’

NK

cells.

Thus,

both

pharmacological and genetic models complemented each other in underlying role
of STAT3 signaling in human NK cell proliferation. Percentage of NK cells was also
found to be lower in the peripheral blood of Job syndrome patients’ compared to
normal donors.
Employing pharmacological and genetic approaches, I showed that STAT3
deficiency in primary human NK cells causes impairment of cytolytic function and
cytokine induced expansion. This is the first report to demonstrate the role of
STAT3 in the transport of cytolytic granules in NK cell and NK cell functional
deficiency in Job syndrome patients, which may provide an immunological basis for
their proclivity to cancer. Restoration of NK cell function upon mbIL21 stimulation,
x

suggests adoptive NK cell therapy as a treatment option for Job syndrome patients. By
assessing the effect of pharmacological STAT3 inhibition on NK cytotoxicity and
proliferation, this study provides potential biomarkers for monitoring side effects of
STAT3 inhibition, which is fast emerging as a therapeutic approach in cancer treatment.
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CHAPTER 1
BACKGROUND

0

Background
Protection from the non-self and aberrant self is provided by the immune
system. Non-self and aberrant self come in different forms and to counter them, the
immune system has multiple tools in its arsenal. It is a complex organization of diverse
types of cells, tissues and organs. Physical barriers such as skin and mucous
membrane, mechanical processes including coughing and sneezing, biochemical
defenses such as anti-microbial peptides, complement system, antibodies and
cytokines, and cellular component comprising phagocytes and cytotoxic lymphocytes,
all come under a big umbrella called the immune system. Some of these defense
mechanisms such as physical barriers and anti-microbial compounds are common to
all living organisms, while more evolved means of defense, such as phagocytic cells,
are found in multi-cellular organisms, both vertebrates and invertebrates. Another
component of cellular immunity, lymphocytes, which include cytolytic effector cells and
antibody producing cells, are unique to vertebrates (1).
The human immune system has all the aforementioned modes of defense at its
disposal. The generic mechanisms, which are the first line of defense against the
invading pathogens, belong to the innate or natural branch of the immune system,
while the pathogen specific mechanisms that are deployed during the later phase of the
infection belong to the adaptive or acquired branch of the immune system. Antigen
specificity and immune memory formation are the characteristics that distinguish
adaptive immunity from innate immunity. Dendritic cells, mast cells, macrophages and
neutrophils, the cellular mediators of innate immunity do not possess these
immunological features, while lymphocytes, T and B cells, which execute the functions
of adaptive immunity, do. However, the third type of lymphocyte, which was till recently
1

considered to be a part of the innate immune system, has been shown to have the
attributes of the adaptive immune system as well. This unique cell, which belongs to
both, innate and adaptive, immune systems, is Natural killer (NK) cell (2).

1.1 NK CELL
Observation of cell mediated cytotoxicity against tumor cells without prior
sensitization to the tumor antigen in assays performed with human peripheral blood
cells led to the discovery and coinage of the term natural killer cells (3). Since, the
discovery in the early 70s the NK cell field has come a long way. In the beginning also
monikered as null cells for having no T and B cell markers (3), NK cells now have an
established identity as a subset of lymphocytes, defined by the expression of CD56, an
isoform of neural cell adhesion molecule (4), and the absence T-cell co-receptor CD3
(5). NK cells are granular lymphocytes found in bone marrow, blood, peripheral organs
such as liver, lung, peritoneal cavity and placenta, and secondary lymphoid organs
including lymph nodes, tonsils, thymus, and spleen (4, 6, 7). In the peripheral blood of
humans, NK cells comprise 2-18% of the lymphocyte population (8). Like CD8 T cells,
they are cytolytic effector lymphocytes. The primary cytolytic mechanism is through
exocytosis of lytic granules, which contain a number of cytotoxic proteins such as
perforin and granzymes. Even though, both, NK and CD8 T cells are cytolytic
lymphocytes that primarily kill their targets through exocytosis of lytic granules, there is
a clear distinction as to the mode of activation between the two. Like T cell receptor
(TCR) on T cells, NK cells do not exclusively express receptors specific for a single
antigen, but express a multitude of activating receptors, which provide a broader ability
to detect target cells expressing diverse types of ligands. Also, like TCR, antigen
recognition by NK cell receptors is not dependent on major histocompatibility complex
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(MHC) molecule dependent pathway of antigen presentation. NK cell receptors are
germ-line encoded and like T cell receptor genes do not undergo somatic
rearrangement and recombination (2, 9). As some of the activating ligands are
expressed by normal cells, to differentiate normal self from abnormal cells, NK cells are
also equipped with cell surface inhibitory receptors that recognize MHC class I classical
and non-classical ligands on cells and mediate inhibitory signals to block cytolytic
activity of NK cells. Thus, the cytolytic activity induced by NK cells is the net result of
the balance between the strengths of activating and inhibitory signals (8). NK cells also
kill target cells through ligands belonging to tumor necrosis factor (TNF) family. Three
TNF-family ligands, viz. FAS ligand (FASL), TNF and TNF related apoptosis inducing
ligand (TRAIL) either expressed on NK cells surface or secreted in the extracellular
environment mediate apoptosis in target cells through the interaction with their
respective receptors (6).
Along with cytolytic capability, NK cells can exert their effect through secretion of
cytokines and chemokines in response to stimulation by target cells and cytokines
secreted by accessory cells (10). NK cell-generated cytokines include interferon (IFN)γ, TNF-α, granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte
colony stimulating factor (G-CSF), interleukin (IL)-10 and IL-3, while chemokines such
as CCL2, CCL3, CCL4, CCL5, XCL1 and CXCL8 are secreted by NK cells (2).

1.1.1 NK Cell Receptors
NK cells detect abnormal cells through the interactions of a large array of
activating receptors expressed on NK cell surface with their corresponding ligands,
whose expression is generally increased on the surface of stressed cells. Natural

3

cytotoxicity receptor (NCR) family, which includes NKp30, NKp44 and NKp46, is a
major group of activating receptors. These receptors interact with pathogen-derived
antigens such as viral hemagglutinins, cell wall core components of bacteria and
malaria parasite, Plasmodium falciparum derived erythrocyte membrane protein-1.
These receptors also interact with cellular ligands such as heparan sulphates and
vimentin (11). Another primary activating receptor is natural killer group 2D (NKG2D).
Its ligands include MHC class-I-related chain (MIC) A and MICB and the UL-16 binding
protein (ULBP) 1, 2, 3, or 4. Expression of these ligands is induced by cellular stress
such as heat shock, DNA damage, transformation and viral and bacterial infections
(12). Other activating receptors that play an important role in NK cell activation include
DNAX accessory molecule-1 (DNAM-1), 2B4 and CD160 (13, 14). DNAM-1 interacts
with poliovirus receptor and nectin-2, whose expression is up-regulated on some tumor
cells (13). 2B4 recognizes CD48 (13), while CD160 binds human leukocyte antigen
(HLA) C (14). In NK cells, cell adhesion receptors such as lymphocyte functionassociate antigen 1 (LFA-1) and CD2 mediate activating signals (13). In addition to
antigen recognition receptors, NK cells express FcγRIIIA (CD16), a low affinity receptor
for the Fc region of IgG, which enables NK cells to mediate antibody dependent cellular
cytotoxicity (ADCC) (15). Most of these receptors (NCRs, NKG2D and CD16) associate
with signaling adaptor proteins containing tyrosine-based activation motifs, which upon
receptor engagement get phosphorylated by Src-family kinases. Phosphorylated
tyrosines provide docking sites for more signaling proteins, which activate signaling
pathways involving phosphatidyl- inositol-3-OH kinase (PI3K), phospholipase C and
Vav. These signaling cascades affect exocytosis of lytic granules. Some of the
activating receptor (2B4 and DNAM-1) do not couple with tyrosine-based activation
motif containing adaptor protein, but possess such motifs in their own cytoplasmic
4

regions (13).
To recognize normal cells and thereby prevent their killing, NK cells are
equipped with inhibitory receptors such as killer cell immunoglobulin-like receptors
(KIRs) and CD94-NKG2A that recognize MHC class I classical and non-classical
ligands on cells and mediate inhibitory signals to block cytolytic activity of NK cells.
Inhibitory receptors do not associate with signaling adaptors, but contain tyrosine
based motifs in their own cytoplasmic region. Instead of being activating, these motifs
are inhibitory. These tyrosine residues are phosphorylated upon engagement of the
inhibitory receptors and recruit tyrosine phosphatases SHP-1 and SHP-2, which in turn
dephosphorylate tyrosine residues associated with activating receptor signaling
complex thereby switching off the activation signals (13).
Activating, adhesion and inhibitory receptors are listed in Table 1.

5

Type

KIR
CD94-NKG2A
CD94-NKG2B
LIR-1

HLA-A, B & C (8)*
HLA-E (18)*
HLA-E (18)*
HLA Class I (8)*

Activating
Adhesion

NKp44
NKp46
NKG2D
DNAM-1
2B4
CD16
CD27
CD160
CD94-NKG2C
CD94-NKG2E
CD11a-CD18
CD11b-CD18
CD2
CD62L

Ligands
Viral HA, pp65, BAT3, B7-H6, Heparin & heparan sulphates
(11)*
Viral HA, Heparin & heparan sulphates (11)*
Viral HA, Heparin & heparan sulphates, Vimentin (11)*
MICA, MICB, ULBP (8)*
Poliovirus receptor, Nectin-2 (8)*
CD48 (8)*
Immunoglobulin G (8)*
CD70 (8)*
HLA-C (8)*
HLA-E (8)*
HLA-E (8)*
ICAM-1 (8)*
ICAM-1 (8)*
CD58 (16)*
GlyCAM-1(17)*

Inhibitory

TABLE 1. NK CELL RECEPTORS

Receptors
NKp30

Abbreviations: CD- Cluster of differentiation; HA- Hemagglutinin; HLA- Human
leukocyte antigen; BAT3- HLA-B associated transcript 3; MICA and MICB- MHC Class I
polypeptide-related sequence A and B; ULBP- UL16 binding protein; KIR-Killer-cell
immunoglobulin-like receptor; LIR- Leukocyte immunoglobulin-like receptor; ICAMIntercellular adhesion molecule; DNAM-1- DNAX accessory molecule-1; GlyCAMGlycosylation-dependent cell adhesion molecule
* The Number in the parenthesis indicates reference.
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1.1.2 NK Cell Differentiation
NK cells are derived from hematopoietic stem cells (HSCs), primarily in the bone
marrow, but evidence also points to their differentiation in secondary lymphoid tissues
(SLTs) such as lymph nodes and tonsils (4). Based on the differentiation capability and
commitment and gradual acquisition of NK specific phenotype, the human NK
differentiation process is divided into 5 distinct stages. HSCs in response to cytokines
such as Flt3 ligand, IL-6 and IL-7 differentiate into NK cell progenitors. Even though
labeled NK progenitors for the ease of classification, these cells in reality are
pluripotent as they are capable of differentiating into T cells and plasmacytoid dendritic
cells. The stage 2 or precursor-NK (pre-NK) cell is marked by the acquisition of IL-15
responsiveness. At this stage, cells express CD122, the β receptor required for IL-2
and IL-15 signal mediation. The stage 2 cells are distinguished by their ability to
differentiate into stage 3 in response to soluble IL-15 or IL-2 and in the absence of
other cytokines and stroma. Even at this stage, the cells are not strictly committed to
the NK cell lineage, but can also differentiate into T cells and dendritic cells. The other
defining feature of this stage is the expression of CD56, which has come to define NK
cells in the absence of T and B cell specific markers. The stage 3 is NK cell
commitment stage. By differentiating into stage 3, the cells commit to NK cell lineage,
as cells at this stage are incapable of differentiating into any other cell type. The stage
3 cells express some NK associated antigens like CD2, 2B4 and NKp44, but not others
such as NKG2D, NKp30, NKp46, CD16, CD94-NKG2 complexes and KIRs. Due to
their inability to secrete IFN-γ and effect perforin mediated cytotoxicity, the functional
attributes of mature NK cells, these cells are identified as immature NK cells.
Transitioning into the 4th stage is marked by the expression of intracellular perforin,
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IFN-γ, and surface expression of activating receptors NKG2D and NKp46. This stage is
also characterized by the acquisition of the ability to mediate perforin and Fas ligand
mediated cytotoxicity and IFN-γ secretion. Expression of CD94-NKG2A complex at this
stage makes sure that attainment of functional capability is accompanied by the ability
to be inhibited through MHC-I on the target cells. Due to the lack of CD16 expression,
the NK cells at this stage are not capable of ADCC. The 5 th and the terminal stage of
differentiation is defined by the expression of CD16 and KIRs, equipping the cells with
ADCC and MHC-I mediated licensing and inhibition (19).

1.1.3 NK Cell Functions
Diverse types of activating receptors enable NK cells to recognize pathogen
infected, stressed and transformed cells. NK cells are also endowed with inhibitory
receptors to identify self-signals. Calibration of activating and inhibitory signals
determines whether NK cell sees a target cell as a self or non-self. Expression of MHC
class I molecules, the predominant self-signals recognized by NK cells, is usually
down-regulated in diseased cells, particularly virally infected cells, and transformed
cells. During NK cell contact with such cells, lack of or diminished inhibitory signals tilt
the balance in favor of NK cell activation, resulting in the target killing. This mode of
target detection is called missing self recognition (2). NK cells employ this mechanism
in the immunosurveillance of virally infected cells and tumor cells.
1.1.3.1

Anti-Cancer Activity of NK Cells

Equipped with cell surface receptors that detect danger signals on malignant
cells and activate cytolytic activity, the inherent function of NK cells is immunesurveillance of transformed cells (6). Tumor recognition and rejection by NK cells have
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been demonstrated both in vitro and in vivo in mice and rats (20-22). In animal models,
anti-tumor activity of several cytokines such as IL-2, IL-10, IL-12, IL-18 and IL-21 has
been shown to be mediated in a NK cell-dependent manner (8, 23-26). Expression of
ligands recognized by activating receptors, NKG2D and DNAM1, is often up-regulated
on malignant cells and as a result these receptors play a major role in anti-cancer
activity of NK cells (8, 13). Mice deficient in NKG2D and DNAM1 receptors have
impaired tumor immunosurveillance by NK cells (27-29). In humans, the critical role
played by NK anti-cancer activity was brought to light by an 11 year follow-up study,
which showed an association of higher incidence of cancer with low NK cytotoxicity in
peripheral blood (30). Also, high levels of tumor-infiltrating NK cells are associated with
positive prognosis (31-33). In acute myeloid leukemia (AML) patients, receiving HLA
haplotype mismatched hematopoietic transplantation, donor derived NK cells, with
mismatched KIR for recipient’s HLA, have been shown to deliver graft-versus-leukemia
effect (34). Anti-tumor effects of therapeutic monoclonal antibodies such as rituximab
(anti-CD20) are also predominantly achieved through NK cell-mediated ADCC (35).
Due to their anti-tumor activity, NK cells have emerged as candidate effector cells for
immune therapy against cancer. Adoptive transfer of activated autologous or allogeneic
NK cells has proven to be a safe and potentially efficacious immunotherapy for cancer
(36, 37). NK cell therapy has been or being tested against multiple types of cancers
(35).
1.1.3.2

Anti-Viral Activity of NK Cells

Along with lysis of malignant cells, NK cells also detect and lyse virally-infected
cells. NK cells are part of the first line of defense against viral infections. A large body
of work in mouse and human has firmly established role of NK cells in the immune
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response against viral infections, particularly herepesviridae infections (38). Studies
with mouse model of mouse cytomegalovirus (MCMV) have been instrumental in
expanding our knowledge of the dynamics of NK cell response to viral infections. NK
cells are activated during the early phase of viral infection and are recruited to the site
of infection. NK cells contain viral replication, before the adaptive immune response
kicks in, by killing virally-infected cells (39). To evade recognition and killing by CD8+
cells, MCMV blocks MHC class I expression on the infected cell. But, reduction in MHC
class I expression makes the cell susceptible to lysis by NK cell. To avoid NK cell
mediated lysis, MCMV encodes MHC class I like proteins m157 and m144, which
engage Ly49 receptors, the counterparts of human KIRs in mouse, to transmit
inhibitory signals and thereby block NK cytolytic activity. Mouse NK cells counter this
virus strategy by expressing an activating form of Ly49 receptor, Ly49H that couples
with signaling adaptor protein DAP12 to transmit activating signals (39, 40). Ly49H+ NK
cells are selectively expanded in the later phase of MCMV infection. This strategy and
counterstrategy by the virus and NK cells underscore the selective evolutionary
pressure; both, MCMV and NK cells are subjected to, and also highlight the critical role
played by NK cells in the defense against MCMV (40). The importance of NK cells in
anti-viral defense is also apparent from the viral strategy of reducing expression of
ligands for NK activating receptors on the infected cell. Expression of ligands for the
mouse NKG2D receptor, retinoic acid early inducible-1 (Rae-1) family of proteins, H60,
and murine ULBP-like transcript 1 (MULT1), is down-regulated by MCMV encoded
proteins (40).
The essentiality of NK cells in anti-viral defense in humans was first brought to
light by the susceptibility to herpesviruses observed in a patient, who had normal T and
B cells, but was devoid of any NK cells. This patient suffered from varicella zoster virus
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(VZV), human cytomegalovirus (HCMV) and herpes simplex virus (HSV) infections
(41). Like MCMV, HCMV employs similar survival strategies such as down-regulation of
expression of human NKG2D receptor ligands, whose expression tend to be upregulated on stressed cells. Unlike in mouse NK cells, a receptor that recognizes
HCMV encoded ligand has not been identified in human NK cells. However, CD94NKG2C, a heterodimeric receptor, which usually recognizes endogenous ligand HLA-E
and transmits activating signals, is the likely candidate as CD94-NKG2C+ NK cells are
preferentially expanded in HCMV infected patients. Viral ligands are also recognized by
other NK cell receptors such as NCRs. NCRs, NKp46 and NKp44, bind viral
hemagglutinins, while NKp30 binds HCMV encoded pp65 (40). Other than containing
HCMV, VZV and HSV infections, NK cells have also been suggested to play a role in
controlling infections by Epstein-Barr virus, human papilloma virus and human
immunodeficiency virus due to the low NK cell activity observed in individuals
susceptible to infections by these viruses (38, 42).
1.1.3.3

NK Cells As Regulators of Innate And Adaptive Immunity

NK cell interactions with cells of innate and adaptive immune systems shape
immune responses. NK cells secreted cytokines and direct cell-to-cell contact play a
major role in the regulation of innate and adaptive immunity. Interactions of NK cells
with dendritic cell (DC) are mutually beneficial. NK cells come in contact with DCs at
the site of inflammation and in secondary lymphoid tissues. At the site of inflammation
DCs are activated through their contact with microbes and microbial-infected cells.
Activated DCs through cytokine secretion and direct contact with NK cells induce
cytolytic capability, cytokine secretion, particularly IFN-γ and proliferation in NK cells.
NK cells in return help DCs mature through IFN-γ and TNF-α secretion and also
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through NK-DC contact in which NKp30 plays a critical role. Expression of antigen
presenting molecules, MHC class I and class II, and co-stimulatory signals such as
CD86 is up-regulated on mature DCs (43). NK cells also influence antigen presentation
by DCs. Cell debris generated by NK mediated lysis of malignant and virally infected
cells is internalized by DCs and then processed and presented on the cell surface
bound to MHC molecules. Mature DCs migrate to secondary lymphoid organs such as
lymph nodes where they present antigens to T cells leading to their activation. Thus,
NK cell mediated maturation of DCs and NK cell influenced antigen presentation by
DCs indirectly influence maturation and activation of T cells (8). In lymph nodes, mature
DCs come in contact with NK cells in the parafollicular region of the T cell area. Here
too, DC secreted cytokines induce proliferation, cytolytic capability and cytokine
secretion in NK cells. Due to close proximity of DCs, NK and T cells in lymph nodes,
the cells influence each other’s activation. DC induced secretion of IFN-γ by NK cells
help CD4+ cells acquire Th1 phenotype, while DC activated secretion of IL-2 by CD4+
cells stimulate proliferation and cytolytic capability of NK cells (44, 45). NK cells are
also known to activate IgM and IgG synthesis in B cells and activated B cells have
been shown to enhance IFN- γ secretion by NK cells (46).
Along with promoting maturation and activation of innate and adaptive immune
cells, NK cells can regulate immune responses by secreting immune suppressive
cytokine IL-10 and by killing immature DCs and MHC deficient CD4+, CD8+ and B cells
(8, 47). In turn, T regulatory cells are known to inhibit NK cell cytolytic activity through
TGF-β mediated mechanism (48). Thus, NK cells acts as a bridge between innate and
adaptive immunity through their contact with various cell types and have both positive
and negative influence on immune responses. In return, NK cell mediated immune
response is also shaped by other immune cells.
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1.1.3.4

Role of NK Cells In Pregnancy

NK cells are the predominant leukocytes found at the maternal-fetus interface.
NK cells comprise >70% of the leukocytes in the decidua. The cytokines and
chemokines secreted by these decidual NK cells (dNK) have been suggested to play a
role in successful trophoblast invasion. Decidual NK cell secreted vascular endothelial
growth factors promote angiogenesis of the placenta. Due to the association of low
number of dNK cells with spontaneous abortion, immunologic tolerance of the fetus has
also been attributed to dNK cells. Along with protecting the fetus from immune assault,
NK cells are also deemed to protect the fetus from the transmission of pathogens from
mother such as HCMV (49).
1.1.3.5

NK Cell Memory
Immune response mediated by clonally expanded cells armed with the

same receptor that recognizes an identical antigen and the ability to mount a rapid and
robust response upon exposure to the same antigen in the future due to the formation
of long lasting memory cells during the initial exposure are the distinguishing
characteristics of the adaptive immune system. The other defining feature of adaptive
immune system is the mode of generating antigen receptor diversity. In T and B cells,
recombination activating genes (RAGs) encoded enzymes mediated somatic nonhomologous recombination and rearrangement of variable (V), diversity (D) and joining
(J) segments of T and B cell receptor genetic locus generate the immense antigen
receptor diversity. NK cell shares some features with T and B cells such as
differentiation from common lymphoid progenitor and like T cell it is a cytotoxic effector
lymphocyte. While NK cells express a large repertoire of receptors with distinct antigen
specificity, this receptor diversity emanates from germ-line encoded receptors, which
13

do not undergo somatic recombination and rearrangement. Due to the lack of RAG
mediated recombination and the ability of NK cells to kill malignant and virally infected
cells without prior sensitization to the antigen, NK cells are categorized as innate
lymphocytes (50). However, recently NK cells have been shown to possess the
distinctive attribute of the adaptive immune system, the formation of immunological
memory. The initial evidence supporting memory NK cell formation was acquired in T
and B cell lacking mice showing hapten induced contact hypersensitivity (51). A hapten
is a small protein modifying chemical. Haptenated proteins elicit immune response.
Initial sensitization with a hapten leads to generation of long living memory T and B
cells, which mount a more potent response upon future challenge with the same
hapten. Microscopic analysis of leukocyte accumulation at the hapten challenged tissue
and NK cell depletion experiments indicated that in T and B cell lacking hapten
sensitized mice, contact hypersensitivity to the subsequent exposure to the same
hapten was mediated by NK cells (51). A recall response observed in these mice four
weeks after initial sensitization demonstrated existence of long lasting memory NK
cells. Contact hypersensitivity observed in naive mice adoptively transferred with NK
cells from sensitized mice further confirmed the identity of these memory cells as NK
cells. The researchers further showed that memory NK cells reside in the liver (51).
Following this initial study, existence of memory NK cells was reported in MCMV
infected mice (52). Like clonal T cell expansion, NK cells expressing Ly49H receptor,
which recognizes MCMV encoded protein m157, are selectively expanded upon MCMV
infection (53), but it was not known whether these cells bear any antigenic memory.
Sun et al. (52) showed that Ly49H+ cells linger for a long time after infection and are far
more effective than naïve cells in rendering protection upon adoptive transfer. Also, the
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recall response was antigen specific. Thus, along with the attributes of an innate
effector lymphocyte, NK cells also have the characteristics of adaptive immunity.

1.1.4 Cytokine Signaling in NK Cells
Orchestrating the immune response is a complex task as it involves regulation
and coordination of multiple cellular processes such as differentiation, proliferation,
migration, activation and suppression in multiple cell types belonging to both, innate
and adaptive, arms of the immune system. This task is accomplished by cytokinemediated signaling. Cytokines are small extracellular proteins secreted by immune and
non-immune cells. It is a large group of proteins with diverse structures and functions.
NK cell development, homeostasis, and NK cell functions are regulated by cytokines
secreted by immune and non-immune cells.
1.1.4.1

Cytokines Involved in NK Development

Many different cytokines such as Flt3 ligand (Flt3L), stem cell factor (SCF), IL-12
and common cytokine receptor γ chain family of cytokines (IL-2, IL-4, IL-7, IL-15, and
IL-21) are known to play a role at different stages of NK differentiation process (19, 54).
Few of these cytokines, IL-2 and IL-15, have been shown to induce NK differentiation
from HSCs in vitro in the absence of other cytokines, while the rest of the cytokines
work in combination with IL-2 or IL-15 (19). NK cell generation, homeostasis and
development is known to be IL-15 dependent as has been demonstrated by reduced
NK cell numbers and impaired NK cell cytotoxicity in mice lacking IL-15 or IL-15
receptor α chain (54-56). IL-15 responsiveness acquired during the NK precursor stage
is considered a major step towards NK lineage commitment (19). IL-2 has also been
reported to play a role in NK cell differentiation and activation (57), but the number of
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mature NK cells is not affected in IL-2 deficient mice and humans, thereby ruling out
any major role of IL-2 in NK cell development in vivo (54, 58). Even though, IL-4 and IL7 have been suggested to have a role in terminal differentiation and homeostasis of NK
cells, studies in mice lacking IL-4 and IL-7, show that these cytokines are dispensable
in NK cell generation and maturity (54). IL-21 has been demonstrated to play a
synergizing role with IL-15 and Flt3L (59) and IL-15, Flt3L and SCF (60) in in vitro
differentiation of NK cells from human HSCs. The evidence implicating IL-21 in human
NK cell development in vivo is provided by NK cells from human subjects with loss of
function mutations in IL-21 receptor gene (61). These patients had normal number of
NK cells, but the IL-21 non-responsive NK cells showed diminished basal cytotoxicity,
suggesting a flaw in functional maturation (61). In mouse too, IL-21, in combination with
IL-2 or IL-15, has been shown to help in the functional maturation of NK cells in vitro
and promote functional maturation in vivo (62). But this evidence in support of the role
of IL-21 in NK differentiation is contrary to the finding of normal number of mature,
functionally valid NK cells in IL-21 receptor knockout mice (63). This finding in mice is
also contrary to the impaired NK cytotoxicity observed in IL-21 receptor deficient
humans (61). The dissimilarity underscores the difference that may exist in the NK
developmental process between mouse and human and serves as a caution while
applying lessons learned from mouse to humans.
1.1.4.2

Cytokines Involved in NK Homeostasis

The homeostatic NK cell survival and proliferation are dependent on IL-15
signaling in mice (64-66), but are independent of IL-15 in humans (67), again
highlighting the difference in the physiology of NK cells between the two. However, NK
cell proliferation in response to viral infections in both, mice and humans has been
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shown to be dependent on IL-15 signaling (68, 69). IL-12 (70, 71) and IL-18 (70) have
also been demonstrated to play a role in NK proliferation in response to MCMV
infection in mice. In vitro studies have demonstrated that cytokines, which have not yet
been shown to play a physiological role in NK cell proliferation in vivo, could also
induce proliferation of NK cells. One of the potent activators of NK cell proliferation is
IL-2 (72, 73). It is used to expand NK cells ex vivo for immunotherapy in cancer (74,
75). Some cytokines do not induce proliferation acting alone, but in combination with
other cytokines they do. For instance, IL-10, IL-12 and IL-18 stimulate proliferation of
mice NK cells pre-activated with IL-2 (76). IL-18 also induces proliferation of mice NK
cell in combination with other cytokines such as IL-12 and IL-15 (77-79). IL-21 too does
not induce NK cell proliferation by itself, but does in combination with IL-2 in human NK
cells (80). IL-21 also supports NK cell survival and enhances it further in combination
with IL-2 (81).
1.1.4.3

Cytokines Involved in NK Functions

Unlike cytolytic T cells, NK cells do not need prior sensitization with target
antigen before killing a target cell. Upon detecting stress signals through interactions of
NK activating receptors with their cognate ligands on target cells, NK cells deliver their
cytolytic function. This ready to kill approach makes it necessary for NK cells to be
equipped with the detection tool, the activating receptors, and the effector tool, lytic
granules containing perforin and granzymes, while on immunosurvelliance duty.
Surface expression of activating receptors and pre-formation of lytic granules occur as
a result of priming of NK cells by cytokines present in their microenvironment (8). Type
1 interferons (IFNα and IFNβ), common γ-chain cytokines (IL-2, IL-15 and IL-21), IL-6,
IL-12 and IL-18 are known to activate cytolytic capability of NK cells (82). These
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cytokines induce expression of lytic effector proteins such as perforin (IFNα, IL-2, IL-6,
IL-12, IL-15 and IL-21) and granzymes (Type I IFNs, IL-2, IL-15, IL-21) (81, 83-86).
Along with the induction of expression of lytic molecules, cytokines also stimulate
expression of NK receptors, whose interactions with their cognate ligands on the target
cells are required for the degranulation of the lytic proteins. NKG2D expression on NK
cells is up-regulated in response to IFN-α, IL-2, IL-15, IL-12 and IL-21 (81, 87-90).
NCRs’ expression is induced by IL-2, IL-15, IL-12 and IL-21 (82), while DNAM-1 and
2B4 expression is modulated by IL-2 and IL-21, respectively (91, 92).
NK cells also effect their functions through cytokine secretion. NK cells are one
of the primary producers of IFN-γ, which is a modulator of innate and adaptive
immunity. IFN-γ shapes innate immunity through activation of macrophage killing
ability. IFN-γ influences adaptive immunity by stimulating antigen presentation through
induction of expression of MHC class I and II proteins in antigen presenting cells and
by promoting acquisition of Th1 phenotype by CD4+ T cells (4). It also exerts direct
effect on virally-infected and malignant cells by inhibiting their proliferation and
increasing their sensitivity to apoptosis (6). The major inducer of IFN- γ generation in
NK cell is IL-12, secreted by activated DCs and macrophages (44, 93). Other cytokines
such as IL-2, IL-15, IL-18 and IL-21 also stimulate expression of IFN- γ in NK cells (4).
The recently discovered feature of memory formation in NK cell has been shown
to be regulated by cytokines. Adoptively transferred mouse NK cells, pre-stimulated
with IL-12 in combination with IL-18 and IL-15, have been shown to retain priming
memory. Stimulation with the same cytokines three weeks after initial stimulation elicits
amplified IFN- γ secretion by these cells (94). A similar recall response has also been
demonstrated in human NK cells (95). Viral antigen-specific memory in mouse NK cells
is also dependent on IL-12 signaling (96).
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Some of the cytokines, which play a critical role in the regulation of NK cell
functions, are depicted in Figure 1.
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Figure 1. Regulation of NK cell functions by cytokines. IL-2 and IL-21
secreted by CD4+ helper T cells and dendritic cell (DC) and macrophage (MΦ)
derived IL-15, IL-12, IL-18 and IFN-α/β prime NK cells for their functions by
inducing expression of NK receptors, perforin, granzymes and cytokines.
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1.2 JAK-STAT SIGNALING
Cytokines mediate their signals by binding and activating their specific transmembrane receptors on the cell surface and thereby triggering a cascade of molecular
events inside the cell. Down-stream of an activated cell surface receptor, signals are
relayed in a sequential pathway through a chain of effector molecules. One such
pathway is Janus kinase (JAK)-signal transducer and activator of transcription (STAT),
which is shared by many cytokines with different structures, receptors and functions to
mediate signals in multiple types of immune and non-immune cells. Cytokines
transmitting signals through receptors belonging to type I and II cytokine receptor
superfamily primarily mediate their signals through JAK-STAT pathway. This is a large
group of cytokines, which includes interferons, most of the interleukins and colony
stimulating factors. Type 1 (IFNα and IFNβ) and 2 (IFN-γ) interferons, common γ-chain
cytokines (IL-2, IL-4, IL-7, IL-15 and IL-21), IL-6, IL-10, IL-12 and IL-18, the cytokines
with indispensible roles in NK cell development, homeostasis, activation and function,
mediate their signals pre-dominantly through JAK-STAT signaling system (97).
The JAKs are a family of tyrosine kinases constitutively associated with
cytoplasmic regions of the cytokine receptors. The family is comprised of four
members, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). Cytokine-bound activated
receptors activate JAKs’ kinase activity and activated JAKs in turn phosphorylate
specific tyrosine residues in the cytoplasmic domain of the cytokine receptors. These
phosphorylated tyrosine residues provide docking sites for latent cytoplasmic
transcription factors STATs through the interaction of their Src homology 2 (SH2)
domains. Conserved tyrosine residues on receptor-bound STATs are phosphorylated
by JAKs. STAT molecules dimerize by reciprocal interactions of their SH2 domains and
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phosphotyrosines. The dimerized STATs translocate to the nucleus, where they bind to
specific DNA elements to regulate transcription of target genes. There are seven
members in the STAT family, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and
STAT6 (98). All STATs share a domain architecture comprising of amino terminal (Nterminal), coiled-coil, DNA binding, linker, SH2 and transactivation domains from amino
terminus to carboxy terminus (99).

1.2.1 Regulation of JAK-STAT Signaling
Regulation of JAK-STAT pathway occurs at multiple levels and by multiple
mechanisms. JAKs are inhibited by suppressor of cytokine signaling (SOCS) family of
proteins. Different SOCS use different mechanisms to block JAK activation. SOCS1
through its SH2 domain binds directly to the phosphorylated tyrosine on the JAKs and
thus directly inhibits the kinase, while SOCS3 inhibits JAKs indirectly by binding to the
activated receptor. Transcription of SOCS is up-regulated by JAK-STAT signaling
thereby providing a negative feedback loop to regulate its own signaling.
Dephosphorylation of tyrosines on JAKs by protein tyrosine phosphatases (PTPs) such
as SH2 domain containing PTPs SHP-1 and SHP-2 also terminates JAK activation.
JAK-STAT signaling is also regulated through degradation of JAKs via ubiquitinproteasome pathway. Like JAKs, activated STATs are also dephosphorylated by PTPs
such as SHP2 and T cell PTP (TCPTP). STATs are deactivated through
dephosphorylation of tyrosine both in the cytoplasm and in the nucleus by SHP2, while
TCPTP activity is restricted in the nucleus. Activated STATs are also disabled by
protein inhibitors of activated STAT (PIAS) family of proteins, which bind to dimerized
STATs in the nucleus (98). STAT family members can also regulate each other’s
activation. STAT1 and STAT3 have reciprocal inhibitory effects either due to
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competition for the same docking sites on the cytokine receptor and/or sequestration of
each other due to STAT1:STAT3 heterodimerization. Deficiency in one of these STATs
enhances temporal activation and signaling response by the other (100). STATs are
also known to activate their own transcription as is evident from the increased STAT1
protein expression in cells stimulated with STAT1 activating cytokines. Thus, there is a
positive feedback mechanism that enhances signaling by a particular STAT (101).

1.2.2 Functions of JAK-STAT Signaling
Immune disorders and disease phenotypes reported in patients carrying
mutations in the individual components of JAK-STAT signaling pathway brought to light
the central role played by JAK-STAT signaling in the differentiation and development of
immune cells, homeostasis, and co-ordination of immune response. Loss of function
and hypomorphic JAK3 mutations found in severe combined immune deficiency (SCID)
patients, characterized by extreme susceptibility to microbial infections due to lack of or
diminished number and function of T and NK cells, established role of JAK3 signaling
downstream of common γ-chain cytokines in lymphocyte development (97, 102).
Susceptibility to mycobacterial, salmonella, Staphylococcal and viral infections and
unresponsive cells to IFN-α, IFN-β and IL-12 stimulation observed in patients with
TYK2 loss of function mutations were instrumental in elucidating the function of TYK2
signaling in anti-bacterial and anti-viral defense of above mentioned cytokines (102). A
similar bacterial and viral infection and cell signaling phenotype detected in patients
carrying loss of function and hypomorphic STAT1 mutations confirmed STAT1 as a
signal relaying STAT downstream of TYK2 in response to IFN-α, IFN-β and IFN- γ
signaling (102). Loss of function mutation in STAT2, another STAT activated by IFN-α
and IFN-β signaling, results in susceptibility to vaccine-strain measles (103). Though,
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most of the JAK-STAT signaling family members have roles restricted to the immune
system, some components such as STAT5 have non-immune functions along with a
role in the immune system. Along with activation, downstream of common γ chain
cytokines (IL-2, IL-7, IL-9, IL-15) (104), STAT5 is also activated in response to growth
hormone receptor stimulation (97). As a result, patients carrying loss of function
STAT5b mutations have non-immunological phenotypes such as growth retardation.
These patients also display complex immune deficiency symptoms. They are
vulnerable to microbial infections, a sign of immune deficiency, and are also prone to
autoimmune disorders such as autoimmune thyroiditis, idiopathic thrombocytopenic
purpura, lymphocytic interstitial pneumonitis, and severe eczema. This seemingly
contradictory immune phenotype is explained by the role played by STAT5b signaling
in the generation of T regulatory (Treg) cells as well as in T cell homeostasis. The
requirement of STAT5b signaling downstream of IL-2 activation for induction of Foxp3,
a transcription factor necessary for Treg differentiation, underlies the low number of
Treg cells, accounting for autoimmune disorders observed in STAT5b deficient
patients. STAT5b signaling is also required for T cell (CD4+ and CD8+) homeostasis
and as a result STAT5b deficient patients suffer from T cell lymphopenia, which
accounts for their susceptibility to microbial infections (102).
Another constituent of JAK-STAT pathway with immune and non-immune
functions is STAT3. Perhaps, STAT3 is the member of the JAK-STAT family with the
most diverse functions that best exemplifies the reach and indispensability of JAKSTAT pathway in systemic cell signaling.
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1.2.3 STAT3
STAT3 was discovered as an activator of acute phase gene expression in
hepatocytes in response to IL-6 stimulation and hence was initially named as acute
phase response factor. Since its discovery, numerous in vitro and in vivo studies have
revealed STAT3 as a transcription factor relaying signals downstream of diverse types
of cellular signals in multitude of tissues (105). The functional diversity is a result of
STAT3’s ability to be activated by different signaling mechanisms. STAT3 is activated
not only by JAKs activated by cytokines, but also by receptor tyrosine kinases activated
by growth factors (Epidermal and platelet-derived growth factor) and src tyrosine
kinases (Src, Lck, Hck, Lyn, Fyn, and Fgr) either independently or downstream of
activated receptor tyrosine kinases and G-protein coupled receptors (106). Despite its
response to varied stimuli and signaling pathways, mode of STAT3 activation remains
the same. The canonical STAT3 activation mechanism involves phosphorylation of
tyrosine (Y) residue located at the interface of SH-2 and transactivation domains (Y705
in human STAT3, which has 770 amino acids) by a tyrosine kinase (107, 108). In
addition to the canonical pathway, STAT3 is activated by other mechanisms.
Phosphorylation of a serine (S) residue located in the transactivation domain (S727 in
human STAT3) unleashes maximal transcription activation potential of STAT3 (106).
The serine can be phosphorylated by kinases such as ERK, CDK1, ATM and ATR
independent of signal promoting tyrosine phosphorylation (109). Unphosphorylated
STAT3 has been shown to form homodimers and translocate to the nucleus and
regulates gene transcription either by itself or by interacting with other transcription
factors such as NFκB (101). Along with homodimerized form, STAT3 regulates gene
expression by forming heterodimers with STAT1 and STAT5 (110). Extranuclear
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function of STAT3 has been reported recently, wherein STAT3 located in mitochondria
was shown to be required for activation of electron transport chain and this function
was dependent upon phosphorylation of S727 (111). Even though STAT3 can be
activated in various ways and has a function outside of its role as a transcription
activator, STAT3 pre-dominantly delivers its function as a transcription factor upon
phosphorylation of its tyrosine residue (107).
1.2.3.1

Functions of STAT3

STAT3 regulates expression of genes involved in fundamental cellular
processes such as cell cycle, apoptosis, cell signaling, transcription, angiogenesis, lipid
metabolism, remodeling of extracellular matrix and cell migration (112). STAT3 also
plays a role in self-renewal of embryonic stem cells by blocking differentiation (105).
Given STAT3’s pleiotropic role, it is not surprising that systemic deletion of STAT3
results in embryonic lethality (113). Due to this limitation, researchers generated tissue
specific deletion of STAT3 in mouse, which has been instrumental in our understanding
of physiological role of STAT3. STAT3 has non-redundant functions in multiple organs
ranging from skin to nervous system. In skin, STAT3 is required for wound healing and
keratinocyte migration, while in thymic and memory epithelium and in sensory and
motor neurons STAT3 is required for pro-survival signals. In liver, STAT3-activated
gene expression promotes acute phase response (107).
1.2.3.2

Role of STAT3 in Cancer

STAT3 is activated by mitogenic signals such as cytokines and growth factors
and activates expression of genes promoting proliferation, survival, migration and
angiogenesis; the processes when out of control give rise to cancers. Constitutive or
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elevated activity and/or expression of STAT3 are associated with various types of
cancers including leukemia, lymphomas, multiple myeloma, melanoma and cancers in
breast, lung, liver, pancreas, prostate, ovary, and head and neck. In many of these
cancers high STAT3 activity and expression are markers of poor prognosis (106).
Oncogenic STAT3 activity could be a result of one or a combination of multiple
processes. It could be secondary to deregulated upstream signaling pathway triggered
by cytokines, growth factors and oncogenic Srcs. Loss of regulation in STAT3 signaling
through repression or silencing of inhibitors of STAT3 signaling such as SOCS3, PTPs
and PIAS3 have been shown to be responsible for over active STAT3. STAT3 by upregulating expression of itself and by activating expression of STAT3 activating
cytokines such as IL-6 and IL-10 promotes its overexpression and sustained activation
through positive feedback. Somatic mutations leading to constitutively active STAT3
have also been reported in some cancers (108). STAT3 also drives oncogenesis by
promoting inflammation in the tumor microenvironment. Persistent inflammation has
been shown to be a cause of certain cancers such as gastric and liver and aids
oncogenesis in others (114). STAT3 regulated IL-6 is one of the main drivers of
inflammation in tumor microenvironment. IL-6, a pro-inflammatory cytokine not only
mediates inflammatory conditions in the malignant cells, but also in the stromal and
immune cells in the tumor microenvironment. IL-6 activates STAT3 in these cells, which
activates expression of genes responsible for inflammation in a positive feedback loop
(114). STAT3 also activates expression of IL-10, an immune suppressive cytokine. IL10 secreted by cancer cells and immune cells suppress anti-cancer response of
immune cells in the tumor microenvironment. IL-10 also activates STAT3 thereby
propagating immune suppression in a positive feedback loop (115).
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1.2.3.3 Role of STAT3 in Immune System
STAT3 mediates signals down-stream of cytokines belonging to different
families such as common γ-chain cytokines (IL-2, IL-7, IL-9, IL-15 and IL-21), gp130
receptor utilizing cytokines (IL-6, IL-11, IL-27, IL-31, oncostatin M, leukemia inhibitory
factor), Type I IFNs (IFNα and β), Type II IFN (IFNγ), IL-10 family (IL-10, IL-19, IL-20,
IL-22, IL-24, IL-26), IL-12, IL-23, Flt3 ligand and colony stimulating factors (G-CSF and
M-CSF). These cytokines play an important role in the differentiation, proliferation,
survival and modulation of activation of myeloid and lymphoid cells (116). Like tissue
specific deletion in non-immune tissues, STAT3 deletion in hematopoietic cells and
specific types of immune cells in mouse have brought to light the critical role played by
STAT3 signaling in immune function.
T cell specific deletion of STAT3 revealed its requirement in IL-6 and IL-2
induced proliferation of T cells. In response to IL-2, STAT3 induces expression of
CD25, the private IL-2 receptor, which is required for high affinity binding of IL-2 (107).
STAT3 deficiency in CD4+ T cells impairs generation of Th17 cells. Th17 cells mediate
anti-microbial immunity, mostly at the epithelial barriers, by secreting pro-inflammatory
cytokines IL-17A, IL-17F, IL-21 and IL-22. These cytokines help recruit and activate
neutrophils at the site of infection and also induce secretion of anti-microbial peptides
from epithelial cells (116). Cytokines involved in Th17 differentiation, IL-6, IL-21 and IL23 mediate their signal through STAT3, which activates transcription of retinoic acidrelated orphan nuclear receptors (RORs) RORγt and RORα, the transcription factors
that drive the genetic program for Th17 differentiation. The cytokines secreted by Th17
cells, IL-17A, IL-17F and IL-21 are also STAT3 targets (117, 118). STAT3 deficiency in
CD4+ helper cells also impairs their ability to secrete IL-10 in response to IL-6 and IL-
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27. Pro-inflammatory cytokines such IL-6 and IL-27 along with the induction of
inflammation mediators also stimulate secretion of immune-suppressive cytokine IL-10
from helper T cells, which prevents a protective inflammatory response from becoming
a pathological one (119). Thus, in helper T cells, STAT3 is required for initiating an
inflammatory response as well as for its regulation. CD8+ T cell specific STAT3 deletion
helped elucidate role of STAT3 in memory T cell formation. Cytokines IL-10 and IL-21
through STAT3 activation trigger the genetic program required for memory T cell
differentiation (120). B cell specific STAT3 deletion impairs T cell dependent
differentiation of B cells into plasma cells (121).
Along with cells of lymphoid origin, STAT3 signaling is also critical for
development and immune response of myeloid cells. STAT3 deficient macrophages
and neutrophils lose their ability to respond to IL-10, which signals through STAT3 to
rein in inflammation. Loss of STAT3 in these cells results in excessive secretion of proinflammatory cytokines such TNF-α, IL-6 and IL-1, leading to inflammatory disorders
(122). Employing bone marrow specific deletion, STAT3 has been shown to be
required for neutrophil mobilization in response to G-CSF and chemokines (123).
Hematopoietic cell specific STAT3 deletion results in decreased number of dendritic
cells (DCs). Flt3 ligand, which mediates its signals through STAT3 activation, is a major
regulator of DC development and as a result STAT3 deficiency leads to impaired
development of DCs (124).
Most of the knowledge about the role of STAT3 in immune function has been
obtained from mouse experiments. Even though mouse is a preferred animal model
due to the ease of handling, genetic maneuverability, and mainly because of the many
similarities between mouse and human physiology, not everything learned from a
mouse model can be extrapolated to humans due to the differences that exist between
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these two species. Monogenic mutations, nature’s own experiment, found in humans
offer an opportunity to study role of the protein coded by that gene in human
physiology. STAT3 gain of function germline mutations were recently discovered in
humans, which caused multiorgan autoimmunity and lymphoproliferation and in one
patient, susceptibility to mycobacterial infections (125, 126). Even though all
pathogenic mechanisms are not yet known, few insights into immune dysregulation
caused by hypermorphic STAT3 have been obtained. The autoimmunity is due to the
low number of Treg cells in these human subjects (125, 126) and Treg deficiency is
likely caused by suppressed STAT5 activation in these patients (125). Suppression of
STAT1 activation was also reported in these patients, but its implications, if any, are not
known (125). Even though any mutation that affects normal function of the protein
provides important information about the physiological role of that protein, more telling
are the loss of function or hypomorphic mutations, which clearly highlight the necessity
of the protein.
There are naturally occurring, albeit rare, heterozygous dominant negative STAT3
mutations in humans, which cause an immunodeficiency called Job syndrome.

1.3 JOB SYNDROME
Job syndrome is a rare immune disorder, initially characterized by the triad of
eczema and recurrent skin and lung infections (127). As boils due to recurrent skin
infections is a cardinal feature of this immunodeficiency, the immune disorder was
named after the biblical character Job, whose body was covered with boils. Later
investigation also identified increased serum levels of IgE as a clinical symptom, which
lent hyper IgE syndrome as an alternative name to the disorder (128). The skin and
lung infections are primarily caused by Staphylococcus aureus. Lungs are also infected
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with Streptococcus pneumoniae and Haemophilus species, albeit less frequently. Hard
to treat secondary Pseudomonas aeruginosa and mycobacterial infections further
exacerbate poor pulmonary conditions and are the main cause of mortality. Fungal
infections such as mucocutaneous candidiasis and Aspergillus are also common (129).
Job syndrome is also characterized by various non-immunological features such as
facial asymmetry, scoliosis, osteopenia, minor trauma fractures, hyperextensibility,
retention of primary teeth and aneurysm (129-131).
In 2007, two groups independently discovered dominant negative STAT3
mutations as the causative factor for the Job syndrome (130, 131). The mutations are
found to be sporadic as well as familial and are mostly restricted to the DNA binding
and SH2 domains (132). Investigations into the pathogenesis of immunodeficiency of
Job syndrome patients have delineated the role of STAT3 signaling in the generation
and function of immune cells of lymphoid and myeloid origin (133). Cells from Job
syndrome patients serve as a naturally occurring STAT3 deficient genetic model, which
has helped decipher role of STAT3 in human physiology.

1.4 GENESIS OF HYPOTHESIS AND SPECIFIC AIMS
NK cells play a crucial role in immune response to virally infected and malignant
cells. Cytolytic activity of NK cells is a result of the balance between the activation of
inhibitory and activating receptors expressed on NK cell surface. The innate ability of
NK cells to use these receptors to recognize and destroy malignant cells has made
them excellent candidate immune cells to be used in adoptive immunotherapy against
cancer. Due to the limited number of NK cells in the peripheral blood, ex vivo
expansion and activation of autologous or allogeneic NK cells before their transfer into
the patient forms the basis of NK cell adoptive immunotherapy.
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Research efforts in our lab are focused on developing NK cell adoptive
immunotherapies against cancers. Activation and expansion of patient- or donorderived NK cells under laboratory conditions to a sufficiently large number is a prerequisite for the success of such a therapeutic approach. Understanding the signaling
mechanisms involved in NK cell proliferation, survival and activation is a key to
optimizing the ex vivo culture conditions of NK cells, which will translate to improved
clinical applications of NK cell immunotherapy.
We previously described robust ex vivo expansion and activation of human NK
cells by co-cultivation with K562 (erythroleukemic cell line) based artificial antigen
presenting cells (aAPC) genetically modified to express membrane-bound IL21
(mbIL21). We found that mbIL21 results in greater proliferation, longer telomere length,
and less senescence than NK cells expanded with aAPC expressing membrane-bound
IL15 (mbIL15) (134). Within the STAT family, IL21 activates STAT3 most efficiently
(135).
Investigations in our lab also revealed that STAT3 signaling activates
expression of NKG2D (136), a primary activating receptor involved in the cytolytic
immune response mediated by NK cells to infections and malignant cells (12). We
showed that STAT3 regulates NKG2D expression at the transcriptional level (136).
Based on these findings, I hypothesized that STAT3 signaling is critical for
human NK cell cytolytic function and proliferation.
I proposed the following specific aims to investigate this hypothesis:
Aim #1: To evaluate the role of STAT3 signaling in cytolytic function of NK cells
Aim #2: To evaluate the role of STAT3 signaling in NK cell proliferation
NK cells from Job syndrome patients carrying dominant negative STAT3
mutations provided an opportunity to test my hypothesis in a naturally occurring genetic
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model. Along with Job syndrome patients’ NK cells, I also validated my hypothesis in
STAT3 knock-down primary human NK cells. Along with genetic models, I also
employed pharmacological approach wherein STAT3 activation was blocked using
small molecule STAT3 inhibitor.
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2 CHAPTER 2
ROLE OF STAT3 SIGNALING IN HUMAN NK CELL
CYTOLYTIC FUNCTION
“This chapter is partly based on the already published results in the Journal Blood.
Zhu S, Phatarpekar PV*, Denman CJ, Senyukov VV, Somanchi SS, Nguyen-Jackson
HT, Mace EM, Freeman AF, Watowich SS, Orange JS, Holland SM, Lee DA.
Transcription of the activating receptor NKG2D in natural killer cells is regulated by
STAT3 tyrosine phosphorylation. Blood. 2014;124(3):403-411. © the American Society
of Hematology."
*Co-first Author
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Role of STAT3 Signaling In Human NK Cell
Cytolytic Function
2.1 INTRODUCTION
Cytokines, the central regulators of immunity, predominantly employ Janus
kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway
to mediate signals in immune cells. In canonical JAK-STAT signaling, signals are
relayed from the extracellular environment to the nucleus to regulate gene expression
in target cells. Upon binding of cytokines to their specific multimeric receptors, JAKs,
tyrosine kinases, constitutively associated with cytoplasmic regions of cytokine
receptors, are activated. Activated JAKs phosphorylate specific tyrosine residues in the
cytoplasmic domain of the cytokine receptors to provide docking sites for latent
cytoplasmic transcription factors STATs through the interaction of their Src homology 2
(SH2) domains. Conserved tyrosine residues on receptor bound STATs are
phosphorylated by JAKs. Phosphorylated STATs dissociate from receptors and
dimerize by reciprocal interactions of their SH2 domains and phosphotyrosines.
dimerized STATs translocate to the nucleus and bind to specific DNA elements to
regulate transcription of target genes. Four JAKS, JAK1, JAK2, JAK3 and TYK2
through seven STATS, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6
mediate signals from diverse types of cytokines in multiple types of immune cells (137).
STATs are composed of multiple domains. The N-terminal domain facilitates
binding of two adjacent DNA bound dimers, which stabilizes DNA-STAT interaction.
The coiled-coil domain which succeeds the N-terminal domain is involved in

35

interactions with different proteins essential for forming transcription activation complex.
C-terminus to the coiled-coil domain is the DNA binding domain and as the name
indicates is at the core of the function of the protein (99). The linker domain, which
bridges the DNA binding domain with the SH2 domain, is essential for the
transcriptional activation (138). The SH2 domain serves two critical functions; initial
binding of the latent STAT to the phosphorylated tyrosine on the cytoplasmic portion of
the cytokine receptor that leads to the phosphorylation of its own tyrosine by JAKs and
upon activation it enables dimer formation with other activated STAT through reciprocal
interactions of SH2 domain and phosphotyrosine. The tyrosine residue, whose
phosphorylation by JAKs activates the STATs, is located at the interface of SH2
domain and the transcriptional activation domain (TAD). The TAD lies at the C-terminus
of the protein and as the name suggests is critical for the transcriptional activation of
target genes (139).
Among STATs, STAT3 is the most pleotropic transcription factor regulating
genes involved in fundamental cellular processes such as proliferation, apoptosis,
differentiation and migration in multiple cell lineages downstream of a plethora of
extracellular signals (107). Given its critical role in cellular processes, it is not surprising
that germline STAT3 deletion is embryonically lethal in mouse (113). Targeted tissue
specific deletion has revealed STAT3’s role in the development and function of multiple
organs as diverse as skin and brain (107). STAT3 is activated by several families of
cytokines that employ JAKs to mediate their signals (116). In addition to JAKs, receptor
tyrosine kinases are known to activate STAT3 downstream of some extracellular
ligands (EGF, M-CSF, PDGF and Flt3 ligand) and tyrosine kinases belonging to src
family also activate STAT3 either directly or downstream of receptor tyrosine kinases or
G-protein coupled receptors (105, 106). As STAT3 relays proliferative and anti36

apoptotic signals initiated by different cytokines and growth factors in various cell types,
dysregulation of these signaling pathways often leads to constitutive hyper-activation of
STAT3 resulting in oncogenic transformation of various tissues. Increased expression
and activation of STAT3 is associated with multiple types of cancers and besides
mediating pro-proliferative and anti-apoptotic signals, STAT3 also promotes growth and
spread of these cancers by activating expression of genes involved in angiogenesis
and metastasis (106). Development of STAT3 inhibitors is a very active area of cancer
therapeutics and many such drugs are at different stages of pre-clinical and clinical
studies (140).
Natural defense against cancer, the Immune system, whose failure to detect and
destroy transformed cells manifests as the disease, is also under the influence of
STAT3 signaling. Many cytokines responsible for initiating and modulating innate and
adaptive immune responses by inducing differentiation and/or regulating activation of
different types of immune cells mediate their signals through STAT3. Cytokine families
critical for normal immune function such as common γ-chain cytokines (IL-2, IL-7, IL-15
and IL-21), IL-6/gp130 (IL-6, IL-11, IL-27, IL-31, oncostatin M and leukemia inhibitory
factor), IFNs (IFN-α, IFN-β and IFN-ϒ), IL-10 (IL-10, IL-19, IL-20, IL-22, IL-24 and IL26), IL-12, IL- 23, colony stimulating factors (G-CSF and M-CSF) and Flt3 ligand
employ STAT3 down-stream of their receptors (116). These signaling molecules play
an important role in the differentiation, proliferation, survival and modulation of
activation of myeloid and lymphoid cells (116). Cell lineage specific STAT3 deletion in
mice has revealed role of STAT3 signaling in differentiation and function of myeloid and
lymphoid cells. STAT3 signaling plays a critical role in dendritic cell differentiation
(124), neutrophil mobilization (123), and IL-10 mediated negative modulation of
macrophage and neutrophil activity (122). In lymphoid cells, STAT3 signaling is
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required for the generation and maintenance of Th17 cells, a subset of T helper cells
responsible for immune response against bacteria and fungi at epithelial surfaces (117,
118) and T cell dependent differentiation of B cells into plasma cells (121).
Dominant negative mutations in STAT3 cause a sporadic or autosomal dominant
primary immunodeficiency called Job syndrome or Hyper IgE syndrome (HIES)
characterized by immunological features such as eczema, recurrent bacterial and
fungal skin and lung infections and elevated serum IgE as well as non-immunological
manifestations such as facial asymmetry, scoliosis, osteopenia, minor trauma fractures,
hyperextensibility, retention of primary teeth and aneurysms (129-131). Majority of the
STAT3 mutations found in Job syndrome are one amino acid change causing missense
mutations, while few have been found to cause in frame deletion of single amino acid
(129, 132, 141). The mutations are mostly restricted to the DNA binding and SH2
domains, with few in the transcriptional activation domain (142-146). A single mutation
each has been reported in the coiled-coil (145) and linker domain (144). Though most
of the mutations are in the exons, few intronic mutations causing exon-skipping leading
to short in frame deletions have also been reported (142, 145, 146). Despite the large
heterogeneity and their locations in different domains, the mutations have been shown
to act in a dominant negative manner and give rise to the same immunological
phenotype (142, 144, 146). The dominant negative mutations do not totally abolish
STAT3 DNA binding activity in Job syndrome patients. As DNA binding and
transcriptional activation is mediated by STAT3 dimers, the normal STAT3 allele
enables dimer formation between wild type STAT3 and retains residual STAT3 activity,
which is about 25% of the activity found in normal individuals (131).
Since the discovery of deficient STAT3 signaling as a causative factor,
investigations into the pathogenesis of immunological dysfunctions in Job syndrome
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patients have revealed role of STAT3 in the development and function of multiple types
of immune cells. Recurrent bacterial and fungal infections in Job syndrome patients
prompted analysis of Th17 cells, which were found to be absent in these patients.
Cellular and molecular evaluation delineated a direct role of STAT3 in the differentiation
and function of these cells (147, 148). Similarly, inquiries into the molecular
mechanisms underlying defective T cell dependent B cell activation and differentiation
into plasma cells in Job syndrome patients established a fundamental role of STAT3 in
the generation and function of T follicular helper cells (149), while investigations into
the etiology of atopic dermatitis revealed requirement of STAT3 in IL-10 directed
dendritic cell induced differentiation of T regulatory cells (150). Decreased number of
central memory CD4+ and CD8+ cells in Job syndrome patients were pivotal in
deciphering the requirement of STAT3 for the differentiation and proliferation of human
central memory T cells and found to be the causative factor for vulnerability of Job
syndrome patients to the varicella zoster virus and Epstein-Barr virus reactivation
(151). Likewise, efforts to unravel the molecular mechanisms causing deficiency of
memory B cells and antigen dependent antibody production in Job syndrome patients
led to the establishment of role of IL-21 induced STAT3 signaling in the differentiation
of human memory B cells and antigen specific plasma cells from naïve B cells (152,
153). Along with the cells of lymphoid origin, immunological defects in Job syndrome
patients also provided insights into the role of STAT3 in cells of myeloid origin.
Investigations of cellular and molecular mechanisms causing atopic conditions in Job
syndrome patients revealed requirement of STAT3 in IL-10 induced generation of
tolerogenic dendritic cells (150) and in IgE mediated signaling in mast cells (154).
Despite having reactivation of herpes virus infections and increased risk of
malignancies as clinical symptoms (144, 151, 155, 156), surprisingly, the immune cell
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that plays critical role in immune responses against these risks, namely the natural
killer (NK) cell, hasn’t received any research attention in Job syndrome patients.
NK cells, cytotoxic lymphocytes of the innate immune system, play a crucial role
in immune response to viruses and tumors, destroying virally infected cells and
neoplasms. NK cells detect abnormal cells through the interactions of activating
receptors expressed on NK cell surface with their corresponding ligands, whose
expression is generally increased on the surface of stressed cells. A large array of
activating receptors such as natural cytotoxicity receptor (NCR) family (NKp30, NKp44,
NKp46), NKG2D, DNAM1, 2B4, CD160, CD16, CD2, and CD94-NKG2C are expressed
on NK cell surface providing broader ability to detect target cells expressing diverse
types of ligands. Upon binding of activating receptors to their cognate ligands, signals
are transmitted inside NK cells to trigger cytolytic activity. As some of these activating
ligands are expressed by normal cells, to differentiate normal self from abnormal cells,
NK cells are also equipped with cell surface inhibitory receptors such as killer cell
immunoglobulin-like receptors (KIRs) and CD94-NKG2A that recognize major histocompatibility (MHC) class I classical and non-classical ligands on cells and mediate
inhibitory signals to block cytolytic activity of NK cells. Thus, the cytolytic activity of NK
cells is the net result of the balance between the strengths of activating and inhibitory
signals (8). NK cells use multiple ways to kill the target cells. NK cells possess
specialized lysosomal organelles called lytic granules containing cytotoxic molecules.
The process of releasing the lytic content in the extracellular space through lytic
granule exocytosis is called degranulation. The major cytolytic proteins in the lytic
granules are perforin and granzymes. NK cells also express apoptosis inducing ligands
belonging to the tumor necrosis factor (TNF) family viz. FAS ligand (FASL) and TNF
related apoptosis inducing ligand (TRAIL) either in a membrane bound form and/or as a
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part of lytic granules. Of the multiple mechanisms at NK cell’s disposal for target cell
lysis, release of death inducing proteins, perforin and granzymes, into the cleft of the
synapse formed between NK and target cell through the exocytosis of lytic granules, is
the predominant one (6, 157). Upon release, perforin forms pores in the plasma
membrane or in the endosomal membrane and facilitate entry of granzymes into the
cytosol of target cells. Granzymes are serine proteases that induce apoptosis in
caspase dependent and independent manner (157).
The process of directed secretion of cytotoxic molecules at the interface of NK
and target cell through degranulation is a well-regulated multistep process. The
process is set in motion by the initial contact between NK cell and a potential target
cell, which is likely mediated through tethering receptors like CD2 and receptors
belonging to selectin family such as CD62L. Lymphocyte function associated antigen 1
(LFA1; CD11:CD18) and macrophage receptor 1 (MAC1; CD11b:CD18), receptors
expressed on NK cells belonging to integrin family, establish firm adhesion between NK
and target cells through their interactions with intercellular adhesion molecule 1
(ICAM1) expressed on target cells (158). Activating receptors such as NCRs, NKG2D,
DNAM1 also contribute to NK adhesion through their interactions with their
corresponding ligands on target cells and these receptors along with LFA1 transmit
activating signals inside the NK cells to initiate immune synapse formation. The
activating signals trigger F-actin reorganization, which is the first critical step required
for the commitment to synapse formation (159). During the contact between NK and
target cell, along with activating receptors, inhibitory receptors also engage their
cognate ligands on target cells and mediate inhibitory signals. Integration of activating
and inhibitory signals at this stage decides the fate of the immune synapse. Strong
inhibitory signal blocks actin reorganization, clustering of activating receptors and
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thereby prevents further activation of NK cells and synapse maturation, which results in
NK detachment from the target (158). In the absence of overriding inhibitory signals,
activating signals induce formation of polymerized filamentous actin (F-actin) from
monomeric globular actin and accumulation of polymerized actin at the NK cell
synapse. Accumulation of F-actin at the synapse is a pre-requisite for the clustering of
activating receptors. Synergistic signals from the cluster of activating receptors
stimulate polarization of cytolytic granules to the synapse. For directed secretion of
perforin and granzymes into the synaptic cleft, cytolytic granules dispersed throughout
the cell have to be congregated near the synapse. This is achieved first by movement
of granules along microtubules to converge at microtubule organizing center (MTOC), a
cellular structure where microtubule formation begins and from which microtubules
radiate in all directions, and then by polarization of MTOC along with lytic granules to
the synapse. Once near the synapse, the granules traverse the clearings created by Factin remodeling to reach the plasma membrane and secrete their lytic content into the
synaptic cleft through exocytosis (158, 159).
Unlike cytolytic T cells, NK cells do not need prior sensitization with target
antigen before killing a target cell. Upon detecting stress signals through interactions of
NK activating receptors with their cognate ligands on target cells, NK cells deliver their
cytolytic function. This ready to kill approach makes it necessary for NK cells to be
equipped with the detection tool, the activating receptors, and the effector tool, lytic
granules containing perforin and granzymes, while on immunosurvelliance duty.
Surface expression of activating receptors and pre-formation of lytic granules occur as
a result of priming of NK cells by cytokines present in their microenvironment (8). Type
1 interferons (IFNα and IFNβ), common γ-chain cytokines (IL-2, IL-15 and IL-21), IL-6,
IL-12 and IL-18 are known to activate cytolytic capability of NK cells and that is mainly
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achieved through STAT mediated signaling (82, 160). Cytokines induce perforin
expression through STAT mediated signaling. IFNα and IL-6 stimulate perforin gene
expression through STAT1 (83, 161), IL-2 and IL-15 through STAT5 (83, 84, 162),
while IL-12 activates via STAT4 (84). Perforin gene has a STAT binding site in its
enhancer region and cytokines have been shown to induce perforin expression through
STAT mediated transcriptional activation (83, 84). Like perforin, granzyme B
expression has also been demonstrated to be modulated through STAT signaling.
During viral infection, type I IFNs stimulate granzyme B expression in NK cells via
STAT1 signaling (86) and granzyme B production is significantly impaired in STAT1
deficient NK cells in response to viral infection (163). Along with perforin and granzyme,
cytokines also induce expression of activating receptors in NK cells. NKG2D
expression on NK cells is up-regulated in response to IFN-α, IL-2, IL-15 and IL-12 (8790). IL-2 stimulation also increases expression of other activating receptors such as
DNAM1, NKp44 and NKp30 (91). IL-21, which also modulates NK cell cytotoxicity, has
been shown to up-regulate expression of activating receptors NKp30, NKp46, NKG2D
and 2B4 (81, 92). Even though role of STATs in cytokine regulated expression of NK
activating receptors has not been experimentally established yet, given that these
cytokines predominantly signal through STAT family members (104, 116), their role in
the regulation of expression of these receptors is very likely. The critical role played by
STATs in cytokine mediated arming of NK cell for cytotoxicity is reflected in the
impaired cytolytic activity of STAT deficient NK cells. NK cells from STAT1 deficient
mouse and human had lower basal (164-166) as well as induced cytotoxicity,
particularly during viral infections (68, 86, 163). Diminished basal and IL-2 and IL-15
induced cytolytic activity was also observed in NK cells from STAT5b deficient mouse
(162), while IL-12 failed to augment cytotoxicity of NK cells from STAT4 deficient
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mouse (167, 168). Cytokines display signaling promiscuity by activating multiple
STATs. Type 1 interferons (IFNα and IFNβ), common γ-chain cytokines (IL-2, IL-15 and
IL-21), IL-12, IL-18 and IL-10, cytokines known to stimulate cytolytic capability of NK
cells, in addition to other STATs also activate STAT3 in NK cells (80, 136, 161, 169173). Despite being activated by several cytokines critical for NK cytolytic function, very
little research effort has gone into understanding the role of STAT3 signaling in NK
cytotoxicity, particularly in human NK cells.
Beyond serving just the academic interests, investigating the role of STAT3 in
NK cytolytic function has far reaching clinical applications. Constitutively active STAT3
is oncogenic (174). Constitutively active STAT3 drives development, maintenance and
spread of multiple cancers by activating a transcriptional profile that promotes
proliferation, survival, angiogenesis and metastasis (106). Besides malignant cell
intrinsic effects, STAT3 signaling also influences tumor microenvironment. STAT3
plays a critical role in tumor microenvironment to promote tumor growth and is
generally considered to be a negative regulator of immunity against tumor. Tumor
secreted factors such as VEGF, IL-6 and IL-10 activate STAT3 signaling in tumor cells,
which helps them escape immune surveillance and activation of STAT3 by tumor
associated factors in immune cells suppresses their activation and thereby the immune
response (115). Thus, STAT3 plays a crucial role at the interface of tumor biology and
immunity. STAT3 is a major drug target in cancer therapeutics and multiple approaches
to block STAT3 signaling are at different stages of clinical development (106, 140,
175). Equally promising therapeutic prospects against cancer are offered by NK cell
immunotherapy. Equipped with cell surface receptors that detect danger signals on
malignant cells and activate cytolytic activity, the inherent function of NK cells is
immune- surveillance of transformed cells. This innate role of NK cells is evident due to
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the fact that low NK cytotoxicity in peripheral blood is associated with higher incidence
of cancer as was observed in an 11 year follow-up study (30). High levels of tumor
infiltrating NK cells are associated with positive prognosis (31-33). Due to their antitumor activity, NK cells have emerged as candidate effector cells for immune therapy
against cancer. Tumor recognition and rejection by NK cells have been demonstrated
both in vitro and in vivo in mice and rats (20-22). The anti-tumor activity of several
cytokines such as IL-2, IL-12, IL-18 and IL-21 is mediated by NK cells (8, 26). Adoptive
transfer of activated autologous or allogeneic NK cells has proven to be a safe and
potentially efficacious immunotherapy for cancer (36, 37). NK cell therapy has been or
being tested against multiple types of cancers (35). In the light of the role NK cells play
in controlling malignancy, it becomes critical to understand the role of STAT3, which
drives malignant growth and also regulates body’s immune response to it, in NK cell
cytolytic function. It is all the more important when STAT3 inhibition and NK cell
immunotherapy are emerging as treatment modalities for cancer.
Due to the limited number of NK cells in the peripheral blood, expanding NK
cells to a sufficiently large number is imperative to the success of NK cell
immunotherapy. Expanding and activating NK cells ex vivo, before their transfer into
the patients, forms the basis of NK immunotherapy. Research efforts in our lab are
focused on developing an ex vivo NK cell expansion platform. We previously described
robust ex vivo expansion and activation of NK cells by co-cultivation with K562
(erythroleukemic cell line) based artificial antigen presenting cells (aAPC) genetically
modified to express membrane-bound IL-21 (mbIL21) (134). Within the STAT family,
IL-21 activates STAT3 most efficiently (104, 135). Intrigued by this initial finding, our
further investigations revealed that STAT3 signaling activates expression of NKG2D
(136), a primary activating receptor involved in the immune response mediated by NK
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cells to infections and tumors (12). In this study the inquiries have been taken further to
probe the role of STAT3 in NK cytolytic function. Job syndrome patients carrying
dominant negative STAT3 mutations offer a naturally occurring genetic model of
STAT3 deficiency. Employing NK cells from Job syndrome patients and siRNA
mediated STAT3 knock-down in primary human NK cells, I studied role of STAT3 in NK
cytolytic activity and the cellular processes involved in delivering the cytolytic function.
The evidence presented in this study establishes a fundamental role of STAT3 in the
cytotoxicity of human NK cells and the cellular processes underlying it.

2.2 MATERIAL AND METHODS
2.2.1 Cell and Cell Lines
Anonymized normal donor buffy coats were obtained from the Gulf Coast
Regional Blood Center (Houston, TX) under a protocol approved by the Institutional
Review Board (IRB) of UT MD Anderson Cancer Center. Peripheral blood was
obtained from STAT3 genotyped Job’s syndrome patients at National Institute of
Allergy and Infectious Diseases and Children’s Hospital of Philadelphia under protocols
approved by the IRB of each respective institution. IRB approval was obtained from UT
MD Anderson Cancer Center to acquire Job’s syndrome samples from collaborators
and to perform this research. The parental K562 cell line was obtained from the
American Type Culture Collection (ATCC). This study was conducted in accordance
with the Declaration of Helsinki.

2.2.2 PBMC Isolation
Peripheral blood mononuclear cells (PBMCs) from buffy coats and blood
samples were obtained by buoyant density centrifugation on Ficoll-Paque following
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previously described protocol (176). Briefly, buffy coats or blood samples mixed with
phosphate buffer saline (PBS) were loaded on top of Ficoll-Paque in a 50 ml tube and
centrifuged at 400g for 20 minutes without brake. The PBMCs settled at the interface of
Ficoll-Paque and plasma were recovered and washed three times with PBS. The RBCs
settled below Ficoll-Paque were used to isolate NK cells from PBMCs.

2.2.3 NK Cell Purification
NK cells were purified from PBMCs by enriching them to  90% purity
(CD3−CD16/56+) with RosetteSep Human NK Cell Enrichment Cocktail (STEMCELL
Technologies, Vancouver, BC, Canada) following manufacturer’s instructions. In brief,
PBMCs were mixed at 1:100 ratio with red blood cells (RBCs) obtained from the same
sample. To the PBMCs:RBCs mixture, Human NK Cell Enrichment Cocktail was added
at 1 µl/106 PBMCs. The solution was mixed well and incubated at room temperature for
20 minutes with gentle mixing every five minutes. After adding PBS with 2% fetal
bovine serum (FBS) to the PBMCs:RBCs mix, the solution was layered on top of FicollPaque and centrifuged at 400g for 20 minutes. The NK cells were recovered from top
of the Ficoll-Paque layer.

2.2.4 Cell Culture Media
The NK and K562 cells were cultured in RPMI 1640 (Cellgro/Mediatech,
Manassas, VA) supplemented with 10% FBS (HyClone, Logan, UT), 2 mM l-glutamine
(Gibco/Invitrogen, Carlsbad, CA), and 1% penicillin/streptomycin (Cellgro/Mediatech).
This media is hereinafter referred to as NK cell media.
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2.2.5 Antibodies
Fluorochrome conjugated mouse monoclonal antibodies (mAb) against human
CD3, CD11b, CD16, CD25, CD27, CD56, CD57, CD62L, CD69, 2B4, DNAM1, NKG2D,
NKp30, NKp44 and NKp46 were obtained from BD Biosciences (San Jose, CA).
Fluorochrome conjugated mouse monoclonal antibodies against human KIR2DL1,
KIR2DL2/3, KIR3DL1 were obtained from Miltenyi (San Diego, CA). Fluorochrome
conjugated mouse monoclonal antibodies against human CD160 was obtained from
BioLegend (San Diego, CA), while fluorochrome-conjugated mouse monoclonal
antibodies against human NKG2A were obtained from R&D (Minneapolis, MN). Rabbit
monoclonal antibodies against human β-actin and STAT3 were obtained from Cell
Signaling Technology (Danvers, MA).

2.2.6 CD3 Depletion
NK cells expanded from PBMCs were depleted of T cells using magnetic
separation system from Miltenyi Biotec (San Diego, CA) following manufacture’s
protocol. Briefly, cells were stained with CliniMACS CD3 microbeads before loading
them onto the MACS LD separation column. The CD3 microbead stained cells were
separated from rest of the cells using QuadroMACS separator.

2.2.7 Ex vivo Expansion of Human NK Cells
NK cells were expanded as previously described with few modifications (176).
Briefly, PBMCs were co-cultured with irradiated (100 cGy) K562 artificial antigen
presenting cells (aAPCs), genetically modified to express membrane bound IL-21
(mbIL-21), at 1:1 (PBMCs:aAPCs) ratio and 50 U/ml recombinant human IL-2 in a T-75
flasks (Corning, Corning, NY) at 106 cells/ml. The K562s expressing mbIL-21 were
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generated as previously described (134). Culture was refreshed with new media
containing 50 U/ml IL-2 every three to four days. At the end of one week of expansion,
PBMCs were re-stimulated with K562s expressing mbIL-21 and 50 U/ml IL-2.

2.2.8 Cell Count and Cell Viability
Cells were counted using hemocytometer. Cell viability was determined by
Trypan blue exclusion method. Briefly, cells were stained with trypan blue and number
of cells stained blue and total number of cells were counted using hemocytometer.
Percentage viability was calculated using the formula [((Total number of cells-number
of blue cells)/Total number of cells) *100].

2.2.9 Cellular Cytotoxicity Assay
NK cell cytolytic activity was determined using the Calcein-release assay as
previously described (176). Briefly, NK cells treated with STAT3 inhibitor S3I-201 and
NK cells electroporated STAT3 siRNA were co-incubated with the target cells (K562).
Before co-incubation with effector cells, the target cells (K562) were labeled with 2
µg/mL of calcein-AM (Sigma-Aldrich, St. Louis, MO) for 1 hour at 37 °C with occasional
shaking. The target cells were dispensed in a 96 well round bottom microplate in such
a way that each well contained 10000 cells. Effector and target cells were co-incubated
at the indicated effector to target (E:T) ratios at 37 °C for 4 hours in a 96 well round
bottom microplate. After incubation, 100 µL of the supernatant was collected and
transferred to a new plate. Absorbance at 570 nm was determined using a SpectraMAX
plus384 (Molecular Devices, Sunnyvale, CA). Percent specific lysis was calculated
according to the formula [(experimental release-spontaneous release) / (maximum
release – spontaneous release)] x 100.
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2.2.10 Lytic Unit Calculation
To obtain a uniform measure to compare NK cytotoxicity assessed in assays
performed at different times, lytic units were calculated. The number of NK cells
required to kill a specified percentage of target cells was delineated as one lytic unit
(177). To determine the lytic unit, a standard curve was plotted using percent specific
lysis versus the log values of their corresponding E:T ratio for each sample. A specific
percentage of target cell lysis was selected based on the criterion that the standard
curves of all the samples in the relevant data set crossed the reference percentage
exactly once (177). The E:T ratio corresponding to the reference percentage was
interpolated from the standard curve. In the assays, where purified NK cells were used,
the number of NK cells required to kill the specified percentage of target cells was
calculated by multiplying the interpolated E:T ratio by 10000 (the number of target cells
in each well). In the assays, where PBMCs were used, the number of NK cells were
obtained using the formula [(E:T ratio x 10000 x % of NK cells in PBMCs)/100]. Lytic
units per one million cells were obtained according to the formula (1,000,000/number of
NK cells in one lytic unit) (177).

2.2.11 siRNA Mediated Gene Silencing
Primary human NK cells isolated from PBMCs and cultured overnight in
complete NK cell media with 50 U/ml IL-2 were nucleofected with siRNA using Amaxa
human NK cell nucleofector kit from Lonza (Allendale, NJ, USA). Before
electroporation, the cells were spun at 100 g for 10 minutes and washed once with NK
media without serum and antibiotics. The cells were resuspended in human NK cell
nucleofector solution at a density of 3-4 x 106 cells/100 µl. The cell suspension was
mixed with the indicated concentration of On-Targetplus SMART pool siRNA for STAT3
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or On-Targetplus non-targeting SMART pool siRNA for control from Dharmacon
(Pittsburg, PA, USA) in a cuvette supplied with the nucleofector kit. The nucleofection
was performed using program X-01 in an Amaxa Nucleofector from Lonza. Upon
nucleofection, the cells were cultured for 2 hours in NK media without serum and
antibiotics in a 12-well plate. After 2 hours, cells were resuspended in RPMI with 10%
serum and 50 U/ml recombinant human IL-2 (Proleukin, Novartis Vaccines and
Diagnostics, Inc.) at a density of 1x 106 cells/ml. The cells were cultured for 48 hours
before use.

2.2.12 Flow-Cytometry Analysis
Flow cytometry buffer, PBS with 2mM EDTA and 0.1% sodium azide, was
used for blocking, staining, washing and resuspending the cells. Before staining with
antibodies, the cells were blocked with 50% FBS for 30 minutes at 4C. Blocked cells
were stained with appropriate fluorochrome conjugated antibodies for 30 minutes at
4C, washed twice and resuspended in flow cytometry buffer. Data was acquired using
a FACSCalibur cytometer (Becton Dickinson, Franklin Lakes, NJ), and was analyzed
using FlowJo Version 9.2 software (FlowJo, Ashland, OR, USA).

2.2.13 RT-PCR
RNA was isolated using RNeasy plus mini kit from Qiagen (Valencia, CA,
USA) and its concentration was measured using NanoDrop spectrophotometer
(Thermo Scientific, Wilmington, DE). Primers were designed using Primer-BLAST
software (178) available at NCBI website (http://www.ncbi.nlm.nih.gov/tools/primerblast). Semi-quantitative reverse transcription PCR (RT-PCR) was performed using
OneStep RT-PCR kit from Qiagen (Valencia, CA, USA) with primers listed in Table 2.
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The reactions were run in PTC-200 peltier thermal cycler (GMI, Ramsey, MN). The RTPCR products were analyzed by electrophoresis through 1.2% agarose gel. Gel was
imaged in Remi molecular imager using ChemiDoc XRS+ system (Bio-Rad, Hercules,
CA). The RT-PCR bands were quantified using ImageJ software (179).
For quantitative real-time PCR, cDNA was synthesized using SuperScript III first
strand synthesis supermix (Invitrogen, Life technologies, Grand Island, NY). The realtime PCR reaction was set up with cDNA and primers listed in Table 2 using IQ SYBR
green supermix in iCycler real time PCR detection system (Bio-Rad, Hercules, CA).
Relative gene expression was quantified using ΔCT method (180).

2.2.14 Western-Blot Analysis
NK cells were lysed with RIPA buffer (Thermo Fisher Scientific, Grand Island,
NY) supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktail.
The protein was quantified using BCA assay kit (Thermo Fisher Scientific, Grand
Island, NY). Proteins were resolved using sodium dodecyl sulfate- Polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF)
membrane. The membrane was probed first with unconjugated primary and then with
horseradish peroxidase conjugated secondary antibody. The protein on the membrane
was

detected

using

enhanced

chemiluminescence

(ECL)

reagents

following

manufacture’s protocol (Amersham, GE Healthcare Life Sciences, Pittsburgh, PA). The
protein bands were quantified using ImageJ software (179).
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2.2.15 Pharmacological Inhibition of STAT3 in NK Cells
S3I-201 (Calbiochem, Gibbstown, NJ), a small molecule STAT3 inhibitor,
reconstituted in DMSO was used to block STAT3 signaling. Purified NK cells were
incubated overnight with or without S3I-201. The control cells were treated with DMSO.

2.2.16 Single Cell Analysis
The single-cell cytotoxicity assay was performed using fabricated nanowell
arrays as described previously (181, 182). Briefly, K562 tumor cells (targets) and
STAT3 siRNA – or control siRNA- transfected NK cells (effectors) were labeled with 1
µM of red PKH26 and green PKH67 respectively for 2 minutes (Sigma-Aldrich, St.
Louis, MO). NK and K562 cells were loaded sequentially onto the nanowell array at a
concentration of 106 cells/mL, let to settle for 3 minutes and the entire chip was
immersed in phenol red free complete medium containing 1/60 (V/V) AnnexinVAlexaFluor-647 (Life Technologies, Carlsbad, CA). Images were acquired on an
AxioObserver mounted with a 5% CO2, 37 0C and 100% humidity incubator, piloted
with Zen software (Carl Zeiss, Jena, Germany) and fitted with a Hamamatsu Orca
Flash 4.0 sCMOS camera and a 20x 0.8 NA objective. Timelapse imaging microscopy
in nanowell grids (TIMING) images were taken for 8 hours at intervals of 6 minutes and
data were processed and analyzed as described previously (183).
Data were post-processed using Excel and GraphPad Prism. Statistical testing
was run using Fisher’s exact test when contingency numbers were compared.

2.2.17 Analysis of Subcellular Cytolytic Processes
Analysis of synaptic strength, granule convergence to MTOC and MTOC
polarization to the synapse were performed as previously described (184-186). Briefly,
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NK and K562 cells were incubated together in suspension at 2:1 (PBMC:K562) ratio for
15 minutes to form conjugates between the two. The cell suspension was then placed
on poly-L-lysine coated glass slide (Sigma-Aldrich, St. Louis, MO) for 15 minutes to let
the cells adhere to the slide. All the steps were carried out at 37 oC. Cells attached to
the slides were fixed and permeabilized with 4% formaldehyde, 0.1% saponin and
0.1% triton X-100 in PBS for 15 minutes. Before staining with the antibodies, cells were
blocked with 10% heat-inactivated mouse serum (Sigma-Aldrich, St. Louis, MO) for 30
minutes. Blocked cells were first stained with biotinylated anti-tubulin mAb (Invitrogen,
Waltham, MA) for 1 hour followed by rinsing and incubation with streptavidinconjugated Pacific blue 405 (Invitrogen, Waltham, MA). Slides were rinsed and
incubated with Alexa Fluor 568-conjugated phalloidin (Invitrogen, Waltham, MA) and
FITC-conjugated anti-perforin mAb (BD Biosciences, San Jose, CA) for 1 hr. After
rinsing the slides, cells were covered with 0.15 mm glass coverslips (VWR Scientific,
Radnor, PA) using Prolong Antifade reagent (Invitrogen, Waltham, MA) (185).
Cell conjugates were imaged with a laser scanning confocal microscope
(DMIRE2; Leica, Buffalo Grove, IL). The acquired images were analyzed using Volocity
software (PerkinElmer, Waltham, MA). In an image, NK and K562 cells were
distinguished on the basis of size difference (NK cell smaller compared to K562) and
the presence of perforin (present in NK and absent in K562).
To determine actin deposition at the interface of NK and K562, the entire
interface was divided into squares, each measuring 1 μm x 1 μm. In each square,
mean fluorescence intensity (MFI) of phalloidin, which stained F-actin, and the area
occupied by phalloidin were quantified. Actin deposition in the square was estimated by
the formula MFI of phalloidin x area occupied by phalloidin. The actin deposited at the
NK-K562 interface, the immune synapse, was quantified by summing up actin
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deposition in all the squares the interface was divided into. The quantified actin
deposition at the interface included actin deposited by NK and K562. To estimate
contribution of NK cell in actin deposition at the synapse, contribution of K562 to actin
deposition and background actin deposition in unconjugated NK cells were subtracted
from the quantified actin deposition at the interface. K562 contributed actin and
background actin deposition in NK were estimated by quantifying actin deposited in
equal number of squares in the cortex of unconjugated K562 cells and unconjugated
NK cells, respectively (184).
Microtubule organizing center (MTOC) was visualized by staining it with
biotinylated anti-tubulin mAb and streptavidin-conjugated Pacific blue 405. During
image analysis, MTOC was delineated as tubulin labeled region with a pixel size
threshold that eliminated measurement of individual microtubules (185). MTOC
polarization was defined as the distance between MTOC and immune synapse and
was measured by drawing a line between MTOC and the center of immune synapse
using Volocity software (185, 186).
Lytic granules were identified by staining with FITC-conjugated anti-perforin
mAb. Granule convergence to MTOC was defined as the shortest distance between
each individual granule and MTOC in the NK cell in conjugation with K562. To measure
the distance, x and y coordinates of the MTOC and all the lytic granules in the cell were
obtained using Volocity software and the mean MTOC to granule distance (MGD) for
the cell was measured using the following formula (186)
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x and y denote coordinates for the MTOC;

xi and yi denote coordinates of each

individual granule; n denote number of granules in the cell (186).

2.2.18 Statistical Analysis
Statistical analysis was performed for the indicated statistical tests using
GraphPad Prism for Macintosh, version 5.0a. P values <.05 were considered
significant.
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TABLE 2. PRIMERS USED FOR RT-PCR AND REAL TIME PCR ANALYSIS
Primer

Sequence 5’ to 3’

Product
length
(base
pairs)

RT-PCR
STAT1 Forward primer

TCAGGCTCAGTCGGGGAATA

STAT1 Reverse primer

ATCACTTTTGTGTGCGTGCC

STAT3 Forward primer

GGAGCTGGCTGACTGGAAGAG

STAT3 Reverse primer

CTCGATGCTCAGTCCTCGCTTG

STAT5a Forward primer

GAGGATCAAGCGTGCTGACCGGC

STAT5a Reverse primer

TGGTTTCAGGTTCCACAGGTTGC

STAT5b Forward primer

CCGCAATGATTACAGTGGCG

STAT5b Reverse primer

TTCAAGTCTCCCAAGCGGTC

801

856

670

828

Real Time PCR
Arl8B Forward primer

GACTGGTTCCGTTCGCTCTTCTGG

Arl8B Reverse primer

TGACTCCTCTGCAATACCGCTCCC

CIP4 Forward primer

TGGTGAAAAAATATCTGCCCAAGAGAC

CIP4 Reverse primer

CCGGCAGTCCCGCTCAAATT

IQGAP1 Forward primer

GGAGGCACTGGCTAAGACGGAAG

IQGAP1 Reverse primer

TCTCTGCATGGCTCTCTGATGTTCTG

KIF5B Forward primer

AAATAGGAATTGCTGTGGGAAATAATGATG

KIF5B Reverse primer

ATACGAAGCTGACATGCTGCTAACTCC

SKIP Forward primer

AGCTATTTTGCTGCATGTGAGGATGAG

SKIP Reverse primer

CTGGAACAACCGCAGGTAGCTCTC

GAPDH Forward primer

GGAGAAGGCTGGGGCTCATTTG

GAPDH Reverse primer

CTTCTGGGTGGCAGTGATGGC
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241

293

220

217

276

244

2.3 RESULTS
In our previous work, we showed that membrane bound IL-21, a STAT3
activating cytokine, stimulates expression of activating receptors and cytolytic activity of
human NK cells (134) and STAT3 activation plays a critical role in the transcriptional
regulation of basal as well as induced expression of the primary activating receptor
NKG2D in human NK cell (136). As cytolytic activity of NK cells is triggered by the
signals transmitted by the activating receptors upon binding to their cognate ligands on
target cells, our previous findings led me to hypothesize that STAT3 activation may
play a role in the regulation of cytolytic function of NK cells. Availability of NK cells from
Job syndrome patients carrying dominant negative STAT3 mutations (Table 3) offered
me an opportunity to test my hypothesis in a physiologically relevant genetic model.

58

Table 3. STAT3 mutations in Job syndrome patients

Sample ID
Job C001
Job C002
Job C003
Job C004
Job C005
Job C006
Job C007
Job C008
Job C009
Job C010
Job C011
Job C012
Job C013
Job C014

Source
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH
NIAID/NIH

Mutation
Nucleotide, cDNA location
1027 G-T
1144 C-T
1144 C-T
1970 A-G
1909 G-A
2003 C-T
1865 C-T
1387-1389 delGTG
1144 C-T
2137 G-A
1294 G-A
1144 C-T
1145 G-A
1145 R-A

Amino acid
V343P
R382W
R382W
Y657C
V637M
S668F
T622I
V463del
R382W
V713M
V432M
R382W
R382Q
R382Q

Domain
DNA binding
DNA binding
DNA binding
SH2
SH2
SH2
SH2
DNA binding
DNA binding
Transactivation
DNA binding
DNA binding
DNA binding
DNA binding

NIAID: National Institute of Allergy and Infectious Diseases; NIH: National Institute
of Health
Nucleotide Key: A- Adenine, G- Guanine, C- Cytosine, T- Thymine
Amino acid key: C-Cysteine, F- Phenylalanine, I- Isoleucine, M- Methionine,
P- Proline, Q- Glutamine, R- Arginine, S- Serine, T- Threonine, VValine, W- Tryptophan, Y- Tyrosine
del: deletion
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2.3.1 NK Cells from Job Syndrome Patients
2.3.1.1

Impaired Cytotoxicity of NK Cells in Job Syndrome Patients

I assessed basal cytotoxicity of NK cells from Job syndrome patients against
K562, an NK sensitive human erythroleukemic cell line (187), which is a standard target
routinely used to measure NK cytolytic function using purified NK cells (188, 189) as
well as PBMCs (190, 191). Due to limited availability of Job syndrome blood samples,
instead of purified NK cells, PBMCs were used in the cytotoxicity assays. Due to
varying percentage of NK cells in the PBMCs, assays were performed in pairs of
PBMCs from one Job syndrome patient and PBMCs from a normal, healthy donor
containing similar percentage of NK cells (Figure 2a). Number of PBMCs used in the
paired assay was adjusted in order to get identical number of NK cells for both, Job
syndrome and normal donor. Comparison between Job syndrome patient and its
correspondingly matched normal donors showed diminished NK cytotoxicity in Job
syndrome patients over a wide range of effector: target ratios (Figure 2a). As the
assays were performed with PBMCs with varying number of NK cells, for bulk
comparison between all the Job syndrome donors and normal donors, lytic unit, defined
as the number of NK cells required to kill a specified percentage of target cells, was
determined from the cytotoxicity curve of each individual sample. Job syndrome
patients were found to have significantly reduced number of lytic units compared to
normal donors (Figure 2b). These results showed that NK cells with dominant negative
STAT3 mutations have impaired cytolytic function.
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Figure 2. Deficient cytolytic function in NK cells from Job syndrome patients.
(a) Cytotoxicity of NK cells was assessed against K562 using PBMCs employing
calcein release assay at different effector to target ratios (E:T). Assay for each donor
was performed in triplicates for each E:T ratio. Data is presented as mean ± standard
deviation (SD) for each E:T ratio for each donor. Due to varying percentage of NK cells
in the PBMCs, assays were performed in pairs of PBMCs from one Job syndrome
patient and PBMCs from a normal, healthy donor containing similar percentage of NK
cells. Number of PBMCs used in the paired assay was adjusted in order to get identical
number of NK cells for both, Job syndrome and normal donor. Data is presented in a
graphical form by plotting percentage specific lysis against its corresponding E:T ratio.
The flow-cytometry graphs beside the cytotoxicity plots show the percentage of NK
cells (CD3- CD56+) in PBMCs. (b) Significantly reduced number of lytic units in Job
syndrome patients. Lytic unit, defined as the number of NK cells required to kill a
specified percentage of target cells, was determined from the cytotoxicity curve of each
individual sample obtained in the calcein assay. A specific percentage of target cell
lysis was selected based on the criterion that the standard curves of all the samples in
the relevant data set crossed the reference percentage exactly once. Based on this
criterion, number of NK cells required to kill 5% of target cells were defined as one lytic
unit for the comparison between normal donors and Job syndrome patients. The E:T
ratio corresponding to the reference percentage was interpolated from the standard
curve. The number of NK cells were obtained using the formula [(E:T ratio x 10000 x %
of NK cells in PBMCs)/100]. Lytic units per one million NK cells were obtained
according to the formula (1000,000/number of NK cells in one lytic unit). Lytic unit of
each donor is shown along with the mean for the group. P value indicated is for twotailed Student’s t test.
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2.3.1.2

Receptor Expression in NK Cells from Job Syndrome Patients

Target cell lysis by NK cell is the culmination of a complex series of events
mediated by various types of receptors expressed on NK cell surface. Initial tethering
and later firm adhesion with target cell are mediated through adhesion receptors such
as L-selectin (CD62L) and macrophage receptor 1 (CD11b) (158). The activating
receptors upon binding to their ligands transmit signals to activate exocytosis of lytic
granules. Signals relayed by a large array of activating receptors such as natural
cytotoxicity receptor (NCR) family (NKp30, NKp44, NKp46), NKG2D, DNAM1, 2B4 and
CD160, expressed on NK cells, have been shown to induce NK cytotoxicity (14, 15).
Signals transmitted by inhibitory receptors belonging to killer cell immunoglobulin-like
receptor (KIR) family (KIR2DL1, KIR2DL2/3, KIR3DL1) and CD94-NKG2A inhibit the
cytolytic process (15, 192). The cytolytic activity of NK cells is the net result of the
balance between the strengths of activating and inhibitory signals (8). Cytotoxic
potential of mature NK cells is indicated by the expression of low affinity Fc receptor
CD16 (193) and epitope CD57 (194) and the absence of TNF receptor family member
CD27 (195). Priming of NK cells for cytotoxic action is denoted by the expression of
CD69 and absence of CD25 (196).
I assessed expression of the different receptors and maturation and activation
markers in NK cells from Job syndrome patients by flow-cytometry to investigate
whether the deficient cytotoxicity is due to the impaired receptor expression. The cells
were found to have normal expression of all the surface molecules except the
activating receptor NKG2D (Figure 3). Both, number of NK cells expressing NKG2D
(Figure 3a) as well as receptor density per cell (Figure 3b) were found to be
significantly reduced compared to NK cells from normal donors.
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Figure 3. Significantly reduced expression of NKG2D receptor in Job syndrome
patients’ NK cells. Basal expression of receptors showed no difference between NK
cells from normal donors and Job syndrome patients, except NKG2D. Expression of
NKG2D was significantly reduced in Job syndrome patients’ NK cells both in terms of
number of NK cells expressing NKG2D, shown as percentage of NK cells expressing
the receptor, as well as receptor density per cell, depicted as mean fluorescence
intensity (MFI). PBMCs isolated from normal donors and Job syndrome patients were
analyzed by flow-cytometry to assess baseline expression of different types of
receptors on NK cells. In the flow-cytometric analysis of PBMCs, lymphocyte population
was distinguished by their forward scatter and side scatter characteristics and from this
gated population, NK cells were identified by gating CD56 + CD3- cells (a). Expression
of different types of receptors; (a) activating, (c) adhesion (d) maturation markers (e)
priming markers and (f) inhibitory was assessed and depicted as percentage of NK
cells expressing the receptor. Each panel also shows representative flow charts
comparing expression of the receptors in that particular category between a normal
donor and Job syndrome patient. Panel b depicts receptor density per cell, shown as
mean fluorescence intensity (MFI), of NKG2D.
In each graph values for individual donor are shown along with the mean for the group.
P value indicated is for two-tailed Student’s t test.
“The percentage of NK cells expressing NKG2D receptor (Panel a) and NKG2D
MFI (Panel b) shown in this figure were originally published in Blood. Zhu S,
Phatarpekar PV*, Denman CJ, Senyukov VV, Somanchi SS, Nguyen-Jackson HT, Mace EM,
Freeman AF, Watowich SS, Orange JS, Holland SM, Lee DA. Transcription of the activating
receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood.
2014;124(3):403-411. © the American Society of Hematology."
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2.3.1.3

Cellular Processes Involved in Cytolytic Function of Job Syndrome
Patients’ NK Cells

Degranulation at the interface of NK and target cell leading to target cell lysis is
the end result of a series of cellular processes. The process is set in motion by immune
synapse formation between NK and target cells. Accumulation of F-actin at the synapse leads to its maturation. Signals transmitted by activating receptors clustered at the
mature synapse cause convergence of lytic granules dispersed throughout the cell to
MTOC and subsequent polarization of MTOC to synapse for directed secretion of lytic
granule contents into the synaptic cleft. Defect in all or any of these processes affects
NK cytotoxicity (158). To investigate whether these cellular processes are intact in Job
syndrome patients’ NK cells, I studied synaptic strength, granule convergence to
MTOC and MTOC polarization to synapse in fixed conjugates of NK cells with K562 using confocal microscopy
2.3.1.3.1 Synaptic Strength

F-actin accumulation at the interface of NK and target cell is the pivotal step in
synapse formation, which enables clustering of activating receptors and subsequent
integration of activating signals that mediate granule convergence to MTOC and later
MTOC polarization to the synapse (159). As a result, amount of F-actin deposited at
the NK: target interface reflects strength of the synapse and is used as a measure of it
(184). To measure amount of F-actin, in fixed, permeabilized NK: K562 conjugates
fluorescent phalloidin, an F-actin binding peptide (197), was used. The signal intensity
of phalloidin fluorophore at the interface of NK and target and the area occupied by
fluorescent phalloidin at the interface were measured in confocal micrographs. The Factin density at the synapse was estimated by multiplying signal intensity of fluorescent
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phalloidin with the area occupied by F-actin (184). Synapse strength estimated by this
method in >60 conjugates, pooled from four donors each, of Job syndrome patients’
and normal donors’ NK cells showed no difference between the two (Figure 4e). Thus,
upon binding to the target formation of synapse appeared to be normal in Job
syndrome patients’ NK cells.
2.3.1.3.1 Granule Convergence

Directed secretion of perforin and granzyme into the synaptic cleft is initiated by
recruitment of lytic granules dispersed throughout the cell to the MTOC, called as
granule convergence (158). Granule convergence to MTOC was measured as the
distance between a lytic granule, visualized by staining with fluorochrome conjugated
perforin antibody, and the MTOC, visualized by staining with biotinylated conjugated
anti-tubulin antibody and fluorochrome conjugated streptavidin, in a confocal
micrograph of a fixed conjugate between NK and K562. Average of granule-MTOC
distance for all the granules in a cell was denoted as the mean granule to MTOC
distance for the cell. Granule convergence measured in >60 conjugates, pooled from
four donors each, of Job syndrome patients and normal donors NK cells showed no
difference between the two (Figure 4f).
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Figure 4. Normal actin deposition at the synapse and granule convergence to
microtubule organizing center (MTOC), but impaired MTOC polarization in Job
syndrome patients’ NK cells. PBMCs and K562 cells were incubated together to
facilitate conjugate formation between the two. The cells were placed on poly-L-lysine
coated glass slides. The cells attached to the slide were permeabilized and stained with
fluorochrome conjugated phalloidin, fluorochrome conjugated anti-perforin antibody and
biotinylated anti-tubulin antibody and fluorochrome-conjugated streptavidin. Phalloidin,
anti-tubulin and anti-perforin were used to stain F-actin, MTOC and lytic granules,
respectively. The conjugates were imaged using scanning confocal microscope. The
images were analyzed using Volocity software. Representative brightfield image and its
corresponding confocal image show conjugate formed between an NK cell from normal
donor and K562 (a and b) and an NK cell from Job syndrome patient and K562 (c and
d). In the image, NK cell was distinguished from K562 on the basis of cell size (NK
smaller compared to K562) and the presence of perforin (present in NK and absent in
K562). F-actin deposited at the interface of the conjugate, immune synapse, is stained
with phalloidin (red). MTOC is stained with anti-tubulin (yellow) and lytic granules are
stained with anti-perforin (green). (e) Synaptic strength was measured in terms of
amount F-actin deposited at the interface of NK and K562. To quantify F-actin, signal
intensity of phalloidin fluorophore at the interface of NK and target and the area
occupied by fluorescent phalloidin at the interface were measured in confocal
micrographs using Volocity software. The F-actin density at the synapse was estimated
by multiplying signal intensity of fluorescent phalloidin with the area occupied by Factin. Synapse strength estimated by this method in conjugates, pooled from four
donors each, of normal donors and Job syndrome patients is represented in graphical
form. (f) Granule convergence to MTOC was defined as the shortest distance between
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each individual granule and MTOC in the NK cell in conjugation with K562. Lytic
granules were identified by staining with anti-perforin antibody and MTOC was
recognized by staining with anti-tubulin antibody. The distance between MTOC and
each lytic granule in a conjugated NK cell was measured using Volocity software.
Average of granule-MTOC distance for all the granules in a cell was denoted as the
mean granule to MTOC distance for the cell. Granule convergence measured in
conjugates, pooled from four donors each, of normal donors and Job syndrome
patients is represented in graphical form. Each data point represents mean granule to
MTOC distance for an individual NK cell in conjugation with K562. (g) MTOC
polarization was defined as the distance between the MTOC of an NK cell, visualized
by staining with anti-tubulin antibody, and the immune synapse, demarcated as the
contact area between the NK and K562 in a conjugate and stained with fluorochrome
conjugated phalloidin. The distance was measured by drawing a line between the
MTOC and the center of immune synapse in a confocal image using Volocity software.
MTOC polarization measured in conjugates, pooled from four donors each, of normal
donors and Job syndrome patients is represented in graphical form.
In each graph mean for the group is denoted. P value indicated is for two-tailed
Student’s t test.

Confocal microscopic analysis of subcellular cytolytic processes and data
processing were performed by my collaborator, Dr. Malini Mukherjee in Dr.
Jordan Orange laboratory at the section of Immunology, Allergy, and
Rheumatology, Baylor College of Medicine, Houston, Texas.
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2.3.1.3.2 MTOC Polarization to the Synapse

Signals transmitted by activating receptors, clustered at the mature synapse,
induce migration of MTOC in NK cell towards the synapse. MTOC along with it also
brings the converged granules to the synapse. It is a critical step in the directed
secretion of lytic content (185). MTOC polarization to the synapse was assessed by
measuring the distance between the MTOC and the center of the synapse in confocal
micrographs of NK cells conjugated with K562. MTOC polarization measured in >60
conjugates, pooled from four donors each, of Job syndrome patients and normal
donors NK cells showed MTOC to be at a significantly greater distance from the
synapse in Job syndrome patients NK cells compared to normal donors (Figure 4g).
The larger distance between the MTOC and synapse in Job syndrome patients’ NK
cells indicated impaired polarization of MTOC and lytic granules.
Thus, even though the initial events of synapse formation and granule
convergence occurred normally, transport of lytic cargo to the synapse was found to be
defective in NK cells from Job syndrome patients.

2.3.2 STAT3 Knock-Down in NK Cells
To corroborate my finding of impaired cytotoxicity and cellular processes
involved in cytolytic function in NK cells with dominant negative STAT3 mutations and
to obtain unequivocal evidence for the role of STAT3 in the regulation of NK cytolytic
function, I also evaluated cytolytic function in STAT3 knock-down (STAT3 KD) primary
human NK cells.
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2.3.2.1

siRNA Mediated Knock-Down of STAT3

Purified human NK cells from normal donors maintained overnight with 50 U/ml
IL-2 were electroporated with control and STAT3 siRNA and cultured thereafter with 50
U/ml IL-2 for 48 hours before analysis. Calibration of STAT3 siRNA concentration
showed incremental decrease in STAT3 mRNA expression in RT-PCR analysis.
However, at concentration above 0.25 μm along with STAT3, GAPDH mRNA also
started decreasing indicating non-specific effect (Figure 5a). As a result, 0.25 μm
siRNA was used for rest of the studies. At 0.25 μm siRNA, STAT3 mRNA expression,
quantified by ImageJ software and normalized to GAPDH, showed about 80%
decrease compared to control siRNA (Figure 5a and 5b). STAT3 protein expression
analyzed by western-blot also showed a corresponding decrease (Figure 5c). RT-PCR
analysis showed no effect of STAT3 siRNA on the expression of STAT1, STAT5a and
STAT5b mRNA (Figure 5b), STAT family members closely related to STAT3 (198,
199). Cell viability, analyzed by trypan blue exclusion method, was not affected by
STAT3 knock-down 48 hr post electroporation (Figure 5d).
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Figure 5. STAT3 siRNA mediated about 80% decrease in STAT3 mRNA and
protein expression in primary human NK cells without any effect on the
expression of other STATs and cell viability. Purified human NK cells from normal
donors maintained overnight with 50 U/ml IL-2 were electroporated with control or
STAT3 siRNA and cultured thereafter with 50 U/ml IL-2 for 48 hours before analysis.
Knock-down of mRNA was assessed by semi-quantitative RT-PCR using gene specific
primers. The RT-PCR products were analyzed by electrophoresis through 1.2%
agarose gel. Gel was imaged and the RT-PCR bands were quantified using ImageJ
software. Relative band intensities of target genes were normalized to GAPDH and
converted to percentage expression by considering expression in control siRNA treated
cells as 100%. (a) Calibration of STAT3 siRNA concentration showed incremental
decrease in STAT3 mRNA as visualized in the gel image and its quantification plotted
as percentage STAT3 expression. However, at concentration above 0.25 μm along
with STAT3, GAPDH mRNA also started decreasing indicating non-specific effect. As a
result, 0.25 μm siRNA concentration was used for rest of the studies (b) mRNA levels
of STAT3, STAT1, STAT5a, STAT5b, and GAPDH in NK cells electroporated with 0.25
μm siRNA were analyzed by semi-quantitative RT-PCR. The gels were imaged and the
bands were quantified as described above. The gel image shown is a representative of
multiple experiments. The graph beside the gel depicts quantification of RT-PCR bands
normalized to GAPDH and represented as percentage expression. N denotes number
of times the experiment was repeated (c) STAT3 knock down was also analyzed at the
protein level by western-blot. Protein lysate, 15 μg/lane, resolved by SDS-PAGE and
transferred to PVDF membrane, was probed with anti-STAT3 and anti-β-actin (loading
control) antibodies. The bands were quantified by ImageJ software. Relative band
intensities were normalized to β-actin and converted to percentage expression by
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considering expression in control siRNA treated cells as 100%. The upper panel shows
western gel image and lower panel depicts quantification in graphical form (d) Cell
viability of siRNA treated cells was assessed by trypan blue exclusion method. N
denotes number of times the experiment was repeated.
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2.3.2.2

Impaired Cytotoxicity of STAT3 Knock-Down NK Cells

Assessment of cytolytic activity by calcein release assay against K562 revealed
small but consistent decrease in cytotoxicity of STAT3 knock-down NK cells compared
to control cells over a wide range of E:T ratios (Figure 6a). Comparison between
control cells and STAT3 knock-down cells also showed significantly diminished number
of lytic units in the latter (Figure 6b).
2.3.2.3

Single Cell Analysis of Cytotoxicity of STAT3 Knock-Down NK Cells

In bulk electroporation, as was performed in the present study to knock-down
STAT3 in primary human NK cells, all the cells may not be electroporated, leaving
some cells without knock-down of the target mRNA. These cells, electroporated in bulk,
if used in a bulk assay such as the calcein assay employed in the present study to
assess the cytotoxicity of NK cells, then the cells with intact STAT3, even if few, could
skew the output. The possibility of existence of cells with intact STAT3 in STAT3 knockdown bulk population may explain the difference between the cytotoxicity of control
cells and STAT3 knock-down cells being smaller as these cells with intact killing
capacity through encounters with multiple target cells may compensate for the cytolytic
deficiency of rest of the cells. Therefore, cytotoxicity of STAT3 knock-down NK cell at a
single cell level was also analyzed. NK cell and K562 cell interactions were studied
using the single cell assay, TIMING (Timelapse Imaging Microscopy in Nanowell
Grids), as described previously (182) (Figure 7a). Among NK cells that established at
least one contact with the target cell (K562) in nanowells containing exactly 1 NK cell
and 1 K562 cell (number of nanowells=791 and 1010, respectively for conditions with
STAT3 knock-down and control NK cells), STAT3 knock-down NK cells were able to
perform lysis (detected using Annexin V staining) at a lower frequency (35%) compared
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to control NK cells (43%) (Figure 7b). Serial killing ability of NK cells was also assessed
by measuring killing frequency in nanowells containing exactly 1 NK cell and 2 K562
cells and where NK cell made at least 2 contacts with the target cells (number of
nanowells=463 and 388, respectively for conditions with STAT3 knock-down and
control NK cells). STAT3 knock-down NK cells were able to perform lysis of both the
target cells at a lower frequency (28.7%) compared to control NK cells (37.4%) (Figure
7c).

79

Figure 6. Impaired cytolytic function in STAT3 knock-down NK cells.
(a) Purified human NK cells from normal donors maintained overnight with 50 U/ml IL-2
were electroporated with control or STAT3 siRNA and cultured thereafter with 50 U/ml
IL-2 for 48 hours before assessment of their cytotoxicity against K562 using calcein
assay. Assay for each donor was performed in triplicates for each E:T ratio. Data is
presented as mean ± standard deviation (SD) for each E:T ratio for each donor. The
experiment was repeated three times with three different donors.
(b) Lytic unit, defined as the number of NK cells required to kill a specified percentage
of target cells, was determined from the cytotoxicity curve of each individual sample
obtained in the calcein assay. A specific percentage of target cell lysis was selected
based on the criterion that the standard curves of all the samples in the relevant data
set crossed the reference percentage exactly once. Based on this criterion, number of
NK cells required to kill 75% of target cells were defined as one lytic unit for the
comparison between control and STAT3 knock-down (STAT3 KD). The E:T ratio
corresponding to the reference percentage was interpolated from the standard curve.
The number of NK cells in the lytic unit were obtained by multiplying the interpolated
E:T ratio by 10000 (the number of target cells in each well). Lytic units per one million
NK cells were obtained according to the formula (1,000,000/number of NK cells in one
lytic unit). Lytic unit of each donor is shown along with the mean for the group. P value
indicated is for two-tailed paired Student’s t test.
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Figure 7. Analysis of cytotoxicity at the single cell level demonstrated cytolytic
function and serial killing ability of STAT3 knock-down NK cells to be impaired.
The single-cell cytotoxicity assay was performed using fabricated nanowell arrays.
STAT3 siRNA – or control siRNA- electroporated NK cells (effectors) and K562 cells
(targets), labeled with green PKH67 and red PKH26, respectively, were loaded
sequentially onto the nanowell array. The entire array chip was immersed in phenol red
free complete medium containing AnnexinV-AlexaFluor-647. Timelapse imaging
microscopy in nanowell grids (TIMING) images were taken for 8 hours at intervals of 6
minutes (a) Representative example of a nanowell containing a K562 cell (red, stained
with PKH red) and a control NK cell (green, stained with PKHgreen). Scale bar 10 µm
(b) Among NK cells that established at least one contact with the target cell in
nanowells containing exactly 1 NK cell and 1 K562 cell (E:T -1:1), cytotoxicity of NK cell
was assessed by detecting lysis of K562, identified using Annexin V staining, and by
counting the number of wells in which the lysis occurred. The tabular presentation of
the data shows the total number of wells, the number of wells in which the target was
killed and not killed and the percentage of target cells killed for STAT3 knock-down
(STAT3 KD) and control conditions. The charts beside the tables represent the same
data in a graphical form (c) The serial killing ability of NK cells was assessed by
measuring killing frequency in nanowells containing exactly 1 NK cell and 2 K562 cells
(E:T-1:2) and where NK cell made at least 2 contacts with the target cells resulting in
the death of both. The tabular presentation of the data shows the total number of wells,
the number of wells in which the target was killed and not killed and the percentage of
target cells killed for STAT3 knock-down (STAT3 KD) and control conditions. The
charts beside the tables represent the same data in a graphical form. P values
indicated are for Fisher’s exact test used for the analysis of contingency tables.
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The single cell cytotoxicity assay was performed by collaborators Drs.
Gabrielle Romain and Navin Varadrajan at the Department of Chemical and
Biomolecular Engineering, University of Houston, Houston, TX.
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2.3.2.1

Receptor Expression in STAT3 Knock-Down NK Cells

No difference in the expression of adhesion, activating and inhibitory receptors
and maturation and activation markers was observed between STAT3 knock-down NK
cells and control cells (Figure 8a-e). Unlike in Job syndrome patients’ NK cells, NKG2D
was normally expressed in STAT3 knock-down NK cells (Figure 8a).
2.3.2.2

Cellular Processes Involved in Cytolytic Function of STAT3 KnockDown NK Cells
Analysis of synapse strength, granule convergence and MTOC polarization in

STAT3 knock-down NK cells showed recapitulation of cellular process phenotype that
was observed in Job syndrome patients’ NK cells.
Synapse strength measured in terms of actin density at the synapse was found
to be no different between STAT3 knock-down NK cells and control cells conjugated
with K562, indicating no effect of STAT3 deficiency on synapse strength (Figure 9e and
h).
Comparison of granule convergence estimated as the average of lytic granule to
MTOC distance for all the granules in the cell was found to be greater in STAT3 knockdown NK cells compared to control cells. However, the difference was statistically not
significant (Figure 9f and I).
MTOC polarization to the synapse assessed by measuring the distance between
the MTOC and the center of the synapse was found to be significantly greater in
STAT3 knock-down NK cells compared to normal donors (Figure 9g and J). This
finding corroborated impaired MTOC polarization observed in NK cells from Job
syndrome patients and revealed requirement of STAT3 for this cellular process.
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Figure 8. No difference in the expression of receptors between control and
STAT3 knock-down (STAT3 KD) NK cells. Purified human NK cells from normal
donors maintained overnight with 50 U/ml IL-2 were electroporated with control or
STAT3 siRNA and cultured thereafter with 50 U/ml IL-2 for 48 hours before assessment
of expression of different types of receptors by flow-cytometry. In the flow-cytometric
analysis, lymphocyte population was distinguished by their forward scatter and side
scatter characteristics and from this gated population, NK cells were identified by gating
CD56+ CD3- cells (a). Expression of different types of receptors; (a) activating, (b)
adhesion (c) maturation markers (d) priming markers and (e) inhibitory was assessed
and depicted as percentage of NK cells expressing the receptor. Each panel also
shows representative flow charts comparing expression of the receptors in that
particular category between control and STAT3 knock-down (STAT3 KD) NK cells. In
each graph values for individual donor are shown along with the mean for the group.
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Figure 9. Normal actin deposition at the synapse and granule convergence, but
impaired microtubule organizing center (MTOC) polarization in STAT3 knockdown NK cells. Purified human NK cells from normal donors maintained overnight
with 50 U/ml IL-2 were electroporated with control or STAT3 siRNA and cultured
thereafter with 50 U/ml IL-2 for 48 hours before assessment of cellular processes
involved in cytolytic function. NK and K562 cells were incubated together to facilitate
conjugate formation between the two. The cells were placed on poly-L-lysine coated
glass slides. The cells attached to the slide were permeabilized and stained with
fluorochrome conjugated phalloidin, fluorochrome conjugated anti-perforin antibody and
biotinylated anti-tubulin antibody and fluorochrome conjugated streptavidin. Phalloidin,
anti-tubulin and anti-perforin were used to stain F-actin, MTOC and lytic granules,
respectively. The conjugates were imaged using scanning confocal microscope. The
images were analyzed using Volocity software. The experiment was repeated two
times with two different donors. Representative brightfield image and its corresponding
confocal image show conjugate formed between a control NK cell and K562 (a and b)
and a STAT3 knock-down NK cell and K562 (c and d). In the image, NK cell was
distinguished from K562 on the basis of cell size (NK smaller compared to K562) and
the presence of perforin (present in NK and absent in K562). F-actin deposited at the
interface of the conjugate, immune synapse, is stained with phalloidin (red). MTOC is
stained with anti-tubulin (yellow) and lytic granules are stained with anti-perforin
(green). (e,h) Synaptic strength was measured in terms of amount F-actin deposited at
the interface of NK and K562. To quantify F-actin, signal intensity of phalloidin
fluorophore at the interface of NK and target and the area occupied by fluorescent
phalloidin at the interface were measured in confocal micrographs using Volocity
software. The F-actin density at the synapse was estimated by multiplying signal
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intensity of fluorescent phalloidin with the area occupied by F-actin. Synapse strength
estimated by this method in conjugates is represented in graphical form. (f,i) Granule
convergence to MTOC was defined as the shortest distance between each individual
granule and MTOC in the NK cell in conjugation with K562. Lytic granules were
identified by staining with anti-perforin antibody and MTOC was recognized by staining
with anti-tubulin antibody. The distance between MTOC and each lytic granule in a
conjugated NK cell was measured using Volocity software. Average of granule-MTOC
distance for all the granules in a cell was denoted as the mean granule to MTOC
distance for the cell. Granule convergence measured in conjugates is represented in
graphical form. Each data point represents mean granule to MTOC distance for an
individual NK cell in conjugation with K562. (g,j) MTOC polarization was defined as the
distance between the MTOC of an NK cell, visualized by staining with anti-tubulin
antibody, and the immune synapse, demarcated as the contact area between the NK
and K562 in a conjugate and stained with fluorochrome conjugated phalloidin. The
distance was measured by drawing a line between the MTOC and the center of
immune synapse in a confocal image using Volocity software. MTOC polarization
measured in conjugates is represented in graphical form.
In each graph mean for the group is denoted. P value indicated is for two-tailed
Student’s t test.
Confocal microscopic analysis of subcellular cytolytic processes and data
processing were performed by my collaborator, Dr. Malini Mukherjee in Dr.
Jordan Orange laboratory at the section of Immunology, Allergy, and
Rheumatology, Baylor College of Medicine, Houston, Texas.
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2.3.3 Molecular Mechanism Underlying Impaired MTOC Polarization
Upon converging to the MTOC, lytic granules along with MTOC start polarizing
toward the immune synapse. The molecular players involved in this mobilization have
been identified. CDC42 interacting protein 4 (CIP4), is one of the essential components
of the molecular machinery driving MTOC polarization. Silencing of CIP4 expression in
NK cells inhibits MTOC polarization (185). Lytic granules and MTOC polarize to
immune synapse by moving along microtubules with the help of the motor protein
kinesin family member 5B (KIF5B). A lytic granule associated small G-protein, ADPribosylation factor like 8b (Arl8b), links the lytic granule to KIF5B. Silencing of Arl8b and
KIF5B in NK cells impairs lytic granule and MTOC polarization to the immune synapse
signifying their key role in the process (200). Another member of the MTOC polarizing
machinery is IQGAP1, a multi-domain scaffolding protein that interacts with both Factin and microtubules, whose silencing also inhibits MTOC polarization (201).
To investigate the cause for impaired MTOC polarization in STAT3 knock-down
NK cells, I analyzed gene expression of Arl8b, KIF5B, CIP4 and IQGAP1 by real-time
PCR. Expression of Arl8b, KIF5B and IQGAP1 was similar in STAT3 knock-down and
control cells (Figure 10a-c). But the expression of CIP4 was significantly lower in
STAT3 knock-down cells (Figure 10d), suggesting it as a likely cause for impaired
MTOC polarization in STAT3 knock-down NK cells.
I also assessed expression of CIP4 in Job syndrome patients’ NK cells.
However, unlike STAT3 knock-down NK cells, CIP4 gene expression was found to be
normal in Job syndrome patients’ NK cells (Figure 10e). This result indicated that a
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different mechanism is responsible for impaired MTOC polarization in Job syndrome
patients’ NK cells.
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Figure 10. No difference in the gene expression of Arl8b, IQGAP1 and KIF5B,
molecules involved in MTOC polarization, between control and STAT3 knockdown (STAT3 KD) NK cells, except significantly reduced gene expression of
CIP4, another molecule required for MTOC polarization, in STAT3 KD NK cells,
but not in NK cells from Job syndrome patients. Purified human NK cells from
normal donors maintained overnight with 50 U/ml IL-2 were electroporated with control
or STAT3 siRNA and cultured thereafter with 50 U/ml IL-2 for 48 hours before
assessment of gene expression by real-time PCR. For real-time PCR, cDNA was
synthesized using SuperScript III first strand synthesis supermix. The real-time PCR
reaction was set up with cDNA and primers listed in Table 2 using IQ SYBR green
supermix in iCycler real time PCR detection system. Relative gene expression was
quantified using ΔCT method with GAPDH as the housekeeping gene. Gene expression
of (a) Arl8b (b) CIP4 (c) IQGAP1 and (d) KI5FB was measured. (e) CIP4 gene
expression was also evaluated in NK cells from normal donors and Job syndrome
patients.
In each graph values for individual donor are shown along with the mean for the group.
P value indicated is for two-tailed paired Student’s t test.
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Real-time PCR
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2.3.3.1 mbIL21 Expanded Job Syndrome Patients’ NK Cells
Previous work in our lab demonstrated robust expansion of human NK cells
stimulated with K562 genetically modified to present membrane bound IL-21 (mbIL21).
These expanded cells had high expression of activating receptors and enhanced
cytolytic activity (134). IL-21 predominantly activates STAT3 in NK cells (80, 136, 171)
and as expected mbIL21 induced expansion and activation of NK cells is mediated
through STAT3 signaling (202). Job syndrome patients have residual STAT3 activity,
which is 25% of the normal (131). To explore whether stimulation of the residual STAT3
activity by mbIL21 improves deficient NKG2D receptor expression, MTOC polarization
and cytotoxicity of Job syndrome patients’ NK cells, I expanded NK cells from PBMCs
of normal donors and Job syndrome patients, by stimulating them with mbIL21 over
three weeks. After three weeks of expansion, T cells were depleted to obtain pure NK
cell population.
2.3.3.2

Receptor Expression in mbIL21 Expanded NK Cells

mbIL21 expanded NK cells showed increased expression of all the activating
receptors analyzed except CD160 over basal expression. CD160 expression
decreased after expansion. Deficient basal expression of NKG2D in Job syndrome
patients’ NK cells was restored in mbIL21 expanded NK cells. Almost entire NK cell
population was NKG2D positive and no difference in expression was observed
between NK cells from Job syndrome patients and normal donors. Expression levels of
other activating receptors were also found to be similar between NK cells from Job
syndrome patients and normal donors, except NKp46 and CD160 (Figure 11a). NKp46
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expression was significantly higher in Job syndrome patients’ NK cells, while CD160
expression was significantly higher in NK cells from normal donors (Figure 11a-b).
Compared to basal expression levels, expression of adhesion receptors, CD11b and
CD62L, decreased in mbIL21 expanded NK cells. No difference in the expression of
CD11b was found between NK cells from Job syndrome patients and normal donors,
but CD62L expression was significantly higher in NK cells from normal donors (Figure
11c-d). Among maturation markers, compared to basal expression levels, CD16
expression showed increased, while CD27 and CD57 expression decreased in mbIL21
expanded NK cells. No difference in expression was observed between NK cells from
Job syndrome patients and normal donors (Figure 11e). Expression of activation
marker CD25 did not change upon expansion, while CD69 expression increased over
the basal levels. No difference in expression was observed between NK cells from Job
syndrome patients and normal donors (Figure 11f). Expression of all the inhibitory
receptors assessed increased in mbIL21 expanded NK cells and similar expression
levels were observed in NK cells from Job syndrome patients and normal donors
(Figure 11g).
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Figure 11. Job syndrome NK cells expanded with mbIL21 stimulation had
enhanced expression of NKG2D receptor, which was similar to the expression of
NKG2D in mbIL21 expanded NK cells from normal donors. The level of
expression of other receptors in mbIL21 expanded NK cells was also similar
between Job syndrome and normal donors, except NKp46, whose expression
was higher in the former and CD160 and CD62L, whose expression was higher in
the latter. NK cells were expanded from PBMCs stimulated with K562s, genetically
modified to present membrane bound IL-21 (mbIL21), over a three week period.
Receptor expression was measured by flow-cytometry. In the flow-cytometric analysis,
lymphocyte population was distinguished by their forward scatter and side scatter
characteristics and from this gated population, NK cells were identified by gating CD56 +
CD3- cells (a). Expression of different types of receptors; (a) activating, (c) adhesion (e)
maturation markers (f) priming markers and (g) inhibitory was assessed and depicted
as percentage of NK cells expressing the receptor. Each panel also shows
representative flow charts comparing expression of the receptors in that particular
category between a normal donor and Job syndrome patient. Panel b depicts receptor
density per cell, shown as mean fluorescence intensity (MFI), of NKp46 and CD160.
Panel d portrays MFI of CD62L.
In each graph values for individual donor are shown along with the mean for the group.
P values indicated are for two-tailed Student’s t test.
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2.3.3.3

Cellular Processes Involved In Cytolytic Function of mbIL21
Expanded NK Cells

Comparison between mbIL21 expanded NK cells from Job syndrome patients
and normal donors, pooled from three donors each, showed no difference in the
synaptic strength and granule convergence (Figure 12e-f). Impaired MTOC polarization
observed in un-stimulated Job syndrome patients’ NK cells were corrected in the
mbIL21-expanded cells. The MTOC to synapse distance was similar in NK cells from
Job syndrome patients and normal donors after mbIL21 expansion (Figure 12g).
2.3.3.4

Cytotoxicity of mbIL21 Expanded NK Cells

mbIL21 expanded NK cells from Job syndrome patients and normal donors
showed enhanced cytotoxicity. The cytotoxicity of NK cells from normal donors was
marginally higher than the NK cells from Job syndrome patients (Figure 13a). NK cells
from normal donors had marginally higher number of lytic units than NK cell from Job
syndrome patients, but the difference was statistically not significant (Figure 13b).
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Figure 12. Impaired MTOC polarization observed in un-stimulated Job syndrome
patients’ NK cells was corrected in the mbIL21 expanded cells. The MTOC to
synapse distance was similar in NK cells from Job syndrome patients and
normal donors after mbIL21 expansion. NK cells were expanded from PBMCs
stimulated with K562s, genetically modified to present membrane bound IL-21
(mbIL21), over a three week period. NK and K562 cells were incubated together to
facilitate conjugate formation between the two. The cells were placed on poly-L-lysine
coated glass slides. The cells attached to the slide were permeabilized and stained with
fluorochrome conjugated phalloidin, fluorochrome conjugated anti-perforin antibody and
biotinylated anti-tubulin antibody and fluorochrome conjugated streptavidin. Phalloidin,
anti-tubulin and anti-perforin were used to stain F-actin, MTOC and lytic granules,
respectively. The conjugates were imaged using scanning confocal microscope. The
images were analyzed using Volocity software. Representative brightfield image and its
corresponding confocal image show conjugate formed between an NK cell from normal
donor and K562 (a and b) and an NK cell from Job syndrome patient and K562 (c and
d). In the image, NK cell was distinguished from K562 on the basis of cell size (NK
smaller compared to K562) and the presence of perforin (present in NK and absent in
K562). F-actin deposited at the interface of the conjugate, immune synapse, is stained
with phalloidin (red). MTOC is stained with anti-tubulin (yellow) and lytic granules are
stained with anti-perforin (green). (e) Synaptic strength was measured in terms of
amount F-actin deposited at the interface of NK and K562. To quantify F-actin, signal
intensity of phalloidin fluorophore at the interface of NK and target and the area
occupied by fluorescent phalloidin at the interface were measured in confocal
micrographs using Volocity software. The F-actin density at the synapse was estimated
by multiplying signal intensity of fluorescent phalloidin with the area occupied by F102

actin. Synapse strength estimated by this method in conjugates, pooled from three
donors each, of normal donors and Job syndrome patients is represented in graphical
form. (f) Granule convergence to MTOC was defined as the shortest distance between
each individual granule and MTOC in the NK cell in conjugation with K562. Lytic
granules were identified by staining with anti-perforin antibody and MTOC was
recognized by staining with anti-tubulin antibody. The distance between MTOC and
each lytic granule in a conjugated NK cell was measured using Volocity software.
Average of granule-MTOC distance for all the granules in a cell was denoted as the
mean granule to MTOC distance for the cell. Granule convergence measured in
conjugates, pooled from three donors each, of normal donors and Job syndrome
patients is represented in graphical form. Each data point represents mean granule to
MTOC distance for an individual NK cell in conjugation with K562. (g) MTOC
polarization was defined as the distance between the MTOC of an NK cell, visualized
by staining with anti-tubulin antibody, and the immune synapse, demarcated as the
contact area between the NK and K562 in a conjugate and stained with fluorochrome
conjugated phalloidin. The distance was measured by drawing a line between the
MTOC and the center of immune synapse in a confocal image using Volocity software.
MTOC polarization measured in conjugates, pooled from three donors each, of normal
donors and Job syndrome patients is represented in graphical form.
Confocal microscopic analysis of subcellular cytolytic processes and data
processing were performed by my collaborator, Dr. Malini Mukherjee in Dr.
Jordan Orange laboratory at the section of Immunology, Allergy, and
Rheumatology, Baylor College of Medicine, Houston, Texas.
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Figure 13. Job syndrome NK cells expanded with mbIL21 stimulation had
enhanced cytotoxicity, which was marginally lower than the cytotoxicity of
mbIL21 expanded NK cells from normal donors (a) NK cells were expanded from
PBMCs stimulated with K562s, genetically modified to present membrane bound IL-21
(mbIL21), over a three week period. The expanded cells were CD3 depleted.
Cytotoxicity was assessed using calcein assay. Assay for each donor was performed in
triplicates for each E:T ratio. Data is presented as mean ± standard deviation (SD) for
each E:T ratio for each donor. (b) Lytic unit, defined as the number of NK cells required
to kill a specified percentage of target cells, was determined from the cytotoxicity curve
of each individual sample obtained in the calcein assay. A specific percentage of target
cell lysis was selected based on the criterion that the standard curves of all the
samples in the relevant data set crossed the reference percentage exactly once. Based
on this criterion, number of NK cells required to kill 75% of target cells were defined as
one lytic unit for the comparison between control and STAT3 knock-down (STAT3 KD).
The E:T ratio corresponding to the reference percentage was interpolated from the
standard curve. The number of NK cells in the lytic unit were obtained by multiplying
the interpolated E:T ratio by 10000 (the number of target cells in each well). Lytic units
per one million NK cells were obtained according to the formula (1000,000/number of
NK cells in one lytic unit). In the graph lytic unit of each donor is shown along with the
mean for the group.
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2.3.4 Pharmacological Inhibition of STAT3 Inhibits NK Cytotoxicity
Constitutively active STAT3 has been shown to be oncogenic in multiple cancers
and as a result, STAT3 inhibitors have been tested in pre-clinical and clinical studies
against various types of cancers (140). NK cells due to their inherent anti-cancer
activity are also fast emerging as a candidate cell for immunotherapy against multiple
types of cancer (35). The anti-tumor activity of several cytokines is also mediated by
NK cells (8). As cancer treatment many a times involves combination of different
treatment modalities, it is imperative to determine the compatibility of different modes of
treatments with each other. To determine the effect of pharmacological STAT3
inhibition on NK cytolytic function, I assessed cytotoxicity of NK cells treated with
STAT3 inhibitor S3I-201. It binds SH2 domain of STAT3 to block dimerization and
thereby inhibits DNA binding and transcriptional activity of STAT3 (203). It has been
shown to inhibit tumor growth in pre-clinical studies (198, 203).
I evaluated cytolytic activity of primary human NK cells from normal donors
treated overnight with and without 10 μM S3I-201, a concentration shown not to affect
viability of NK cells in a previous study from our lab (136). Along with the drug
treatment, the cells were also activated overnight with 100 U/ml IL-2, a concentration
commonly used to activate cytolytic function of NK cells (204-206). Comparison
between S3I-201 treated and non- treated NK cells showed a substantial decrease in
cytotoxicity in S3I-201 treated NK cells against K562 at all the E:T ratios tested (Figure
14a). S3I-201 treated NK cells had reduced number of lytic units (Figure 14b). The
results show that pharmacological inhibition STAT3 adversely affects NK cytolytic
function.
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Figure 14. Pharmacological inhibition of STAT3 reduces cytolytic function of
human NK cells (a) Purified human NK cells from normal donors were treated
overnight with IL-2 in the presence and absence of small molecule STAT3 inhibitor S3I201. Control cells were treated with the solvent for the drug DMSO. Cytotoxicity against
K562 was assessed using calcein assay. Assay for each donor was performed in
triplicates for each E:T ratio. Data is presented as mean ± standard deviation (SD) for
each E:T ratio for each donor. The experiment was repeated three times with three
different donors. (b) Lytic unit, defined as the number of NK cells required to kill a
specified percentage of target cells, was determined from the cytotoxicity curve of each
individual sample obtained in the calcein assay. A specific percentage of target cell
lysis was selected based on the criterion that the standard curves of all the samples in
the relevant data set crossed the reference percentage exactly once. Based on this
criterion, number of NK cells required to kill 25% of target cells were defined as one
lytic unit for the comparison between control and STAT3 knock-down (STAT3 KD). The
E:T ratio corresponding to the reference percentage was interpolated from the standard
curve. The number of NK cells in the lytic unit were obtained by multiplying the
interpolated E:T ratio by 10000 (the number of target cells in each well). Lytic units per
one million NK cells were obtained according to the formula (1000,000/number of NK
cells in one lytic unit). In the graph lytic unit of each donor is shown along with the
mean for the group.

108

109

2.4 DISCUSSION
In this study, I showed that Job syndrome patients’ NK cells with dominant
negative STAT3 mutations have impaired cytolytic function, NKG2D receptor
expression, and MTOC polarization. I confirmed these findings in STAT3 knock-down
primary human NK cell, which also showed deficient cytolytic function and MTOC
polarization. I further showed that membrane bound IL-21 stimulation of Job syndrome
patients’ NK cells with dominant negative STAT3 mutations enhances NK cytotoxicity,
restores NKG2D receptor expression to normal levels and corrects defective MTOC
polarization. Finally, I showed that pharmacological inhibition of STAT3 reduces NK
cytolytic function.
Cytokine signaling drives differentiation, homeostasis, and functional maturation
of NK cells (207). As cytokine signals are pre-dominantly mediated through activation
of members of STAT family, multiple STATs play a critical role in the regulation of basal
as well as induced cytotoxicity of NK cells. IL-2 and IL-15, cytokines belonging to
common γ chain family, are implicated in the differentiation, proliferation, survival and
functional activation of NK cells (58). Both cytokines mainly activate STAT5 (104) and
this signaling preference is reflected in the diminished basal as well as IL-2 and IL-15
induced cytolytic activity of NK cells from STAT5b deficient mice (162) and loss of antitumor activity in STAT5 deficient mice NK cells (208). The other STAT that has been
shown to be important for NK cytolytic function is STAT1. Anti-viral response of NK
cells is activated by IFN α/β (38, 86), which predominantly mediate their signals
through STAT1 activation (173, 209). IFN α activates cytolytic activity of NK cells
through STAT1 signaling (161, 165). The dependence on STAT1 signaling is
manifested in the reduced NK cytotoxicity during viral infection in STAT1 deficient mice
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(68, 163). STAT1 signaling also plays a role in NK cell development by enabling
functional maturation (210). As a result, not only induced, but also basal NK cytotoxicity
decreases in STAT1 deficient mice (164, 165). In humans too, STAT1 deficiency
results in diminished basal as well as induced NK cytotoxicity (166). IL-12, a potent
activator of NK cytolytic activity (211-214), predominantly stimulates STAT4 (173).
Even though STAT4 is not known to influence basal NK cytolytic function, in STAT4
deficient mouse, NK cells fail to augment cytotoxicity in response to IL-12 (167, 168).
Compared to these STATs, very little is known about the function of STAT3 signaling in
NK cytolytic activity, especially in human NK cells, and as a result its role is not well
defined.
Monogenic immune deficiencies have helped delineate the role of number of
biomolecules in the immune system. Immune disorders caused by genetic deficiencies
of different components of JAK-STAT signaling pathway are instrumental in expanding
our understanding of the function of the individual members in the biology of multiple
types of immune cells (97, 102, 137). Investigations into the pathogenesis of
immunological dysfunctions in Job syndrome patients have revealed the role of STAT3
in the development and function of immune cells of lymphoid origin, Th17, T follicular
helper cells, T regulatory cells, central memory T cells, memory B cells, and antigen
specific plasma cells (147-153), as well as of myeloid origin, tolerogenic dendritic cells
and mast cells (150, 154). I took advantage of nature’s own genetic experiment to
study the role of STAT3 in NK effector function. The cytolytic functional defect reported
in this study is the first NK cell deficiency reported in this immune disorder carrying
dominant negative STAT3 mutations. Due to the paucity of PBMCs from Job syndrome
patients, instead of using purified NK cells, the cytotoxicity assays in this study were
performed with PBMCs. As other types of immune cells in the PBMCs could influence
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cytotoxicity of NK cells, as has been demonstrated by the inhibition of NK cytotoxicity
by T regulatory cells (215, 216), it was difficult to infer whether the diminished
cytotoxicity is due to NK cell intrinsic STAT3 deficiency or indirect effect of STAT3
deficiency in other immune cells. Thus, to confirm whether the effect is due to NK cell
intrinsic STAT3 deficiency and to further validate the results obtained with Job
syndrome patients’ NK cells, I evaluated cytotoxicity of STAT3 knock-down primary NK
cells from normal human donors. The diminished cytolytic function observed in these
cells unequivocally showed that NK cell intrinsic STAT3 deficiency impairs cytotoxicity.
The degree of inhibition of cytotoxicity observed in STAT3 knock-down NK cells was
not to the extent as was observed in Job syndrome patients’ NK cells. There could be
two plausible reasons for the dissimilar decrease observed; the different types of
STAT3 deficiencies in the two genetic models and different culture conditions. The
presence of dominant negative STAT3 allele in Job syndrome patients’ NK cells
renders these cells chronically deficient in STAT3 signaling, while siRNA mediated
STAT3 knock-down creates an acute STAT3 deficiency. The ability to affect the
cytolytic ability in a fundamental way such as impairment of functional maturity during
development is possible in the former, but not in the latter case. The other reason could
be the presence of 50 U/ml IL-2 in the culture medium of STAT3 knock-down NK cells.
As nucleofection process puts cells under stress and decreases cell viability (Weaver,
1993), to increase the chances of cell survival cytokine support was provided to the
siRNA nucleofected cells 24 hrs before and 48 hrs after nucleofection i.e. throughout
the culture period. The Job syndrome patients’ PBMCs on the other hand were not
stimulated with any cytokine before the assessment of basal cytotoxicity. IL-2 is a
potent activator of NK cells. Along with promoting cell survival and proliferation, it
stimulates NK cytotoxicity (217-219). Though, IL-2 activates STAT3 in NK cells (80,
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169, 173, 206, 220), the pre-dominant STAT activated by IL-2 is STAT5 (80, 173) and it
activates NK cytotoxicity mainly through STAT5 signaling (162). As STAT5 expression
is intact in STAT3 knock-down NK cells, IL-2 activated STAT5 may have alleviated the
adverse effect of STAT3 deficiency on NK cytotoxicity.
Yet another reason that could explain the smaller difference in cytotoxicity
between STAT3 knock-down and control NK cells is the possibility of cells with intact
STAT3 in STAT3 knock-down NK population. In bulk electroporation, as was performed
in the present study to knock-down STAT3 in primary human NK cells, all the cells may
not be electroporated, leaving some cells without knock-down of the target mRNA.
These cells, electroporated in bulk, if used in a bulk assay such as the calcein assay,
employed in the present study to assess the cytotoxicity of NK cells, then the cells with
intact STAT3, even if few, could skew the output. The possibility of existence of cells
with intact STAT3 in STAT3 knock-down bulk population may explain the difference
between the cytotoxicity of control cells and STAT3 knock-down cells being smaller as
these cells with intact killing capacity through encounters with multiple target cells may
compensate for the cytolytic deficiency of rest of the cells. To overcome this limitation
of calcein assay, cytolytic activity of STAT3 knock-down NK cells was assessed at the
single cell level, which also revealed lower frequency of killing in STAT3 knock-down
NK cells compared to control cells.
This is the first study to report that STAT3 deficiency causes impaired
cytotoxicity in primary human NK cells. Very few studies have investigated the role of
STAT3 in the cytolytic function of human NK cells. Similar to my results, silencing of
STAT3 expression in NK92 cells, a human NK cell line, using siRNA has been shown
to reduce cytotoxicity, while silencing of suppressor of cytokine signaling 3 (SOCS3), a
negative regulator of STAT3 signaling (221), increased NK92 cytotoxicity against K562
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(222). Pharmacological inhibition of STAT3 in primary human NK cells has also been
shown to decrease basal cytotoxicity (223). However, the evidence presented in this
particular study is not very conclusive due to the type of STAT3 inhibitor used. Iannello
et al. (223) used cucurbitacin or JSI-124 to block STAT3. Even though JSI-124 is used
as a STAT3 specific inhibitor (224, 225), along with STAT3, it also inhibits activation of
JAK2 and JAK3 and thus actually is a JAK-STAT inhibitor (226, 227). In fact, JSI-124
blocks activation of STAT5 (228) at a concentration well below the one used by
Iannello et al. (10 μM) (223). As STAT5 deficiency impairs basal NK cytotoxicity (162),
the effect of JSI-124 could have been mediated through STAT5 inhibition. The only
other study to implicate STAT3 in human NK cell cytotoxicity reported a decrease in IL2 induced STAT3 activation and a concurrent reduction in cytotoxicity of primary human
NK cells treated with immunosuppressant FK506 (170). Though the evidence
implicating STAT3 in NK cytotoxicity was not direct, the fact that only STAT3 activation
was inhibited, while IL-2 induced STAT1 and STAT5 activation remained unaffected in
FK506 treated NK cells suggested requirement of STAT3 activation in IL-2 induced
human NK cell cytotoxicity (170).
Contrary to human NK cells, STAT3 deficiency in mouse NK cells either
enhances cytolytic function or does not have any effect. Ablation of STAT3 in
hematopoietic cells of mice did not affect NK cell cytolytic activity in tumor free mice,
but in tumor bearing mice, STAT3 ablation increased cytolytic activity compared to wild
type (229). This observation suggests that STAT3 deficiency by itself may not impart
any beneficiary effect on NK cell cytotoxicity, but in the context of tumor
microenvironment, it does in mouse NK cells. STAT3 deficiency in mouse NK cells
does not seem to have an uniform effect on the cytotoxicity, but is rather influenced by
the type of target cells as it is apparent from a study in which NK cell specific deletion
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of STAT3 did not show any effect on cytotoxicity assessed in vitro against different
targets such RMA, RMA-Rae1, YAC-1 and v-abl cell lines, but increased cytotoxicity
against a melanoma cell line B16F10 (230). This increase was due to the high
expression level of ligands for DNAM-1 receptor on the target cell and enhanced
expression of the receptor on STAT3 deficient NK cells (230). Interestingly, no
difference was observed in the cytotoxicity of STAT3 deficient and wild type NK cells
against v-abl cells in assays performed in vitro, but in vivo, STAT3 deficient cells
displayed enhanced anti-tumor activity against the same cells (230). The different
outcomes in in vitro and in vivo settings indicate that cell extrinsic factors play a critical
role in determining the effect of STAT3 deficiency on mouse NK cytotoxicity. Even
though STAT3 deficiency does not always equate to an increase in mouse NK
cytotoxicity, it does so depending upon the target and the microenvironment in which
NK interacts with the target, whereas in human NK cells, reported results so far
associate STAT3 deficiency with impaired cytotoxicity. As there are similarities between
mouse and human immune systems so are the differences (231). With respect to NK
cells, the differences are highlighted by the structurally divergent families of inhibitory
receptors, KIRs in human and Ly49s in mouse, different types of ligands for human and
mouse NKG2D receptor (231), and difference in the function of 2B4 receptor, mainly
activating in human and inhibitory in mouse, due to the coupling with divergent types of
intracellular signaling molecules (232). Cytolytic activity of NK cells is a result of the
balance between the activation of inhibitory and activating receptors expressed on NK
cell surface (8) and as a result the tumor model used to assess cytolytic activity may
play a major role in the outcome of NK cell activity, particularly with respect to the
modulation of specific activating or inhibitory ligands. The difference in the structure,
function, and ligands for some of the receptors between mouse and human NK cells
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underscores the caution that should be exercised while applying lessons learned from
mouse to humans. It may also be possible that STAT3 deficiency may affect
expression of receptors and intracellular signaling molecules differently in mouse and
human NK cells.
Cytolytic activity of NK cells is the net result of the balance between the
strengths of signals mediated by activating and inhibitory receptors (8). To investigate
the cause of impaired cytotoxicity in STAT3 deficient human NK cells, I assessed
receptor expression. Out of all the activating, inhibitory, adhesion receptors and
activation and maturation markers measured, expression of NKG2D receptor was
found to be different between Job syndrome patients’ NK cells and normal donors’ NK
cells. Previously, we reported transcriptional activation of NKG2D by STAT3 (136) and
consistent with earlier finding NKG2D receptor expression was found to be impaired in
NK cells carrying dominant negative STAT3 mutations. The decrease in Job syndrome
patients’ NK cell cytolytic activity against K562 could be attributed to the impaired
NKG2D expression as NK cells lyse K562 pre-dominantly in a NKG2D dependent
manner (233, 234). Despite of STAT3 deficiency NKG2D receptor expression was
found to be normal in STAT3 knock-down NK cells. The normal expression may be
attributed to IL-2 present in the culture medium. IL-2 modulates NKG2D expression at
post-transcriptional level by increasing transcription and translation of DAP10, the
adaptor protein NKG2D associates with to mediate signal. Pairing with DAP10 is
required for NKG2D receptor expression and IL-2 induces NKG2D expression by
enhancing availability of DAP10 (89). The normal expression of NKG2D may also
explain the smaller decrease in cytotoxicity observed in STAT3 knock-down NK cells
compared to the drastic reduction observed in Job syndrome patients’ NK cells. The
only other receptor that has been shown to be modulated by STAT3 is DNAM-1, which
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showed up-regulated expression in STAT3 deficient mouse NK cells (230). No such
change in the expression of DNAM-1 was observed in Job syndrome patients’ NK cells
as well as in STAT3 knock-down human NK cells, again emphasizing the difference
between mouse and human NK cells.
Signaling cascades initiated by activating receptors enable synthesis and
deposition of F-actin at the NK-target interface, convergence of lytic granules dispersed
throughout the NK cell to MTOC and polarization of granules and MTOC towards the
immune synapse. These are the critical cellular processes involved in NK lytic activity
(158). Assessment of these cellular processes demonstrated normal deposition of Factin at the synapse in STAT3 deficient NK cells. Normal deposition of F-actin suggests
that the signaling axis of activating receptor signals- Src family kinase- Vav
phosphorylation- Rac1 activation- actin nucleators- actin polymerization is intact and
functional in STAT3 deficient NK cells (13, 235-239). Normal convergence of lytic
granules to MTOC indicates that STAT3 deficiency does not affect Src family kinase
mediated dynein motor dependent transport of lytic granules along microtubules (186,
240). Convergence of lytic granules to MTOC is the first step in the directed traffic of
these lysosomal organelles towards immune synapse. Upon convergence, movement
of MTOC along with the lytic granules in the direction of the synapse is called MTOC
polarization. I observed impaired polarization of MTOC to synapse in both Job
syndrome patients’ and STAT3 knock-down NK cells. During polarization to the
immune synapse, the transport of MTOC and lytic granules along the microtubules is
powered by plus-end motor protein kinesin-1 (KIF5B), which associates with MTOC
and lytic granules through a small G-protein, Arl8b (200). The transport of MTOC and
lytic granules along the microtubules towards the actin rich immune synapse is
facilitated by proteins, which could associate with both microtubules and actin. CDC42
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interacting protein 4 (CIP4) and IQGAP1 are two such proteins. CIP4 can interact with
actin through Wiskott-Aldrich syndrome protein (WASp), an actin associated actin
polymerization activating protein (236), and with MTOC through its binding with tubulin
(185). Activation of NK cells by a target cell triggers localization of CIP4 at MTOC and
its interaction with WASp (185). IQGAP1 is a multi-domain scaffolding protein that can
also interact with F-actin and microtubules (201). Individual silencing of these proteins
have been shown to impair MTOC and lytic granule polarization in NK cells (185, 200,
201). To investigate whether the expression of these molecules is affected by STAT3
deficiency, I quantified mRNA expression by Real-time PCR. Expression of Arl8b,
KIF5B and IQGAP1 was found to be similar in STAT3 knock-down and control NK
cells, but CIP4 expression was found to be significantly reduced in STAT3 knock-down
NK cells, suggesting it as a likely cause for impaired MTOC polarization. However,
CIP4 gene expression was found to be normal in Job syndrome patients’ NK cells
indicating that a different mechanism is responsible for the impaired MTOC polarization
observed in these cells. As discussed earlier, the two genetic models used in this study
do not exactly mimic each other, which may result in differential regulation of
expression of genes such CIP4. Signals mediated by NKG2D receptors trigger MTOC
polarization (241, 242). However, the reduced expression of NKG2D observed in Job
syndrome patients’ NK cells as a possible cause of MTOC impairment is unlikely as
STAT3 knock-down NK cells with normal expression of NKG2D receptor also had
impaired MTOC polarization. Thus, the causative factor responsible for impaired MTOC
polarization in Job syndrome patients’ NK cells remains elusive.
Despite of impaired MTOC and lytic granule polarization in STAT3 knock-down
NK cells, the decrease in cytotoxicity was marginal. This could be attributed to the lytic
granules which are known to exist near the immune synapse in NK cell and do not
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require MTOC polarization for their delivery to the synapse (243-245). These granules
are responsible for initial rapid release of lytic molecules in the synaptic cleft (245). As
suggested in an earlier study (185), pre-activation of NK cells during the culture period
such as IL-2 activation as was done in this study may have increased the number of
pre-docked lytic granules in STAT3 knock-down NK cells. Even though it is not known
how many lytic granules are required to kill K562, the target cell used in the present
study, considering its sensitivity to NK cell mediated lysis, exocytosis of few lytic
granules may be sufficient to do the job.
One of the primary functions of NK cells is tumor immunosurveillance (6, 8, 246,
247). This innate role of NK cells is reflected in the association of low NK cytotoxicity in
the peripheral blood with higher incidence of cancer as was observed in an 11-year
follow-up study (30). NK immunosurveillance of tumor cells is pre-dominantly mediated
through NKG2D receptor (27). NKG2D is a primary activating receptor on NK cells. In
humans, its ligands include MHC class-I-related chain (MIC) A and MICB and the UL16 binding proteins (ULBP). Expression of these ligands is induced by cellular stress
such as heat shock, DNA damage, transformation, and viral and bacterial infection. Not
surprisingly, NKG2D plays a critical role in the immune response mediated by NK to
infections and tumors (12). As observed in the present study, Job syndrome patients
with dominant negative STAT3 mutations have both the factors, impaired NKG2D
receptor expression and NK cytotoxicity, that could cause a predisposition to cancer. In
fact, autosomal dominant Job syndrome patients do carry higher risk of malignancy,
particularly lymphoma (144, 155, 156, 248-251). Very few instances of other types of
malignancies such as vulvar cancer (252) and pulmonary adenocarcinoma (253) have
been reported. The possibility of deficient NK cytolytic function due to impaired NKG2D
receptor expression as a putative cause of proclivity to lymphoma development in Job
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syndrome patients is supported by the earlier reports of impaired NK cytotoxicity
observed in lymphoma patients (254, 255) and a recent study linking the cytotoxic
impairment to reduced NKG2D receptor expression on NK cells (256). The risk of
lymphoma development is 259 fold higher in autosomal dominant Job syndrome
patients compared to general population (155). Many cases of lymphoma in autosomal
dominant Job syndrome patients were reported before the discovery of dominant
negative STAT3 mutations as the causative factor of the syndrome, but confirmation of
STAT3 mutations in subsequent cases has established a firm link between STAT3
deficiency and occurrence of lymphoma (144, 156, 250, 251). STAT3 deficiency not
only inhibits NK cytotoxicity through NK intrinsic effects, but tumor specific STAT3
deletion also adversely affects NK infiltration and NK cytotoxicity as has been shown in
a STAT3 deleted BCR/ABL induced lymphoma model (257). Thus, impaired cytotoxicity
of STAT3 deficient NK cells and reduced NK immunosurveillance influenced by STAT3
deficient lymphoma could be promoting lymphogenesis in Job syndrome patients.
Even though Job syndrome patients carry dominant negative STAT3 mutations,
they are not totally devoid of STAT3 activity. As STATs mediate their transcriptional
activation function as dimers, the 25% probability of functional dimer formation, due to
the one normal STAT3 allele present, retains residual STAT3 activity in Job syndrome
patients’ cells, which is 25% of the wild type (131). I wanted to investigate whether
stimulation of the residual functional STAT3 by IL-21 could improve deficient NKG2D
receptor expression, MTOC polarization, and cytotoxicity of Job syndrome patients’ NK
cells. IL-21, a cytokine belonging to common γ chain family, pre-dominantly activates
STAT3 (80, 136, 171) and marginally activates STAT1, STAT4, and STAT5 in NK cells
(80, 92, 136, 171, 258). IL-21 is a potent activator of NK cells. It induces expression of
activating receptors, effector cytolytic proteins, granzymes and perforin, and cytolytic
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activity of NK cells (80, 81, 92, 136, 223, 259). In vivo anti-tumor effects of IL-21 are
mediated by NK cells (26) and these anti-tumor effects are NKG2D dependent (260).
IL-21 induced expression of activating receptors and perforin, and activation of cytolytic
function in NK cells is mediated through STAT3 activation (136, 223). Previous work in
our lab demonstrated robust expansion of human NK cells stimulated with K562,
genetically modified to present membrane bound IL-21 (mbIL21). These expanded
cells had high expression of activating receptors and enhanced cytolytic activity (134).
In the present study, NK cells, expanded from PBMCs stimulated with mbIL21 over a
three-week period, were found to have similar expression of NKG2D receptor in Job
syndrome patients and normal donors. MTOC polarization was also found to be normal
in mbIL21 expanded Job syndrome patients’ NK cells. Thus, the deficient NKG2D
receptor expression and MTOC polarization in resting Job syndrome patients’ NK can
be corrected by mbIL21 stimulation. Consistent with these results, mbIL21 activation
also enhanced cytolytic function of Job syndrome patients’ NK cells. Though the
cytotoxicity of mbILl21 expanded Job syndrome patients’ NK cells was marginally lower
than mbIL21 expanded NK cells from normal donors, there was no significant
difference as was observed at basal level.
As discussed earlier, deficient NK cytotoxicity caused by impaired NKG2D
receptor expression is the likely reason for Job syndrome patients’ predisposition
towards lymphoma development. The finding that mbIL21 activation restores NKG2D
receptor expression to normal levels and enhances cytotoxicity of Job syndrome
patients’ NK cells offers an adoptive NK cell immunotherapy approach to treat
lymphoma in these patients.
Due to oncogenic properties of STAT3 signaling in multiple cancers, inhibition of
STAT3 is emerging as a therapeutic approach in cancer treatment. Multiple
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approaches to block STAT3 signaling are at different stages of clinical development
(106, 140, 175). In the light of the finding of the present study that STAT3 deficiency
inhibits NK cytolytic activity, it is critical to determine the effect of this therapeutic
approach on the function of the immune cell whose primary function is tumor
immunosurveillance. It is all the more important when equally promising treatment
options against cancer are offered by NK cells. High levels of tumor infiltrating NK cells
are associated with positive prognosis (31-33). The anti-tumor activity of several
cytokines such as IL-2, IL-12, IL-18, and IL-21 is mediated by NK cells (8, 26). Adoptive
transfer of activated autologous or allogeneic NK cells has proven to be a safe and
potentially efficacious immunotherapy for cancer (36, 37) and has been or being tested
against multiple types of cancers (35). As cancer treatment many a times involves
combination of different treatment modalities, it is imperative to determine the
compatibility of different modes of treatments with each other. Development of Small
molecule inhibitors of STAT3 is one of the most actively researched areas in cancer
therapeutics (140). S3I-201 is one such inhibitor, which binds SH2 domain of STAT3 to
block its dimerization and thereby inhibits DNA binding and transcriptional activity
(203). It has been shown to inhibit tumor growth in pre-clinical studies (198, 203). In a
previous study, we reported suppression of NKG2D receptor expression in S3I-201
treated primary human NK cells (136). Assessment of the effect of this drug on the
cytotoxicity of human NK cells in the present study showed that S3I-201 reduces
cytolytic activity of NK cells. Thus, pharmacological inhibition of STAT3 impairs NKG2D
receptor expression and cytolytic function; the former could be the cause of the latter,
thereby disarming NK cells. These results indicate that blocking STAT3 as a
therapeutic approach in cancer treatment may have adverse effects on NK cell cytolytic
function and caution needs to be exercised, while employing this mode of treatment.
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2.5 CONCLUSION
The evidence presented in this report shows that STAT3 deficiency in human
NK cells causes impairment of cytolytic function. I used two genetic models to study the
role of STAT3 in NK cytolytic function; NK cells from Job syndrome patients carrying
dominant negative STAT3 mutations, a naturally occurring genetic model of STAT3
deficiency, and siRNA mediated knock-down of STAT3 in primary human NK cells. NK
cells from Job syndrome patients displayed significantly reduced cytotoxicity compared
to NK cells from normal donors. Investigations into the probable underlying causes of
impaired cytolytic function of Job syndrome patients’ NK cells revealed reduced
expression of NKG2D receptor, a primary activating receptor involved in activating
cytotoxicity of NK cells. Among the subcellular cytolytic processes probed, synapse
formation and granule convergence were found to be normal, while MTOC polarization
to the synapse was defective. The cytolytic phenotypes of STAT3 deficient Job
syndrome patients’ NK cells were recapitulated in STAT3 knock-down primary human
NK cells. Assessment of cytolytic activity by conventional bulk assay as well as single
cell analysis showed suppressed cytolytic function in STAT3 knock-down NK cells.
Impaired MTOC polarization was also observed in these cells. Thus, two genetic
models complemented each other in highlighting role of STAT3 in MTOC polarization
and cytolytic function of human NK cells. Job syndrome patients are not totally devoid
of STAT3 activity. One normal allele of STAT3 enables them to retain about 25%
activity of the wild type. In this study, I showed that stimulation of Job syndrome NK
cells with membrane bound form of STAT3 activating cytokine IL-21 restores NKG2D
expression and MTOC polarization to normal levels and improves cytolytic function.
Lastly, I studied the effect of pharmacological inhibition of STAT3 on NK cell cytolytic
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function. Deregulated STAT3 activity is associated with different types of cancers and
as a result, STAT3 is considered a promising therapeutic target. Various ways to block
STAT3 are under clinical consideration and small molecule inhibitors are one of the
important ones. One of the major functions of NK cells is immunosurveillance of
malignant cells. In the light of the finding of the present study, I found it imperative to
evaluate the effect of pharmacological inhibition of STAT3 on NK cytolytic function.
Treatment of primary human NK cells with small molecule STAT3 inhibitor S3I-201
suppressed NK cytolytic function, thereby showing a possible side effect of this
therapeutic approach.
This is the first report to show that STAT3 deficiency in primary human NK cells
causes impairment of MTOC polarization and cytolytic activity. This is also the first
report of NK cell functional deficiency in Job syndrome patients. Reduced NKG2D
expression and impaired NK cytolytic function, observed in this study, may provide an
immunological basis for the proclivity of Job syndrome patients to lymphoma and
restoration of NK cell function upon mbIL21 stimulation, as demonstrated in this study,
suggests an adoptive NK cell therapy as a therapeutic approach to treat Job syndrome
patients. By assessing the effect of small molecule STAT3 inhibitor on NK cytolytic
function, this study provides a potential biomarker for monitoring side effects of STAT3
inhibition.
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Chapter 3
ROLE OF STAT3 SIGNALING IN HUMAN NK CELL
EXPANSION
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Role of STAT3 Signaling In Human NK Cell Expansion
3.1 INTRODUCTION
NK cells, effector lymphocytes of the innate immune system, control microbial
infections, particularly viral and are the first line of defense against cancer cells. Like T
and B cells, NK cells do not require prior sensitization with antigen to execute their
effector functions. NK cells are equipped with an array of germline encoded activating
receptors to detect ligands expressed on stressed cells and inhibitory receptors to
detect self-signals such as MHC class I molecules. The balance between the strength
of signals mediated by the two types of receptors determines whether NK cells
discharge their effector function upon contact with the target cell (8).
Immune response entails availability of a pool of effector cells in normal
conditions and further expansion of these cells during infections. Steady-state number
of NK cells is maintained through homeostatic proliferation as has been shown in both
mice (65, 261, 262) and humans (263, 264). The homeostatic NK cell survival and
proliferation are dependent on IL-15 signaling in mice (64-66), but are independent of
IL-15 in humans (67).
In addition to proliferation during steady state, NK cells also proliferate in
response to viral infections. NK proliferative responses to various types of viral
infections in mice such as mouse cytomegalovirus (MCMV) (38, 53, 68, 265),
lymphocytic choriomeningitis virus (LCMV) (266), and vaccinia virus (163) and a wide
range of viral infection in humans such as human cytomegalovirus (HCMV) (267, 268),
Epstein-Barr virus (EBV) (269), human immunodeficiency virus (HIV) (270), hepatitis C
virus (271) and hantavirus (69) have been reported. In the early phase of viral infection,
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NK cells proliferate in response to cytokine signaling. In MCMV and LCMV infections in
mice this effect has been shown to be Type I interferon (IFNα/β) dependent (38, 272).
Type I IFNs do not directly mediate pro-proliferative signals in NK cells, but promote
proliferation by inducing generation of IL-15 (68). The role of IL-15 in NK proliferative
response to viral infection has also been established in humans (69). IL-12 (70, 71) and
IL-18 (70) have also been demonstrated to play a role in NK proliferation in response to
MCMV infection in mice, but whether these cytokines directly act on NK cells or
promote proliferation through an indirect mechanism remains to be determined.
Cytokine induced NK cell proliferation in the early phase of viral infection is
nonselective, while in the later phase NK cells expressing activating receptors that
recognize virus induced ligands are selectively expanded (272). This is best
exemplified by the well-studied preferential proliferation of Ly49H+ NK cells in response
to MCMV infection in mice (52, 53, 265, 273, 274). Ly49H is an activating receptor
expressed in mouse NK cells that recognizes MCMV encoded ligand m157 (272).
Ly49H transmits signals in NK cells by coupling with signaling adaptor protein DAP12
and these signals directly promote proliferation of NK cells (273). In humans too,
selective expansion of NK cells such as KIR+ NK cells in response to HIV (275) and
CD94/NKG2C+ in response to HCMV (267) infection have been reported, but evidence
supporting direct involvement of these receptors’ signaling in NK proliferation is lacking.
In vitro studies have demonstrated that cytokines and activating receptors, which
have not yet been shown to play a physiological role in NK cell proliferation in vivo,
could also induce proliferation of NK cells. One of the potent activators of NK cell
proliferation is IL-2 (72, 73). It is used to expand NK cells ex vivo for immunotherapy in
cancer (74, 75). Some cytokines do not induce proliferation acting alone but in
combination with other cytokines they do. For instance, IL-10, IL-12, and IL-18
127

stimulate proliferation of mice NK cells pre-activated with IL-2 (76). IL-18 also induces
proliferation of mice NK cell in combination with other cytokines such as IL-12 and IL15 (77-79). IL-21 too does not induce NK cell proliferation by itself, but does in
combination with IL-2 in human NK cells (80). Stimulation of activating receptors also
promotes NK cell proliferation. Individual stimulation of NKG2D, NKp30, and NKp46
induces proliferation in human NK cells (276).
Cytokines known to induce proliferation of NK cells mediate their signals
employing JAK-STAT pathway. IL-15, established to be the major endogenous cytokine
responsible for survival and proliferation of NK cells in vivo in mice and IL-2 which is
routinely used to expand NK cells from mouse and human in vitro activate STAT 1, 3,
4, and 5 in NK cells (171, 173, 277). Out of all the STATs, STAT5 is predominantly
activated by IL-2 and IL-15 (171, 173). The importance of STAT5 signaling in NK cell
proliferation is reflected in the reduced proliferative response of NK cells from STAT5
knock-out mice to IL-2 and IL-15 (162). Out of the two members of the STAT5 group,
STAT5a and STAT5b, these effects are more pronounced in STAT5b knock-out mice,
thereby signifying its role in mouse NK cell proliferation (162). IL-2 and IL-15 also
support NK cell survival (58) and signals promoting survival are also pre-dominantly
mediated through STAT5 (208, 278). Apart from STAT5, the only other STAT that has
been implicated in NK cell proliferation is STAT1. NK proliferative response to viral
infection is dependent on type I IFN mediated STAT1 signaling. The pro-proliferative
effects are not due to NK cell intrinsic STAT1 signaling, but due to the availability of IL15 that is generated as a result of Type I IFN mediated STAT1 signaling (68).
The cytokines, IL-2, IL-15, IL-10, IL-12 and IL-18, which have been shown to
induce proliferation of NK cells either in vivo or in vitro, activate STAT3 in NK cells (80,
136, 169-173). STAT3 is considered to be a pro-proliferative and pro-survival
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transcription factor. STAT3 target genes such as cyclin D1, D2, D3, cdc25A, and c-Myc
(174, 279, 280) promote cell cycle progression, while Bcl-XL (281) and survivin (282)
prevent apoptosis. However it is not known whether STAT3 signaling plays any role in
NK cell proliferation and survival.
Anti-cancer activity of NK cells has generated a great deal of interest in NK cell
immunotherapy against cancer. Due to the limited number of NK cells in the peripheral
blood, expanding NK cells to a sufficiently large number is imperative to the success of
NK cell immunotherapy. Expanding and activating NK cells ex-vivo, before their
transfer into the patients, forms the basis of NK immunotherapy. Research efforts in our
lab are focused on developing an ex vivo NK cell expansion platform. We previously
described robust ex vivo expansion of NK cells by co-cultivation with K562
(erythroleukemic cell line) based artificial antigen presenting cells (aAPC) genetically
modified to express membrane-bound cytokines (134). We observed significantly
higher fold expansion of NK cells activated with membrane bound IL-21 (mbIL21) than
those activated with membrane bound IL-15 (mbIL15) (134). As out of all the STATs,
IL-21 activates STAT3 most efficiently (104, 135), I hypothesized that STAT3 may play
a role in NK cell proliferation.
In this investigation, I studied role of STAT3 in membrane bound cytokine
activated primary human NK cell proliferation by blocking STAT3 employing
pharmacological and genetic tools. In the pharmacological model, I blocked STAT3
using a small molecule STAT3 inhibitor, while in the genetic model NK cells from Job
syndrome patients carrying dominant negative STAT3 mutations were used. Both the
approaches showed significant reduction in the proliferation of NK cells thereby
underlining requirement of STAT3 in NK cell proliferation.
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3.2 MATERIAL AND METHODS
3.2.1 Cell and cell lines
Anonymized normal donor buffy coats were obtained from the Gulf Coast
Regional Blood Center (Houston, TX) under a protocol approved by the Institutional
Review Board (IRB) of UT MD Anderson Cancer Center. Peripheral blood was
obtained from STAT3 genotyped Job’s syndrome patients at National Institute of
Allergy and Infectious Diseases and Children’s Hospital of Philadelphia under protocols
approved by the IRB of each respective institution. IRB approval was obtained from UT
MD Anderson Cancer Center to acquire Job’s syndrome samples from collaborators
and to perform this research. This study was conducted in accordance with the
Declaration of Helsinki.

3.2.2 PBMC Isolation
Peripheral blood mononuclear cells (PBMCs) from buffy coats and blood
samples were obtained by buoyant density centrifugation on Ficoll-Paque following
previously described protocol (176). Briefly, buffy coats or blood samples mixed with
phosphate buffer saline (PBS) were loaded on top of Ficoll-Paque in a 50 ml tube and
centrifuged at 400g for 20 minutes without brake. The PBMCs settled at the interface of
Ficoll-Paque and plasma were recovered and washed three times with PBS. The red
blood cells (RBCs) settled below Ficoll-Paque were used to isolate NK cells from
PBMCs.
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3.2.3 NK Cell Purification
NK cells were purified from PBMCs by enriching them to  95% purity
(CD3−CD16/56+) with RosetteSep Human NK Cell Enrichment Cocktail (STEMCELL
Technologies, Vancouver, BC, Canada) following manufacturer’s instructions. In brief,
PBMCs were mixed at 1:100 ratio with red blood cells (RBCs) obtained from the same
sample. To the PBMCs:RBCs mixture, Human NK Cell Enrichment Cocktail was added
at 1 µl/106 PBMCs. The solution was mixed well and incubated at room temperature for
20 minutes with gentle mixing every five minutes. After adding PBS with 2% fetal
bovine serum (FBS) to the PBMCs:RBCs mix, the solution was layered on top of FicollPaque and centrifuged at 400g for 20 minutes. The NK cells were recovered from top
of the Ficoll-Paque layer.
The NK cells were cultured in RPMI 1640 (Cellgro/Mediatech, Manassas, VA)
supplemented

with

10%

FBS

(HyClone,

Logan,

UT),

2

mM

l-glutamine

(Gibco/Invitrogen, Carlsbad, CA), and 1% penicillin/streptomycin (Cellgro/Mediatech).
This media is hereinafter referred to as NK cell media.

3.2.4 Antibodies
Murine anti-human CD3, CD56, and isotype control mAbs were obtained from
BD Biosciences (Bedford, MA).

3.2.5 Ex vivo expansion of human NK cells
NK cells were expanded as previously described with few modifications (176).
Briefly, PBMCs or purified NK cells were co-cultured with irradiated (100 cGy) K562
artificial antigen presenting cells (aAPCs), genetically modified to express membrane
bound cytokines, at 1:2 (PBMCs/NK:aAPCs) ratio and 50 U/ml recombinant human IL-2
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in a T-75 flask (Corning, Corning, NY) at 106 cells/ml. The K562s expressing
membrane bound cytokines were generated as previously described (134). Culture was
refreshed with new media containing 50 U/ml IL-2 every three to four days. In
expansions extended beyond one week, a portion of the expanded cells was carried
forward by recursive stimulation with K562s expressing membrane bound cytokine and
50 U/ml IL-2. In the expansions started with purified NK cells, fold expansion of NK
cells was calculated by dividing the number of viable NK cells at the end of a weeklong
expansion with the number of viable NK cells at the start of expansion. In the
expansions started with PBMCs, fold expansion of NK cells was calculated by dividing
the number of NK cells in the PBMCs at the end of weeklong expansion by the number
of NK cells in the PBMCs at the start of expansion. Number of NK cells in the PBMCs
were calculated by estimating the percentage of CD3 - CD56+ cells by flow-cytometric
analysis. Inferred fold NK cell expansion was calculated from the resulting cultures as if
all the cells were carried forward in the expansion (134).

3.2.6 Cell Count and Cell Viability
Cells were counted using hemocytometer. Cell viability was determined by
Trypan blue exclusion method. Briefly, cells were stained with trypan blue and number
of cells stained blue and total number of cells were counted using hemocytometer.
Percentage viability was calculated using the formula [((Total number of cells-number
of blue cells)/Total number of cells) *100].

3.2.7 Flow-Cytometry Analysis
Flow cytometry buffer, PBS with 2mM EDTA and 0.1% sodium azide, was used
for blocking, staining, washing and resuspending the cells. Before staining with
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antibodies, the cells were blocked with 50% FBS for 30 minutes at 4C. Blocked cells
were stained with appropriate fluorochrome conjugated antibodies for 30 minutes at
4C, washed twice and resuspended in flow cytometry buffer. Data was acquired using
a FACSCalibur cytometer (Becton Dickinson, Franklin Lakes, NJ), and was analyzed
using FlowJo Version 9.2 software (FlowJo, Ashland, OR, USA).

3.2.8 Pharmacological inhibition of STAT3 in NK cells
S3I-201 (Calbiochem, Gibbstown, NJ), a small molecule STAT3 inhibitor,
reconstituted in DMSO was used to block STAT3 signaling. Purified NK cells were
incubated for an hour with or without S3I-201 before stimulating them with aAPCs and
IL-2. Cells were pre-treated with the drug every time media was refreshed. Control cells
were treated with the solvent, DMSO.

3.2.9 Proliferation Assessment By CFSE Dilution
Proliferation of NK cells was assessed by the 5,6-carboxyfluorescein diacetate
succinimidyl ester (CFSE) dilution method (283). Briefly, freshly purified NK cells,
resuspended in pre-warmed PBS containing 0.1% BSA at 106 cells/ml, were stained
with 2 μM CFSE (Molecular Probes, Eugene, OR) by incubating them at 37 oC for 10
minutes. At the end of incubation period, staining was quenched by adding cold NK cell
media 5 times the volume of the staining solution and by incubating them on ice for 5
minutes. Cells were pelleted and washed three times with NK cell media. CFSE stained
cells were expanded as described earlier. At the end of one week of expansion CFSE
staining was measured by flow-cytometry.
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3.2.10 Apoptosis Assessment
Apoptotic NK cells were identified using apoptosis detection kit from BD
Pharmingen

(Franklin

modifications.

Lake,

NJ) following manufacturer’s protocol with

few

Briefly, NK cells were washed twice with cold PBS and then

resuspended in 1X binding buffer at a density of 10 6 cells/ml. 100 μl of cell suspension
(105 cells) was transferred to a 5 ml flow cytometry tube. 3 μl of Phycoerythrin (PE)
conjugated Annexin V was added to the tube and mixed by gentle vortexing. The cells
were incubated in dark for 15 minutes at room temperature. After incubation, cells were
washed twice with 1X binding buffer and then resuspended in 400 μl 1X binding buffer
containing 5 μl 7-Amino-Actinomycin (7-AAD). The cells were incubated in dark for 10
minutes at room temperature. PE-Annexin V and 7-AAD staining were analyzed by
flow-cytometry.

3.2.11 Statistical Analysis
Statistical analysis was performed for the indicated statistical tests using
GraphPad Prism for Macintosh, version 5.0a. P values <.05 were considered
significant.

134

3.3 RESULTS
Ex vivo NK cell expansion platform, developed in our lab, demonstrated robust
expansion of human NK cells activated with K562 cells genetically modified to present
membrane bound IL-21 (mbIL21) (134). As IL-21 pre-dominantly signals through
STAT3 activation (104, 135), I hypothesized that STAT3 activation may play a role in
the induction of proliferation of human NK cells. I used pharmacological and genetic
models to test my hypothesis.

3.3.1 Pharmacological Inhibition of STAT3
3.3.1.1

STAT3 inhibitor S3I-201 reduces mbIL21 stimulated expansion of
human NK cells

I employed pharmacological approach to block STAT3 with a small molecule
inhibitor S3I-201. It binds SH2 domain of STAT3 to block dimerization and thereby
inhibits DNA binding and transcriptional activity of STAT3 (203). Human NK cells
purified from peripheral blood mononuclear cells (PBMCs) were expanded by
stimulation with mbIL21 for one week in the presence and absence S3I-201. At the end
of the week, viable cells were counted by differentiating viable cells from non-viable
cells by staining the cells with trypan blue. The number of NK cells was significantly
higher in the cultures without STAT3 inhibitor (Figure 15).
3.3.1.2

STAT3 inhibition decreases proliferation and survival of human
NK cells stimulated with mbIL21

Expansion of cell number is the net result of two processes; increase in cell
number due to proliferation and decrease in cell number due to cell death. I evaluated
the effect of pharmacological inhibition of STAT3 on proliferation of NK cells using
CFSE dilution assay. CFSE, a cell permeable fluorescent dye, reacts covalently with
amine containing intracellular molecules thereby fluorescently labeling the cell. CFSE
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fluorescence per cell is progressively halved after each cell division (284). Thus, more
the number of cell divisions a cell undergoes, lesser the fluorescence intensity the
daughter cells end up with. Flow-cytometric analysis revealed significantly higher CFSE
fluorescence in S3I-201 treated NK cells than in control cells at the end of one week of
expansion with mbIL21 indicating fewer cell divisions in S3I-201 treated NK cells
compared

to

control

cells

(Figure

16b).

This

observation

suggested

that

pharmacological blocking of STAT3 inhibits mbIL21 stimulated proliferation of human
NK cells. I also evaluated the effect of STAT3 inhibition on the survival of NK cells by
assessing viability and apoptosis. Viability of cells was evaluated by staining the cells
with 7-AAD, a cell membrane impermeable fluorescent compound with strong affinity
for DNA that stains non-viable cells with compromised cell membranes. Apoptotic cells
were detected by staining the cells with fluorescent tagged Annexin V, a protein that
binds phosphotidylserine that is exposed on the surface of apoptotic cells (285). Both,
7-AAD and Annexin V, stainings were measured by flow-cytometry. Percentage of
viable cells was found to decrease (Figure 16d) and percentage of apoptotic cells was
found to increase (Figure 16e) in S3I-201 treated NK cells indicating that
pharmacological inhibition of STAT3 negatively affects survival of mbIL21 activated
human NK cells.
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Figure 15. Pharmacological inhibition of STAT3 decreases mbIL21 stimulated
expansion of human NK cells. Purified NK cells were incubated for an hour with or
without small molecule STAT3 inhibitor S3I-201 before stimulating them with irradiated
K562 artificial antigen presenting cells (aAPCs), genetically modified to express
membrane bound IL-21 (mbIL21), at 1:2 (NK:K562) ratio and 50 U/ml recombinant
human IL-2. Control cells were treated with the solvent, DMSO. Culture was refreshed
with new media containing 50 U/ml IL-2 every three to four days. Cells were pre-treated
with the drug every time media was refreshed. At the end of one week of expansion,
viable cells were counted by trypan blue exclusion method. Fold expansion of NK cells
was calculated by dividing the number of viable NK cells at the end of a weeklong
expansion with the number of viable NK cells at the start of expansion. P value
indicated is for two-tailed paired Student’s t test.
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Figure 16. Pharmacological inhibition of STAT3 decreases proliferation and
survival of mbIL21 stimulated human NK cells. Significantly higher CFSE
fluorescence in S3I-201 treated NK cells than in control cells at the end of one
week of expansion with mbIL21, indicating fewer cell divisions in S3I-201 treated
NK cells compared to control cells. Lower percentage of viable cells and higher
percentage of apoptotic cells in S3I-201 treated NK cells at the end of one week
of expansion with mbIL21, indicating reduced survival. Purified NK cells, stained
with CFSE, were incubated for an hour with or without small molecule STAT3 inhibitor
S3I-201, before stimulating them with irradiated K562 artificial antigen presenting cells
(aAPCs), genetically modified to express membrane bound IL-21 (mbIL21), at 1:2
(NK:K562) ratio and 50 U/ml recombinant human IL-2. Control cells were treated with
the solvent, DMSO. Culture was refreshed with new media containing 50 U/ml IL-2
every three to four days. Cells were pre-treated with the drug every time media was
refreshed. At the end of one week of expansion mean fluorescence intensity (MFI) of
CFSE was measured by flow cytometry (a) Representative flow-charts showing live NK
cells gated on the basis of forward and side scatter and CFSE staining of this gated
population for control and S3I-201 treated cells (b) CFSE MFI in control and S3I-201
treated cells (c) At the end of one week of expansion viability and apoptosis of the
entire population (100%) were assessed by flow-cytometric analysis of 7AAD and
Annexin V staining (d) Cells stained negative for both, 7AAD and Annexin V were
considered viable. Percentage of viable cells at the end of one week expansion is
shown (e) Cells stained with just Annexin V were considered apoptotic. Percentage of
apoptotic cells at the end of one week expansion is shown. P values indicated are for
two-tailed paired Student’s t test.
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3.3.1.3 STAT3 inhibitor S3I-201 reduces mbIL15-15Rα stimulated expansion of
human NK cells
To evaluate whether inhibition of STAT3 has any bearing on the expansion of
NK cells stimulated with a cytokine, which does not pre-dominantly activate STAT3, I
assessed the effect of S3I-201 on NK cells expanded with K562s genetically modified
to present membrane bound IL-15 in complex with its receptor α (mbIL15-15Rα), the
way IL15 is trans-presented to NK cells physiologically (286). IL-15 is a potent inducer
of proliferation of mouse and human NK cells (58, 287, 288) and though it activates
multiple STATs including STAT3 in NK cells (220), its pro-proliferative effect is mainly
attributed to STAT5 signaling at least in mouse (162). NK cell expansion, measured by
counting viable NK cells at the end of one week of activation with mbIL15-15Rα,
showed significant reduction in the expansion of S3I-201 treated NK cells compared to
control (Figure 17). Thus, pharmacological blocking of STAT3 not only inhibited
expansion of NK cells stimulated with cytokine such as IL21, which pre- dominantly
activates STAT3, but also of NK cells stimulated with cytokines such as IL15, which
pre- dominantly activates STAT other than STAT3.
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Figure 17. Pharmacological inhibition of STAT3 decreases mbIL15-15Rα
stimulated expansion of human NK cells. Purified NK cells were incubated for an
hour with or without small molecule STAT3 inhibitor S3I-201 before stimulating them
with irradiated K562 artificial antigen presenting cells (aAPCs), genetically modified to
express membrane bound IL-15 in complex with its receptor α (mbIL15-15Rα), at 1:2
(NK:K562) ratio and 50 U/ml recombinant human IL-2. Control cells were treated with
the solvent, DMSO. Culture was refreshed with new media containing 50 U/ml IL-2
every three to four days. Cells were pre-treated with the drug every time media was
refreshed. At the end of one week of expansion, viable cells were counted by trypan
blue exclusion method. Fold expansion of NK cells was calculated by dividing the
number of viable NK cells at the end of a weeklong expansion with the number of
viable NK cells at the start of expansion. P value indicated is for two-tailed paired
Student’s t test.
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3.3.2 Impaired Expansion of Job Syndrome Patients’ NK Cells
Availability of NK cells from Job syndrome patients carrying dominant negative
STAT3 mutations (Table 2) offered me an opportunity to test my hypothesis in a
physiologically relevant genetic model. I expanded NK cells from Job syndrome
patients’ PBMCs by stimulating them with membrane bound cytokine presenting K562
cells. The cells were expanded over a three-week period by carrying forward a portion
of expanded cells from the previous week. Fold expansion of NK cells from Job
syndrome patients was found to be lower than NK cells from normal donors. Impaired
expansion of Job syndrome patients’ NK cells was observed in mbIL21 (Figure 18) as
well as in mbIL15-15Rα based expansion platforms (Figure 19). The fold expansion at
the end of first and second week was lower in Job syndrome patients’ NK cells than in
NK cells from normal donors, but the difference was not statistically significant (Figure
18a and b for mbIL21 expanded cells and Figure 19a and b for mbIL15-15Rα
expanded cells). A statistically significant difference in fold expansion was observed at
the end of third week (Figure 18c for mbIL21 and Figure 19c for mbIL15-15Rα).
Inferred fold expansion showed a widening difference between Job syndrome patient’s
NK cells and normal donor’s NK cells over the three-week expansion period (Figure
18d for mbIL21 and Figure 19d for mbIL15-15Rα). Thus, consistent with the results
obtained with pharmacological inhibition of STAT3, genetic deficiency of STAT3 also
impaired expansion of NK cells activated with mbIL21 as well as mbIL15-15Rα.
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Figure 18. Impaired expansion of Job syndrome patients’ NK cells stimulated
with mbIL21. The absolute fold expansion at the end of first and second week
was lower in Job syndrome patients’ NK cells than in NK cells from normal
donors, but the difference was not statistically significant. A statistically
significant difference in fold expansion was observed at the end of third week.
Inferred fold expansion showed a widening difference between Job syndrome
patient’s NK cells and normal donor’s NK cells over the three week expansion
period. PBMCs were stimulated with irradiated K562 artificial antigen presenting cells
(aAPCs), genetically modified to express membrane bound IL-21 (mbIL21), at 1:2
(PBMC:K562) ratio and 50 U/ml recombinant human IL-2. Culture was refreshed with
new media containing 50 U/ml IL-2 every three to four days. Beyond one week, a
portion of the expanded cells was carried forward by recursive stimulation with mbIL21
and 50 U/ml IL-2. At the end of one week of expansion, viable cells were counted by
trypan blue exclusion method. Fold expansion of NK cells was calculated by dividing
the number of NK cells in the PBMCs at the end of weeklong expansion by the number
of NK cells in the PBMCs at the start of expansion. Number of NK cells in the PBMCs
were calculated by estimating the percentage of CD3 - CD56+ cells by flow-cytometric
analysis. Inferred fold NK cell expansion was calculated from the resulting cultures as if
all the cells were carried forward in the expansion. (a) Fold expansion at the end of first
week (b) Fold expansion at the end of second week (c) Fold expansion at the end of
third week (d) Inferred fold expansion over the three week expansion period.
In each graph values for individual donor are shown along with the mean for the group.
P value indicated is for two-tailed Student’s t test.
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Expansion with mbIL21 stimulation
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Figure 19. Impaired expansion of Job syndrome patients’ NK cells stimulated
with mbIL15-15Rα. The absolute fold expansion at the end of first and second
week was lower in Job syndrome patients’ NK cells than in NK cells from normal
donors, but the difference was not statistically significant. A statistically
significant difference in fold expansion was observed at the end of third week.
Inferred fold expansion showed a widening difference between Job syndrome
patient’s NK cells and normal donor’s NK cells over the three week expansion
period. PBMCs were stimulated with irradiated K562 artificial antigen presenting cells
(aAPCs), genetically modified to express membrane bound IL-15 in complex with its
receptor α (mbIL15-15Rα), at 1:2 (PBMC:K562) ratio and 50 U/ml recombinant human
IL-2. Culture was refreshed with new media containing 50 U/ml IL-2 every three to four
days. Beyond one week, a portion of the expanded cells was carried forward by
recursive stimulation with mbIL21 and 50 U/ml IL-2. At the end of one week of
expansion, viable cells were counted by trypan blue exclusion method. Fold expansion
of NK cells was calculated by dividing the number of NK cells in the PBMCs at the end
of weeklong expansion by the number of NK cells in the PBMCs at the start of
expansion. Number of NK cells in the PBMCs were calculated by estimating the
percentage of CD3- CD56+ cells by flow-cytometric analysis. Inferred fold NK cell
expansion was calculated from the resulting cultures as if all the cells were carried
forward in the expansion. (a) Fold expansion at the end of first week (b) Fold expansion
at the end of second week (c) Fold expansion at the end of third week (d) Inferred fold
expansion over the three week expansion period. In each graph values for individual
donor are shown along with the mean for the group. P value indicated is for two-tailed
Student’s t test.
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3.3.3 Lower percentage of NK cells in the peripheral Blood of Job
Syndrome Patients
To investigate whether genetic defect in STAT3 has any bearing on the number
of NK cells in the peripheral blood of Job syndrome patients, I evaluated the
percentage of NK cells, defined as CD3- CD56+, in the lymphocyte population. NK cells
comprise around 2-18% of peripheral blood lymphocytes in human (8), which was
reflected in the range of percentages of NK cells observed in normal donors (Figure
20c). Even though majority of Job syndrome patients had NK cell percentages within
the normal range, they were mostly at the lower end of the scale. The difference in the
percentage of NK cells between normal and Job syndrome donors was statistically
significant (Figure 20c).
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Figure 20.

Lower percentage of NK cells in the PBMCs of Job syndrome

patients. PBMCs isolated from normal and Job syndrome donors were analyzed by
flow-cytometry. NK cells were identified as CD3-CD56+. Representative flow-chart
showing percentage of CD3-CD56+ cells is shown for (a) normal and (b) Job syndrome
donor. (C) Percentage of NK cells in the PBMCs is shown in graphical form.
In the graph values for individual donor are shown along with the mean for the group.
P value indicated is for two-tailed Student’s t test.
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3.4 DISCUSSION
In this investigation, employing pharmacological blocking of STAT3, I showed
that inhibition of STAT3 impairs human NK cells expansion stimulated with membrane
bound cytokines, IL-21 and IL-15. I validated this finding in NK cells from Job syndrome
patients carrying dominant negative STAT3 mutations. Both, pharmacological and
genetic evidence underscored the importance of STAT3 in human NK cell expansion.
IL-21, a cytokine belonging to common γ chain family, has mitogenic effect on
lymphocytes (59, 135, 289). IL-21 by itself cannot induce proliferation, but does so as a
co-stimulator with other cytokines and mitotic factors (59, 135). Activation of JAK-STAT
signaling pathway is central to the IL-21 mediated signals in immune cells. It activates
multiple forms of STATs including STAT1, STAT3, STAT5a, and STAT5b. Out of these
STATs, STAT3 is most strongly activated (135). In mouse T cells and human B cells,
the mitogenic signals of IL-21 are mediated through activation of STAT1 and STAT3
(135, 153).
Like in B and T cells, IL-21 acts as a mitogen in NK cells. In mouse and human
NK cells, IL-21 promotes proliferation in combination with either IL-2 or IL-15 (80, 290).
We utilized the mitogenic property of IL-21 signaling to develop a human NK cell
expansion platform in which cells are stimulated with K562s genetically modified to
present membrane bound IL-21 (mbIL21) and soluble IL-2 (134). This expansion
system supported log-phase growth in NK cell numbers over a six week period and
resulted in significantly greater fold expansion than expansion of NK cells stimulated
with K562s genetically modified to present membrane bound IL-15 (mbIL15) and
soluble IL-2 (134). In NK cells, IL-21 activates STAT1, STAT3, STAT4, and STAT5,
and out of all STATs, activates STAT3 predominantly (80, 92, 171). However, not much
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is known about the role of individual STATs in IL-21 mediated pro-proliferative signals
in NK cells. Very few studies have investigated the signaling mechanisms involved in
IL-21 induced proliferation in NK cells.
In

this study,

using small molecule

inhibitor S3I-201,

I showed

that

pharmacological blocking of STAT3 inhibits proliferation of human NK cells stimulated
with mbIL21. These results validated an earlier report, which suggested that mbIL21
induced expansion of human NK cells is mediated through STAT3 activation (202).
However, the evidence presented in this particular study is not very conclusive due to
the type of STAT3 inhibitor used. Wang et al. (202) used a small molecule inhibitor JSI124 to block STAT3. Even though, JSI-124 is used as a STAT3 specific inhibitor (224,
225), along with STAT3, it also inhibits activation of JAK2 and JAK3 and thus actually it
is a JAK-STAT inhibitor (226, 227). JSI-124 also blocks activation of STAT5 (228). As
IL-21 activates STAT5 in NK cells (80, 92) and STAT5 deficiency is known to impair NK
cell proliferation and survival (162, 208), the effect of JSI-124 could have been
mediated through STAT5 inhibition. Compared to JSI-124, S3I-201 is a STAT3 specific
inhibitor as it preferentially inhibits STAT3 DNA binding activity over that of other
STATs with a two-fold higher potency (203). Along with proliferation, IL-21 has also
been shown to support survival of human NK cells (81, 223). However, the signaling
mechanism involved in the transmission of pro-survival signals was not known. In this
investigation, along with the inhibition of proliferation, blockage of STAT3 also
increased apoptosis of NK cells activated with mbIL21 thereby highlighting the critical
role of activated STAT3 in the pro-proliferative as well as pro-survival signals mediated
by IL-21. STAT3 is a pro-survival transcription factor as it activates expression of antiapoptotic genes such as Bcl-2, Bcl-XL (291), and survivin (282) and down-regulates
expression of pro-apoptotic genes such as BCL2L11 (Bim) (225). IL-21 has also been
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shown to promote survival of NK cells through the up-regulation of expression of antiapoptotic proteins Bcl-2 and Bcl-XL (223). The evidence presented in the current study
suggests involvement of STAT3 in IL-21 mediated activation of expression of Bcl-2 and
Bcl-XL.
Pharmacological blocking of STAT3 not only inhibited expansion of NK cells
stimulated with mbIL21, which pre- dominantly activates STAT3, but also of NK cells
stimulated with mbIL15-15Rα, which pre- dominantly activates STAT5 and activates
STAT3 only marginally (292). In vivo IL-15 is trans presented to NK ceIls by accessory
cells such as dendritic cells, which express IL-15 in complex with the α subunit of its
receptor on their membranes. The IL15-IL15Rα complex mediates signals in NK cells
by interacting with β and γ subunits of IL-15 receptor expressed on the NK cell
membrane (293). IL-15 induced proliferation and survival of NK cells are considered to
be mediated mainly through the activation of STAT5 (162, 208). Along with STAT5, IL15 also activates STAT3, albeit marginally (171). However, evidence presented in the
current study suggests that STAT3 plays a major role, disproportionate to its activation,
in IL-15 induced proliferation of NK cells. A recent study also implied involvement of
STAT3 activation in the proliferation of mouse NK cells stimulated with IL-2 (294), a
cytokine, which also activates STAT5 pre-dominantly, and STAT3 marginally in NK
cells (80) and whose proliferative effects were considered to be mediated through
STAT5 activation (162).
Even though, the concentration (25 μM) of the pharmacological inhibitor, S3I201, used in the present study was well below its IC50 for STATs other than STAT3, a
non-specific effect cannot be entirely ruled out due to the sequence similarity between
SH2 domain of STAT3, the binding target of S3I-201, and SH2 domains of other
STATs,

particularly

STAT1

(295).

To
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validate

the

results

obtained

using

pharmacological inhibitor and to obtain unequivocal evidence in support of the role of
STAT3 in NK cell expansion, I expanded NK cells from Job syndrome patients’ carrying
dominant negative STAT3 mutations. Both, mbIL21 and mbIL15-15Rα stimulation
induced significant expansion of Job syndrome patients’ NK cells, but the expansion
was significantly impaired compared to NK cell from normal donors. These results were
consistent with the results obtained with pharmacological inhibition. Thus, both
pharmacological and genetic evidence signify requirement of STAT3 in NK cell
expansion.
Steady-state number of NK cells in vivo is maintained through homeostatic
proliferation (263, 264). To evaluate whether impaired expansion of Job syndrome
patients’ NK cell observed ex vivo has any bearing on NK cells in vivo, I assessed
percentage of NK cells in the lymphocyte population of the peripheral blood. NK cells
comprise around 2-18% of peripheral blood lymphocytes in human (8). Even though
the percentages of NK cells in Job syndrome patients were within the normal range,
they were at the lower end of the spectrum. The low NK percentage may result from a
deficiency in either differentiation, proliferation or survival or a combination of these
processes. Therefore, the low NK percentage cannot be attributed to just impaired
proliferation unless all the aforementioned processes are studied.

3.5 CONCLUSION
In this investigation, using pharmacological and genetic models, I showed that
inhibition of STAT3 significantly reduces expansion of human NK cells stimulated not
only with IL-21 that predominantly activates STAT3, but also the expansion stimulated
with IL-15, which predominantly activates STAT5 and activates STAT3 only marginally.
Thus, STAT3 signaling is critical for human NK cell expansion ex vivo. In mbIL-21
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stimulated NK cell expansion, STAT3 signaling is critical for proliferation and survival.
Even though fold expansion of Job syndrome patients’ NK cells was significantly
reduced compared to NK cells from normal donors, Job syndrome patients’ NK cells
expanded considerably in response to cytokine stimulation, suggesting adoptive NK
immunotherapy potential in Job syndrome patients. This treatment option is promising
in the light of the finding of low percentage of NK cells in the peripheral blood of Job
syndrome patients.
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FUTURE DIRECTIONS
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4.1 FUTURE DIRECTIONS
In this investigation, I evaluated the role of STAT3 in the functions of human NK
cells. Findings of this study established role of STAT3 signaling in human NK cell
cytolytic activity and expansion. However, much work remains to be done to
understand the role of STAT3 in NK cell biology in its entirety.
In this study, to investigate the underlying causes of impaired cytotoxicity of
STAT3 deficient NK cells, I explored function of STAT3 in NK receptor expression and
subcellular cytolytic processes, both of which were found to be affected in STAT3
deficient NK cells. However, other factors that also have bearing on cytolytic function
were not probed. Conjugate formation between NK and target cells, the very first step
that sets the stage for the cytolytic encounter and expression of perforin and granzyme,
the cytolytic molecules that effect the lysis (158), need to be assessed in STAT3
deficient cells. NK cells also mediate cytolysis through CD16, an Fc receptor, which
upon binding to the antibody attached to a target cell activates degranulation (8). I did
not assess antibody dependent cellular cytotoxicity in STAT3 deficient NK cells. Even
though CD16 expression level, measured in the present study, was unchanged in
STAT3 deficient cells, effect of STAT3 deficiency on signaling pathways triggered by
CD16 cannot be ruled out.
In addition to cytolysis of infected and malignant cells, NK cells also mediate
their functions through other means. In order to understand role of STAT3 in NK cell
functions, it is critical to assess all NK cell effector functions in STAT3 deficient cells.
NK cells are equipped with apoptosis inducing ligand FASL and TRAIL, which play
important role in immunosurveillance of malignant cells, particularly in liver (296). Along
with cytolytic capability, NK cells also exert their effect through secretion of cytokines
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and chemokines in response to stimulation by target cells and cytokines secreted by
accessory cells (10). NK cell generated cytokines include IFN-γ, TNF-α, granulocyte
macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor
(G-CSF), interleukin (IL)-10 and IL-3, while chemokines such as CCL2, CCL3, CCL4,
CCL5, XCL1, and CXCL8 are also secreted by NK cells (2). Compared to leukocytes
from normal donors, leukocytes from Job syndrome donors have been reported to
secrete higher levels of IFN-γ and TNF-α in response to lipopolysaccharide and IL-12
stimulation, indicating deregulation (130). In NK92 cells, an NK cell line, IL-2 stimulated
IL-10 secretion requires STAT3 activation (222). As NK cells are the major source of
cytokines, particularly IFN-γ, it would be of interest to assess cytokine secretion in
STAT3 deficient NK cells in response to stimulation by cytokines and activating
receptors. Assessment of expression of FASL, TRAIL, cytokines and chemokines in
Job syndrome patients’ NK cells will provide important insights into the regulation of NK
function by STAT3.
NK cells from Job syndrome patients are an excellent genetic tool to study the
role of STAT3 in NK cell function. However, Job syndrome is a rare immunodeficiency
and hence availability of cells from Job syndrome patients is a major limiting factor.
This constraint warrants procurement of alternative genetic model that is easily
accessible. In the present investigation, I used siRNA mediated STAT3 knock-down in
primary human NK cells to validate the results I obtained with Job syndrome patients’
NK cells. But, the former genetic model does not exactly mimic the latter. siRNA
mediated STAT3 knock-down generates acute STAT3 deficiency, while Job syndrome
patients’ NK cells have chronic STAT3 deficiency right from their inception. This
difference may account for the differences observed between the two in the present
investigation. A genetic model closely mimicking Job syndrome patients’ NK cells
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would require presence of the dominant negative STAT3 allele in NK cells throughout
the development process, which entails transfection of dominant negative STAT3 in
hematopoietic stem cells. Even then, the model will be far from perfect, as the cells
would still have, unlike Job syndrome patients’ cells, two normal copies of STAT3 gene
and one copy of dominant negative STAT3. A mouse carrying dominant negative Job
syndrome STAT3 gene has been generated (297), however, due to the differences
between mouse and human NK cells, as discussed earlier, not everything learned in
mouse can be extrapolated to humans. This is especially true in case of role of STAT3
in NK cells, as STAT3 deficiency in these two species has not generated uniform
phenotypes.
In this investigation, I also studied proliferation of Job syndrome patients’ NK
cells and human NK cells treated with STAT3 inhibitor, both of which showed impaired
proliferation. However, the molecular mechanisms involved were not investigated.
STAT3 is a pro-proliferative and pro-survival transcription factor. Whole genome
transcriptome analysis and gene transcription analysis by microarray of STAT3
deficient NK cells will help identify direct and indirect target genes of STAT3 involved in
human NK cell proliferation and survival. A protein expression analysis by reverse
phase protein array (RPPA) will further validate these targets at the functional level.
Constitutively active STAT3 and over activation of STAT3 are oncogenic. STAT3
is a therapeutic target in many cancers and various strategies to block STAT3
activation are under clinical consideration. In the light of the finding of my investigation
that STAT3 deficiency causes impairment of NK cell cytolytic function, I was interested
in determining the effect of pharmacological inhibition of STAT3 on NK cell cytolytic
activity. In vitro cytotoxicity assays showed that treatment with small molecule STAT3
inhibitor S3I-201 suppresses cytolytic activity of human NK cells. This finding bears
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importance because NK cells are the first line of defense against malignant cells. To
determine whether impairment of NK cytolytic function is a likely adverse effect of
STAT3 blocking in cancer treatment, cytotoxicity of NK cells from patients in clinical
trials receiving STAT3 inhibitors should be assessed. Such an assessment will also
help determine the compatibility of adoptive NK cell therapy, an emerging
immunotherapy approach for cancer treatment, with the pharmacological blocking of
STAT3, should these two treatment options be used in combination.

162

BIBLIOGRAPHY
1.
2.

3.
4.
5.

6.

7.

8.
9.

10.

11.
12.
13.

14.

15.

16.

Beck, G., and Habicht, G. S. (1996) Immunity and the invertebrates. Scientific
American 275, 60-63, 66
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L.,
Yokoyama, W. M., and Ugolini, S. (2011) Innate or adaptive immunity? The
example of natural killer cells. Science 331, 44-49
Oldham, R. K. (1983) Natural killer cells: artifact to reality: an odyssey in biology.
Cancer metastasis reviews 2, 323-336
Caligiuri, M. A. (2008) Human natural killer cells. Blood 112, 461-469
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., and Caligiuri, M. A. (2002)
Natural killer cell receptors: new biology and insights into the graft-versusleukemia effect. Blood 100, 1935-1947
Smyth, M. J., Hayakawa, Y., Takeda, K., and Yagita, H. (2002) New aspects of
natural-killer-cell surveillance and therapy of cancer. Nature reviews. Cancer 2,
850-861
Gregoire, C., Chasson, L., Luci, C., Tomasello, E., Geissmann, F., Vivier, E.,
and Walzer, T. (2007) The trafficking of natural killer cells. Immunological
reviews 220, 169-182
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., and Ugolini, S. (2008)
Functions of natural killer cells. Nature immunology 9, 503-510
Long, E. O., Kim, H. S., Liu, D., Peterson, M. E., and Rajagopalan, S. (2013)
Controlling natural killer cell responses: integration of signals for activation and
inhibition. Annual review of immunology 31, 227-258
Fauriat, C., Long, E. O., Ljunggren, H. G., and Bryceson, Y. T. (2010)
Regulation of human NK-cell cytokine and chemokine production by target cell
recognition. Blood 115, 2167-2176
Kruse, P. H., Matta, J., Ugolini, S., and Vivier, E. (2014) Natural cytotoxicity
receptors and their ligands. Immunology and cell biology 92, 221-229
Ogasawara, K., and Lanier, L. L. (2005) NKG2D in NK and T cell-mediated
immunity. Journal of clinical immunology 25, 534-540
Watzl, C., and Long, E. O. (2010) Signal transduction during activation and
inhibition of natural killer cells. Current protocols in immunology / edited by John
E. Coligan ... [et al.] Chapter 11, Unit 11 19B
Le Bouteiller, P., Barakonyi, A., Giustiniani, J., Lenfant, F., Marie-Cardine, A.,
Aguerre-Girr, M., Rabot, M., Hilgert, I., Mami-Chouaib, F., Tabiasco, J.,
Boumsell, L., and Bensussan, A. (2002) Engagement of CD160 receptor by
HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to
mediate cytotoxicity. Proceedings of the National Academy of Sciences of the
United States of America 99, 16963-16968
Bryceson, Y. T., March, M. E., Ljunggren, H. G., and Long, E. O. (2006)
Activation, coactivation, and costimulation of resting human natural killer cells.
Immunological reviews 214, 73-91
Kim, E. O., Kim, T. J., Kim, N., Kim, S. T., Kumar, V., and Lee, K. M. (2010)
Homotypic cell to cell cross-talk among human natural killer cells reveals
differential and overlapping roles of 2B4 and CD2. The Journal of biological
chemistry 285, 41755-41764

163

17.

18.

19.
20.
21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

Nicholson, M. W., Barclay, A. N., Singer, M. S., Rosen, S. D., and van der
Merwe, P. A. (1998) Affinity and kinetic analysis of L-selectin (CD62L) binding to
glycosylation-dependent cell-adhesion molecule-1. The Journal of biological
chemistry 273, 763-770
Lion, E., Willemen, Y., Berneman, Z. N., Van Tendeloo, V. F., and Smits, E. L.
(2012) Natural killer cell immune escape in acute myeloid leukemia. Leukemia
26, 2019-2026
Freud, A. G., and Caligiuri, M. A. (2006) Human natural killer cell development.
Immunological reviews 214, 56-72
Trinchieri, G. (1989) Biology of natural killer cells. Advances in immunology 47,
187-376
Barlozzari, T., Reynolds, C. W., and Herberman, R. B. (1983) In vivo role of
natural killer cells: involvement of large granular lymphocytes in the clearance of
tumor cells in anti-asialo GM1-treated rats. Journal of immunology 131, 10241027
Gorelik, E., Rosen, B., Copeland, D., Weatherly, B., and Herberman, R. B.
(1984) Evaluation of role of natural killer cells in radiation-induced
leukemogenesis in mice. Journal of the National Cancer Institute 72, 1397-1403
Kundu, N., Beaty, T. L., Jackson, M. J., and Fulton, A. M. (1996) Antimetastatic
and antitumor activities of interleukin 10 in a murine model of breast cancer.
Journal of the National Cancer Institute 88, 536-541
Zheng, L. M., Ojcius, D. M., Garaud, F., Roth, C., Maxwell, E., Li, Z., Rong, H.,
Chen, J., Wang, X. Y., Catino, J. J., and King, I. (1996) Interleukin-10 inhibits
tumor metastasis through an NK cell-dependent mechanism. The Journal of
experimental medicine 184, 579-584
Heinzerling, L., Dummer, R., Pavlovic, J., Schultz, J., Burg, G., and Moelling, K.
(2002) Tumor regression of human and murine melanoma after intratumoral
injection of IL-12-encoding plasmid DNA in mice. Experimental dermatology 11,
232-240
Wang, G., Tschoi, M., Spolski, R., Lou, Y., Ozaki, K., Feng, C., Kim, G.,
Leonard, W. J., and Hwu, P. (2003) In vivo antitumor activity of interleukin 21
mediated by natural killer cells. Cancer research 63, 9016-9022
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N.,
Knoblaugh, S., Cado, D., Greenberg, N. M., and Raulet, D. H. (2008) NKG2Ddeficient mice are defective in tumor surveillance in models of spontaneous
malignancy. Immunity 28, 571-580
Gilfillan, S., Chan, C. J., Cella, M., Haynes, N. M., Rapaport, A. S., Boles, K. S.,
Andrews, D. M., Smyth, M. J., and Colonna, M. (2008) DNAM-1 promotes
activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells
and tumors. The Journal of experimental medicine 205, 2965-2973
Iguchi-Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara-Hanaoka, S.,
Honda, S., Yasui, T., Kikutani, H., Shibuya, K., and Shibuya, A. (2008)
Accelerated tumor growth in mice deficient in DNAM-1 receptor. The Journal of
experimental medicine 205, 2959-2964
Imai, K., Matsuyama, S., Miyake, S., Suga, K., and Nakachi, K. (2000) Natural
cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11year follow-up study of a general population. Lancet 356, 1795-1799
Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M. A.,
Vallejo, C., Martos, J. A., and Moreno, M. (1997) The prognostic significance of
164

32.

33.

34.

35.

36.

37.

38.

39.
40.
41.

42.
43.

44.
45.

46.

intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79,
2320-2328
Ishigami, S., Natsugoe, S., Tokuda, K., Nakajo, A., Che, X., Iwashige, H.,
Aridome, K., Hokita, S., and Aikou, T. (2000) Prognostic value of intratumoral
natural killer cells in gastric carcinoma. Cancer 88, 577-583
Villegas, F. R., Coca, S., Villarrubia, V. G., Jimenez, R., Chillon, M. J., Jareno,
J., Zuil, M., and Callol, L. (2002) Prognostic significance of tumor infiltrating
natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung
cancer 35, 23-28
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A.,
Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., and Velardi, A.
(2002) Effectiveness of donor natural killer cell alloreactivity in mismatched
hematopoietic transplants. Science 295, 2097-2100
Cheng, M., Chen, Y., Xiao, W., Sun, R., and Tian, Z. (2013) NK cell-based
immunotherapy for malignant diseases. Cellular & molecular immunology 10,
230-252
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H.,
Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., Orchard, P. J.,
Blazar, B. R., Wagner, J. E., Slungaard, A., Weisdorf, D. J., Okazaki, I. J., and
McGlave, P. B. (2005) Successful adoptive transfer and in vivo expansion of
human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.
H., and Leung, W. (2010) NKAML: a pilot study to determine the safety and
feasibility of haploidentical natural killer cell transplantation in childhood acute
myeloid leukemia. Journal of clinical oncology : official journal of the American
Society of Clinical Oncology 28, 955-959
Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., and Salazar-Mather, T.
P. (1999) Natural killer cells in antiviral defense: function and regulation by
innate cytokines. Annual review of immunology 17, 189-220
Lanier, L. L. (2008) Evolutionary struggles between NK cells and viruses. Nature
reviews. Immunology 8, 259-268
Jost, S., and Altfeld, M. (2013) Control of human viral infections by natural killer
cells. Annual review of immunology 31, 163-194
Biron, C. A., Byron, K. S., and Sullivan, J. L. (1989) Severe herpesvirus
infections in an adolescent without natural killer cells. The New England journal
of medicine 320, 1731-1735
Orange, J. S. (2006) Human natural killer cell deficiencies. Current opinion in
allergy and clinical immunology 6, 399-409
Brilot, F., Strowig, T., and Munz, C. (2008) NK cells interactions with dendritic
cells shape innate and adaptive immunity. Frontiers in bioscience : a journal and
virtual library 13, 6443-6454
Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L., and Vivier, E. (2005) Naturalkiller cells and dendritic cells: "l'union fait la force". Blood 106, 2252-2258
Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M. C., and
Moretta, A. (2006) Effector and regulatory events during natural killer-dendritic
cell interactions. Immunological reviews 214, 219-228
Yuan, D. (2004) Interactions between NK cells and B lymphocytes. Advances in
immunology 84, 1-42
165

47.
48.

49.

50.
51.

52.
53.

54.

55.

56.

57.

58.
59.

60.

Crouse, J., Xu, H. C., Lang, P. A., and Oxenius, A. (2015) NK cells regulating T
cell responses: mechanisms and outcome. Trends in immunology 36, 49-58
Pedroza-Pacheco, I., Madrigal, A., and Saudemont, A. (2013) Interaction
between natural killer cells and regulatory T cells: perspectives for
immunotherapy. Cellular & molecular immunology 10, 222-229
Jabrane-Ferrat, N., and Siewiera, J. (2014) The up side of decidual natural killer
cells: new developments in immunology of pregnancy. Immunology 141, 490497
Sun, J. C., Lopez-Verges, S., Kim, C. C., DeRisi, J. L., and Lanier, L. L. (2011)
NK cells and immune "memory". Journal of immunology 186, 1891-1897
O'Leary, J. G., Goodarzi, M., Drayton, D. L., and von Andrian, U. H. (2006) T
cell- and B cell-independent adaptive immunity mediated by natural killer cells.
Nature immunology 7, 507-516
Sun, J. C., Beilke, J. N., and Lanier, L. L. (2009) Adaptive immune features of
natural killer cells. Nature 457, 557-561
Dokun, A. O., Kim, S., Smith, H. R., Kang, H. S., Chu, D. T., and Yokoyama, W.
M. (2001) Specific and nonspecific NK cell activation during virus infection.
Nature immunology 2, 951-956
Vosshenrich, C. A., Ranson, T., Samson, S. I., Corcuff, E., Colucci, F.,
Rosmaraki, E. E., and Di Santo, J. P. (2005) Roles for common cytokine
receptor gamma-chain-dependent cytokines in the generation, differentiation,
and maturation of NK cell precursors and peripheral NK cells in vivo. Journal of
immunology 174, 1213-1221
Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers,
M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., Brasel, K., Morrissey, P.
J., Stocking, K., Schuh, J. C., Joyce, S., and Peschon, J. J. (2000) Reversible
defects in natural killer and memory CD8 T cell lineages in interleukin 15deficient mice. The Journal of experimental medicine 191, 771-780
Lodolce, J. P., Boone, D. L., Chai, S., Swain, R. E., Dassopoulos, T., Trettin, S.,
and Ma, A. (1998) IL-15 receptor maintains lymphoid homeostasis by supporting
lymphocyte homing and proliferation. Immunity 9, 669-676
Granucci, F., Zanoni, I., Pavelka, N., Van Dommelen, S. L., Andoniou, C. E.,
Belardelli, F., Degli Esposti, M. A., and Ricciardi-Castagnoli, P. (2004) A
contribution of mouse dendritic cell-derived IL-2 for NK cell activation. The
Journal of experimental medicine 200, 287-295
Becknell, B., and Caligiuri, M. A. (2005) Interleukin-2, interleukin-15, and their
roles in human natural killer cells. Advances in immunology 86, 209-239
Parrish-Novak, J., Dillon, S. R., Nelson, A., Hammond, A., Sprecher, C., Gross,
J. A., Johnston, J., Madden, K., Xu, W., West, J., Schrader, S., Burkhead, S.,
Heipel, M., Brandt, C., Kuijper, J. L., Kramer, J., Conklin, D., Presnell, S. R.,
Berry, J., Shiota, F., Bort, S., Hambly, K., Mudri, S., Clegg, C., Moore, M., Grant,
F. J., Lofton-Day, C., Gilbert, T., Rayond, F., Ching, A., Yao, L., Smith, D.,
Webster, P., Whitmore, T., Maurer, M., Kaushansky, K., Holly, R. D., and Foster,
D. (2000) Interleukin 21 and its receptor are involved in NK cell expansion and
regulation of lymphocyte function. Nature 408, 57-63
Sivori, S., Cantoni, C., Parolini, S., Marcenaro, E., Conte, R., Moretta, L., and
Moretta, A. (2003) IL-21 induces both rapid maturation of human CD34+ cell
precursors towards NK cells and acquisition of surface killer Ig-like receptors.
European journal of immunology 33, 3439-3447
166

61.

62.
63.

64.

65.

66.

67.

68.

69.

70.

71.

72.

73.

Kotlarz, D., Zietara, N., Uzel, G., Weidemann, T., Braun, C. J., Diestelhorst, J.,
Krawitz, P. M., Robinson, P. N., Hecht, J., Puchalka, J., Gertz, E. M., Schaffer,
A. A., Lawrence, M. G., Kardava, L., Pfeifer, D., Baumann, U., Pfister, E. D.,
Hanson, E. P., Schambach, A., Jacobs, R., Kreipe, H., Moir, S., Milner, J. D.,
Schwille, P., Mundlos, S., and Klein, C. (2013) Loss-of-function mutations in the
IL-21 receptor gene cause a primary immunodeficiency syndrome. The Journal
of experimental medicine 210, 433-443
Brady, J., Hayakawa, Y., Smyth, M. J., and Nutt, S. L. (2004) IL-21 induces the
functional maturation of murine NK cells. Journal of immunology 172, 2048-2058
Kasaian, M. T., Whitters, M. J., Carter, L. L., Lowe, L. D., Jussif, J. M., Deng, B.,
Johnson, K. A., Witek, J. S., Senices, M., Konz, R. F., Wurster, A. L.,
Donaldson, D. D., Collins, M., Young, D. A., and Grusby, M. J. (2002) IL-21
limits NK cell responses and promotes antigen-specific T cell activation: a
mediator of the transition from innate to adaptive immunity. Immunity 16, 559569
Cooper, M. A., Bush, J. E., Fehniger, T. A., VanDeusen, J. B., Waite, R. E., Liu,
Y., Aguila, H. L., and Caligiuri, M. A. (2002) In vivo evidence for a dependence
on interleukin 15 for survival of natural killer cells. Blood 100, 3633-3638
Prlic, M., Blazar, B. R., Farrar, M. A., and Jameson, S. C. (2003) In vivo survival
and homeostatic proliferation of natural killer cells. The Journal of experimental
medicine 197, 967-976
Ranson, T., Vosshenrich, C. A., Corcuff, E., Richard, O., Muller, W., and Di
Santo, J. P. (2003) IL-15 is an essential mediator of peripheral NK-cell
homeostasis. Blood 101, 4887-4893
Lebrec, H., Horner, M. J., Gorski, K. S., Tsuji, W., Xia, D., Pan, W. J., Means,
G., Pietz, G., Li, N., Retter, M., Shaffer, K., Patel, N., Narayanan, P. K., and
Butz, E. A. (2013) Homeostasis of human NK cells is not IL-15 dependent.
Journal of immunology 191, 5551-5558
Nguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X.
Q., Liew, F. Y., Caligiuri, M. A., Durbin, J. E., and Biron, C. A. (2002)
Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of
NK cell responses to viral infection. Journal of immunology 169, 4279-4287
Braun, M., Bjorkstrom, N. K., Gupta, S., Sundstrom, K., Ahlm, C., Klingstrom, J.,
and Ljunggren, H. G. (2014) NK cell activation in human hantavirus infection
explained by virus-induced IL-15/IL15Ralpha expression. PLoS pathogens 10,
e1004521
Andrews, D. M., Scalzo, A. A., Yokoyama, W. M., Smyth, M. J., and DegliEsposti, M. A. (2003) Functional interactions between dendritic cells and NK
cells during viral infection. Nature immunology 4, 175-181
Sun, J. C., Ma, A., and Lanier, L. L. (2009) Cutting edge: IL-15-independent NK
cell response to mouse cytomegalovirus infection. Journal of immunology 183,
2911-2914
London, L., Perussia, B., and Trinchieri, G. (1986) Induction of proliferation in
vitro of resting human natural killer cells: IL 2 induces into cell cycle most
peripheral blood NK cells, but only a minor subset of low density T cells. Journal
of immunology 137, 3845-3854
Talmadge, J. E., Wiltrout, R. H., Counts, D. F., Herberman, R. B., McDonald, T.,
and Ortaldo, J. R. (1986) Proliferation of human peripheral blood lymphocytes
167

74.
75.

76.

77.

78.

79.

80.

81.

82.
83.

84.

85.
86.

87.

88.

induced by recombinant human interleukin 2: contribution of large granular
lymphocytes and T lymphocytes. Cellular immunology 102, 261-272
Klingemann, H. G., and Martinson, J. (2004) Ex vivo expansion of natural killer
cells for clinical applications. Cytotherapy 6, 15-22
Koehl, U., Esser, R., Zimmermann, S., Tonn, T., Kotchetkov, R., Bartling, T.,
Sorensen, J., Gruttner, H. P., Bader, P., Seifried, E., Martin, H., Lang, P.,
Passweg, J. R., Klingebiel, T., and Schwabe, D. (2005) Ex vivo expansion of
highly purified NK cells for immunotherapy after haploidentical stem cell
transplantation in children. Klinische Padiatrie 217, 345-350
Cai, G., Kastelein, R. A., and Hunter, C. A. (1999) IL-10 enhances NK cell
proliferation, cytotoxicity and production of IFN-gamma when combined with IL18. European journal of immunology 29, 2658-2665
Tomura, M., Zhou, X. Y., Maruo, S., Ahn, H. J., Hamaoka, T., Okamura, H.,
Nakanishi, K., Tanimoto, T., Kurimoto, M., and Fujiwara, H. (1998) A critical role
for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. Journal of
immunology 160, 4738-4746
Lauwerys, B. R., Renauld, J. C., and Houssiau, F. A. (1999) Synergistic
proliferation and activation of natural killer cells by interleukin 12 and interleukin
18. Cytokine 11, 822-830
French, A. R., Holroyd, E. B., Yang, L., Kim, S., and Yokoyama, W. M. (2006) IL18 acts synergistically with IL-15 in stimulating natural killer cell proliferation.
Cytokine 35, 229-234
Wendt, K., Wilk, E., Buyny, S., Schmidt, R. E., and Jacobs, R. (2007)
Interleukin-21 differentially affects human natural killer cell subsets. Immunology
122, 486-495
Skak, K., Frederiksen, K. S., and Lundsgaard, D. (2008) Interleukin-21 activates
human natural killer cells and modulates their surface receptor expression.
Immunology 123, 575-583
Zwirner, N. W., and Domaica, C. I. (2010) Cytokine regulation of natural killer
cell effector functions. BioFactors 36, 274-288
Yu, C. R., Ortaldo, J. R., Curiel, R. E., Young, H. A., Anderson, S. K., and
Gosselin, P. (1999) Role of a STAT binding site in the regulation of the human
perforin promoter. Journal of immunology 162, 2785-2790
Yamamoto, K., Shibata, F., Miyasaka, N., and Miura, O. (2002) The human
perforin gene is a direct target of STAT4 activated by IL-12 in NK cells.
Biochemical and biophysical research communications 297, 1245-1252
Leong, J. W., and Fehniger, T. A. (2011) Human NK cells: SET to kill. Blood
117, 2297-2298
Hwang, I., Scott, J. M., Kakarla, T., Duriancik, D. M., Choi, S., Cho, C., Lee, T.,
Park, H., French, A. R., Beli, E., Gardner, E., and Kim, S. (2012) Activation
mechanisms of natural killer cells during influenza virus infection. PloS one 7,
e51858
Konjevic, G., Mirjacic Martinovic, K., Vuletic, A., and Babovic, N. (2010) In-vitro
IL-2 or IFN-alpha-induced NKG2D and CD161 NK cell receptor expression
indicates novel aspects of NK cell activation in metastatic melanoma patients.
Melanoma research 20, 459-467
Sutherland, C. L., Chalupny, N. J., Schooley, K., VandenBos, T., Kubin, M., and
Cosman, D. (2002) UL16-binding proteins, novel MHC class I-related proteins,
168

89.

90.

91.

92.

93.

94.

95.

96.

97.

98.
99.
100.

101.
102.
103.

bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Journal of immunology 168, 671-679
Park, Y. P., Choi, S. C., Kiesler, P., Gil-Krzewska, A., Borrego, F., Weck, J.,
Krzewski, K., and Coligan, J. E. (2011) Complex regulation of human NKG2DDAP10 cell surface expression: opposing roles of the gammac cytokines and
TGF-beta1. Blood 118, 3019-3027
Smyth, M. J., Swann, J., Kelly, J. M., Cretney, E., Yokoyama, W. M.,
Diefenbach, A., Sayers, T. J., and Hayakawa, Y. (2004) NKG2D recognition and
perforin effector function mediate effective cytokine immunotherapy of cancer.
The Journal of experimental medicine 200, 1325-1335
Dybkaer, K., Iqbal, J., Zhou, G., Geng, H., Xiao, L., Schmitz, A., d'Amore, F.,
and Chan, W. C. (2007) Genome wide transcriptional analysis of resting and IL2
activated human natural killer cells: gene expression signatures indicative of
novel molecular signaling pathways. BMC genomics 8, 230
Burgess, S. J., Marusina, A. I., Pathmanathan, I., Borrego, F., and Coligan, J. E.
(2006) IL-21 down-regulates NKG2D/DAP10 expression on human NK and
CD8+ T cells. Journal of immunology 176, 1490-1497
Michel, T., Hentges, F., and Zimmer, J. (2012) Consequences of the crosstalk
between monocytes/macrophages and natural killer cells. Frontiers in
immunology 3, 403
Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A., and
Yokoyama, W. M. (2009) Cytokine-induced memory-like natural killer cells.
Proceedings of the National Academy of Sciences of the United States of
America 106, 1915-1919
Romee, R., Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R.,
Sullivan, R. P., Cooper, M. A., and Fehniger, T. A. (2012) Cytokine activation
induces human memory-like NK cells. Blood 120, 4751-4760
Sun, J. C., Madera, S., Bezman, N. A., Beilke, J. N., Kaplan, M. H., and Lanier,
L. L. (2012) Proinflammatory cytokine signaling required for the generation of
natural killer cell memory. The Journal of experimental medicine 209, 947-954
O'Shea, J. J., Holland, S. M., and Staudt, L. M. (2013) JAKs and STATs in
immunity, immunodeficiency, and cancer. The New England journal of medicine
368, 161-170
Shuai, K., and Liu, B. (2003) Regulation of JAK-STAT signalling in the immune
system. Nature reviews. Immunology 3, 900-911
Levy, D. E., and Darnell, J. E., Jr. (2002) Stats: transcriptional control and
biological impact. Nature reviews. Molecular cell biology 3, 651-662
Regis, G., Pensa, S., Boselli, D., Novelli, F., and Poli, V. (2008) Ups and downs:
the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Seminars
in cell & developmental biology 19, 351-359
Yang, J., and Stark, G. R. (2008) Roles of unphosphorylated STATs in signaling.
Cell research 18, 443-451
Casanova, J. L., Holland, S. M., and Notarangelo, L. D. (2012) Inborn errors of
human JAKs and STATs. Immunity 36, 515-528
Hambleton, S., Goodbourn, S., Young, D. F., Dickinson, P., Mohamad, S. M.,
Valappil, M., McGovern, N., Cant, A. J., Hackett, S. J., Ghazal, P., Morgan, N.
V., and Randall, R. E. (2013) STAT2 deficiency and susceptibility to viral illness
in humans. Proceedings of the National Academy of Sciences of the United
States of America 110, 3053-3058
169

104.

105.
106.
107.
108.
109.
110.
111.

112.

113.

114.
115.

116.

117.

118.

119.

Rochman, Y., Spolski, R., and Leonard, W. J. (2009) New insights into the
regulation of T cells by gamma(c) family cytokines. Nature reviews. Immunology
9, 480-490
Akira, S. (2000) Roles of STAT3 defined by tissue-specific gene targeting.
Oncogene 19, 2607-2611
Johnston, P. A., and Grandis, J. R. (2011) STAT3 signaling: anticancer
strategies and challenges. Molecular interventions 11, 18-26
Levy, D. E., and Lee, C. K. (2002) What does Stat3 do? The Journal of clinical
investigation 109, 1143-1148
Zhang, H. F., and Lai, R. (2014) STAT3 in Cancer-Friend or Foe? Cancers 6,
1408-1440
Carpenter, R. L., and Lo, H. W. (2014) STAT3 Target Genes Relevant to Human
Cancers. Cancers 6, 897-925
Delgoffe, G. M., and Vignali, D. A. (2013) STAT heterodimers in immunity: A
mixed message or a unique signal? Jak-Stat 2, e23060
Wegrzyn, J., Potla, R., Chwae, Y. J., Sepuri, N. B., Zhang, Q., Koeck, T.,
Derecka, M., Szczepanek, K., Szelag, M., Gornicka, A., Moh, A., Moghaddas,
S., Chen, Q., Bobbili, S., Cichy, J., Dulak, J., Baker, D. P., Wolfman, A., Stuehr,
D., Hassan, M. O., Fu, X. Y., Avadhani, N., Drake, J. I., Fawcett, P., Lesnefsky,
E. J., and Larner, A. C. (2009) Function of mitochondrial Stat3 in cellular
respiration. Science 323, 793-797
Dauer, D. J., Ferraro, B., Song, L., Yu, B., Mora, L., Buettner, R., Enkemann, S.,
Jove, R., and Haura, E. B. (2005) Stat3 regulates genes common to both wound
healing and cancer. Oncogene 24, 3397-3408
Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N.,
Kishimoto, T., and Akira, S. (1997) Targeted disruption of the mouse Stat3 gene
leads to early embryonic lethality. Proceedings of the National Academy of
Sciences of the United States of America 94, 3801-3804
Yu, H., Pardoll, D., and Jove, R. (2009) STATs in cancer inflammation and
immunity: a leading role for STAT3. Nature reviews. Cancer 9, 798-809
Yu, H., Kortylewski, M., and Pardoll, D. (2007) Crosstalk between cancer and
immune cells: role of STAT3 in the tumour microenvironment. Nature reviews.
Immunology 7, 41-51
Tangye, S. G., Cook, M. C., and Fulcher, D. A. (2009) Insights into the role of
STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE
syndrome. Journal of immunology 182, 21-28
Harris, T. J., Grosso, J. F., Yen, H. R., Xin, H., Kortylewski, M., Albesiano, E.,
Hipkiss, E. L., Getnet, D., Goldberg, M. V., Maris, C. H., Housseau, F., Yu, H.,
Pardoll, D. M., and Drake, C. G. (2007) Cutting edge: An in vivo requirement for
STAT3 signaling in TH17 development and TH17-dependent autoimmunity.
Journal of immunology 179, 4313-4317
Yang, X. O., Panopoulos, A. D., Nurieva, R., Chang, S. H., Wang, D., Watowich,
S. S., and Dong, C. (2007) STAT3 regulates cytokine-mediated generation of
inflammatory helper T cells. The Journal of biological chemistry 282, 9358-9363
Stumhofer, J. S., Silver, J. S., Laurence, A., Porrett, P. M., Harris, T. H., Turka,
L. A., Ernst, M., Saris, C. J., O'Shea, J. J., and Hunter, C. A. (2007) Interleukins
27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nature
immunology 8, 1363-1371
170

120.

121.

122.

123.

124.
125.

126.

127.
128.

129.
130.

131.

Cui, W., Liu, Y., Weinstein, J. S., Craft, J., and Kaech, S. M. (2011) An
interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation
of memory CD8+ T cells. Immunity 35, 792-805
Fornek, J. L., Tygrett, L. T., Waldschmidt, T. J., Poli, V., Rickert, R. C., and
Kansas, G. S. (2006) Critical role for Stat3 in T-dependent terminal
differentiation of IgG B cells. Blood 107, 1085-1091
Takeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., and
Akira, S. (1999) Enhanced Th1 activity and development of chronic enterocolitis
in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49
Nguyen-Jackson, H., Panopoulos, A. D., Zhang, H., Li, H. S., and Watowich, S.
S. (2010) STAT3 controls the neutrophil migratory response to CXCR2 ligands
by direct activation of G-CSF-induced CXCR2 expression and via modulation of
CXCR2 signal transduction. Blood 115, 3354-3363
Laouar, Y., Welte, T., Fu, X. Y., and Flavell, R. A. (2003) STAT3 is required for
Flt3L-dependent dendritic cell differentiation. Immunity 19, 903-912
Milner, J. D., Vogel, T. P., Forbes, L., Ma, C. A., Stray-Pedersen, A., Niemela, J.
E., Lyons, J. J., Engelhardt, K. R., Zhang, Y., Topcagic, N., Roberson, E. D.,
Matthews, H., Verbsky, J. W., Dasu, T., Vargas-Hernandez, A., Varghese, N.,
McClain, K. L., Karam, L. B., Nahmod, K., Makedonas, G., Mace, E. M., Sorte,
H. S., Perminow, G., Rao, V. K., O'Connell, M. P., Price, S., Su, H. C., Butrick,
M., McElwee, J., Hughes, J. D., Willet, J., Swan, D., Xu, Y., Santibanez-Koref,
M., Slowik, V., Dinwiddie, D. L., Ciaccio, C. E., Saunders, C. J., Septer, S.,
Kingsmore, S. F., White, A. J., Cant, A. J., Hambleton, S., and Cooper, M. A.
(2015) Early-onset lymphoproliferation and autoimmunity caused by germline
STAT3 gain-of-function mutations. Blood 125, 591-599
Haapaniemi, E. M., Kaustio, M., Rajala, H. L., van Adrichem, A. J., Kainulainen,
L., Glumoff, V., Doffinger, R., Kuusanmaki, H., Heiskanen-Kosma, T., Trotta, L.,
Chiang, S., Kulmala, P., Eldfors, S., Katainen, R., Siitonen, S., KarjalainenLindsberg, M. L., Kovanen, P. E., Otonkoski, T., Porkka, K., Heiskanen, K.,
Hanninen, A., Bryceson, Y. T., Uusitalo-Seppala, R., Saarela, J., Seppanen, M.,
Mustjoki, S., and Kere, J. (2015) Autoimmunity, hypogammaglobulinemia,
lymphoproliferation, and mycobacterial disease in patients with activating
mutations in STAT3. Blood 125, 639-648
Davis, S. D., Schaller, J., and Wedgwood, R. J. (1966) Job's Syndrome.
Recurrent, "cold", staphylococcal abscesses. Lancet 1, 1013-1015
Buckley, R. H., Wray, B. B., and Belmaker, E. Z. (1972) Extreme
hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 49,
59-70
Sowerwine, K. J., Holland, S. M., and Freeman, A. F. (2012) Hyper-IgE
syndrome update. Annals of the New York Academy of Sciences 1250, 25-32
Holland, S. M., DeLeo, F. R., Elloumi, H. Z., Hsu, A. P., Uzel, G., Brodsky, N.,
Freeman, A. F., Demidowich, A., Davis, J., Turner, M. L., Anderson, V. L.,
Darnell, D. N., Welch, P. A., Kuhns, D. B., Frucht, D. M., Malech, H. L., Gallin, J.
I., Kobayashi, S. D., Whitney, A. R., Voyich, J. M., Musser, J. M., Woellner, C.,
Schaffer, A. A., Puck, J. M., and Grimbacher, B. (2007) STAT3 mutations in the
hyper-IgE syndrome. The New England journal of medicine 357, 1608-1619
Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T.,
Kawamura, N., Ariga, T., Pasic, S., Stojkovic, O., Metin, A., and Karasuyama, H.
171

132.
133.

134.

135.

136.

137.

138.

139.
140.

141.

142.

143.

144.

(2007) Dominant-negative mutations in the DNA-binding domain of STAT3
cause hyper-IgE syndrome. Nature 448, 1058-1062
Freeman, A. F., and Holland, S. M. (2009) Clinical manifestations, etiology, and
pathogenesis of the hyper-IgE syndromes. Pediatric research 65, 32R-37R
Kane, A., Deenick, E. K., Ma, C. S., Cook, M. C., Uzel, G., and Tangye, S. G.
(2014) STAT3 is a central regulator of lymphocyte differentiation and function.
Current opinion in immunology 28, 49-57
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L.
M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., Champlin, R.
E., Cooper, L. J., and Lee, D. A. (2012) Membrane-bound IL-21 promotes
sustained ex vivo proliferation of human natural killer cells. PloS one 7, e30264
Zeng, R., Spolski, R., Casas, E., Zhu, W., Levy, D. E., and Leonard, W. J.
(2007) The molecular basis of IL-21-mediated proliferation. Blood 109, 41354142
Zhu, S., Phatarpekar, P. V., Denman, C. J., Senyukov, V. V., Somanchi, S. S.,
Nguyen-Jackson, H. T., Mace, E. M., Freeman, A. F., Watowich, S. S., Orange,
J. S., Holland, S. M., and Lee, D. A. (2014) Transcription of the activating
receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine
phosphorylation. Blood 124, 403-411
Villarino, A. V., Kanno, Y., Ferdinand, J. R., and O'Shea, J. J. (2015)
Mechanisms of Jak/STAT signaling in immunity and disease. Journal of
immunology 194, 21-27
Yang, E., Wen, Z., Haspel, R. L., Zhang, J. J., and Darnell, J. E., Jr. (1999) The
linker domain of Stat1 is required for gamma interferon-driven transcription.
Molecular and cellular biology 19, 5106-5112
Horvath, C. M. (2000) STAT proteins and transcriptional responses to
extracellular signals. Trends in biochemical sciences 25, 496-502
Wang, X., Crowe, P. J., Goldstein, D., and Yang, J. L. (2012) STAT3 inhibition, a
novel approach to enhancing targeted therapy in human cancers (review).
International journal of oncology 41, 1181-1191
Yong, P. F., Freeman, A. F., Engelhardt, K. R., Holland, S., Puck, J. M., and
Grimbacher, B. (2012) An update on the hyper-IgE syndromes. Arthritis research
& therapy 14, 228
Renner, E. D., Rylaarsdam, S., Anover-Sombke, S., Rack, A. L., Reichenbach,
J., Carey, J. C., Zhu, Q., Jansson, A. F., Barboza, J., Schimke, L. F., Leppert, M.
F., Getz, M. M., Seger, R. A., Hill, H. R., Belohradsky, B. H., Torgerson, T. R.,
and Ochs, H. D. (2008) Novel signal transducer and activator of transcription 3
(STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3
phosphorylation in hyper-IgE syndrome. The Journal of allergy and clinical
immunology 122, 181-187
Jiao, H., Toth, B., Erdos, M., Fransson, I., Rakoczi, E., Balogh, I., Magyarics, Z.,
Derfalvi, B., Csorba, G., Szaflarska, A., Megarbane, A., Akatcherian, C., Dbaibo,
G., Rajnavolgyi, E., Hammarstrom, L., Kere, J., Lefranc, G., and Marodi, L.
(2008) Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients
from different ethnic groups. Molecular immunology 46, 202-206
Chandesris, M. O., Melki, I., Natividad, A., Puel, A., Fieschi, C., Yun, L.,
Thumerelle, C., Oksenhendler, E., Boutboul, D., Thomas, C., Hoarau, C.,
Lebranchu, Y., Stephan, J. L., Cazorla, C., Aladjidi, N., Micheau, M., Tron, F.,
Baruchel, A., Barlogis, V., Palenzuela, G., Mathey, C., Dominique, S., Body, G.,
172

145.

146.

147.

148.

149.

150.

151.

Munzer, M., Fouyssac, F., Jaussaud, R., Bader-Meunier, B., Mahlaoui, N.,
Blanche, S., Debre, M., Le Bourgeois, M., Gandemer, V., Lambert, N., Grandin,
V., Ndaga, S., Jacques, C., Harre, C., Forveille, M., Alyanakian, M. A., Durandy,
A., Bodemer, C., Suarez, F., Hermine, O., Lortholary, O., Casanova, J. L.,
Fischer, A., and Picard, C. (2012) Autosomal dominant STAT3 deficiency and
hyper-IgE syndrome: molecular, cellular, and clinical features from a French
national survey. Medicine 91, e1-19
Woellner, C., Gertz, E. M., Schaffer, A. A., Lagos, M., Perro, M., Glocker, E. O.,
Pietrogrande, M. C., Cossu, F., Franco, J. L., Matamoros, N., Pietrucha, B.,
Heropolitanska-Pliszka, E., Yeganeh, M., Moin, M., Espanol, T., Ehl, S.,
Gennery, A. R., Abinun, M., Breborowicz, A., Niehues, T., Kilic, S. S., Junker, A.,
Turvey, S. E., Plebani, A., Sanchez, B., Garty, B. Z., Pignata, C., Cancrini, C.,
Litzman, J., Sanal, O., Baumann, U., Bacchetta, R., Hsu, A. P., Davis, J. N.,
Hammarstrom, L., Davies, E. G., Eren, E., Arkwright, P. D., Moilanen, J. S.,
Viemann, D., Khan, S., Marodi, L., Cant, A. J., Freeman, A. F., Puck, J. M.,
Holland, S. M., and Grimbacher, B. (2010) Mutations in STAT3 and diagnostic
guidelines for hyper-IgE syndrome. The Journal of allergy and clinical
immunology 125, 424-432 e428
Schimke, L. F., Sawalle-Belohradsky, J., Roesler, J., Wollenberg, A., Rack, A.,
Borte, M., Rieber, N., Cremer, R., Maass, E., Dopfer, R., Reichenbach, J.,
Wahn, V., Hoenig, M., Jansson, A. F., Roesen-Wolff, A., Schaub, B., Seger, R.,
Hill, H. R., Ochs, H. D., Torgerson, T. R., Belohradsky, B. H., and Renner, E. D.
(2010) Diagnostic approach to the hyper-IgE syndromes: immunologic and
clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis.
The Journal of allergy and clinical immunology 126, 611-617 e611
Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K.
M., Kanno, Y., Spalding, C., Elloumi, H. Z., Paulson, M. L., Davis, J., Hsu, A.,
Asher, A. I., O'Shea, J., Holland, S. M., Paul, W. E., and Douek, D. C. (2008)
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyperIgE syndrome. Nature 452, 773-776
Ma, C. S., Chew, G. Y., Simpson, N., Priyadarshi, A., Wong, M., Grimbacher, B.,
Fulcher, D. A., Tangye, S. G., and Cook, M. C. (2008) Deficiency of Th17 cells in
hyper IgE syndrome due to mutations in STAT3. The Journal of experimental
medicine 205, 1551-1557
Ma, C. S., Avery, D. T., Chan, A., Batten, M., Bustamante, J., Boisson-Dupuis,
S., Arkwright, P. D., Kreins, A. Y., Averbuch, D., Engelhard, D., Magdorf, K.,
Kilic, S. S., Minegishi, Y., Nonoyama, S., French, M. A., Choo, S., Smart, J. M.,
Peake, J., Wong, M., Gray, P., Cook, M. C., Fulcher, D. A., Casanova, J. L.,
Deenick, E. K., and Tangye, S. G. (2012) Functional STAT3 deficiency
compromises the generation of human T follicular helper cells. Blood 119, 39974008
Saito, M., Nagasawa, M., Takada, H., Hara, T., Tsuchiya, S., Agematsu, K.,
Yamada, M., Kawamura, N., Ariga, T., Tsuge, I., Nonoyama, S., Karasuyama,
H., and Minegishi, Y. (2011) Defective IL-10 signaling in hyper-IgE syndrome
results in impaired generation of tolerogenic dendritic cells and induced
regulatory T cells. The Journal of experimental medicine 208, 235-249
Siegel, A. M., Heimall, J., Freeman, A. F., Hsu, A. P., Brittain, E., Brenchley, J.
M., Douek, D. C., Fahle, G. H., Cohen, J. I., Holland, S. M., and Milner, J. D.
173

152.

153.

154.

155.

156.

157.
158.
159.

160.

161.
162.

163.

(2011) A critical role for STAT3 transcription factor signaling in the development
and maintenance of human T cell memory. Immunity 35, 806-818
Speckmann, C., Enders, A., Woellner, C., Thiel, D., Rensing-Ehl, A., Schlesier,
M., Rohr, J., Jakob, T., Oswald, E., Kopp, M. V., Sanal, O., Litzman, J., Plebani,
A., Pietrogrande, M. C., Franco, J. L., Espanol, T., Grimbacher, B., and Ehl, S.
(2008) Reduced memory B cells in patients with hyper IgE syndrome. Clinical
immunology 129, 448-454
Avery, D. T., Deenick, E. K., Ma, C. S., Suryani, S., Simpson, N., Chew, G. Y.,
Chan, T. D., Palendira, U., Bustamante, J., Boisson-Dupuis, S., Choo, S.,
Bleasel, K. E., Peake, J., King, C., French, M. A., Engelhard, D., Al-Hajjar, S.,
Al-Muhsen, S., Magdorf, K., Roesler, J., Arkwright, P. D., Hissaria, P., Riminton,
D. S., Wong, M., Brink, R., Fulcher, D. A., Casanova, J. L., Cook, M. C., and
Tangye, S. G. (2010) B cell-intrinsic signaling through IL-21 receptor and STAT3
is required for establishing long-lived antibody responses in humans. The
Journal of experimental medicine 207, 155-171
Siegel, A. M., Stone, K. D., Cruse, G., Lawrence, M. G., Olivera, A., Jung, M. Y.,
Barber, J. S., Freeman, A. F., Holland, S. M., O'Brien, M., Jones, N., Nelson, C.
G., Wisch, L. B., Kong, H. H., Desai, A., Farber, O., Gilfillan, A. M., Rivera, J.,
and Milner, J. D. (2013) Diminished allergic disease in patients with STAT3
mutations reveals a role for STAT3 signaling in mast cell degranulation. The
Journal of allergy and clinical immunology 132, 1388-1396
Leonard, G. D., Posadas, E., Herrmann, P. C., Anderson, V. L., Jaffe, E. S.,
Holland, S. M., and Wilson, W. H. (2004) Non-Hodgkin's lymphoma in Job's
syndrome: a case report and literature review. Leukemia & lymphoma 45, 25212525
Kumanovics, A., Perkins, S. L., Gilbert, H., Cessna, M. H., Augustine, N. H., and
Hill, H. R. (2010) Diffuse large B cell lymphoma in hyper-IgE syndrome due to
STAT3 mutation. Journal of clinical immunology 30, 886-893
Krzewski, K., and Coligan, J. E. (2012) Human NK cell lytic granules and
regulation of their exocytosis. Frontiers in immunology 3, 335
Orange, J. S. (2008) Formation and function of the lytic NK-cell immunological
synapse. Nature reviews. Immunology 8, 713-725
Mace, E. M., Dongre, P., Hsu, H. T., Sinha, P., James, A. M., Mann, S. S.,
Forbes, L. R., Watkin, L. B., and Orange, J. S. (2014) Cell biological steps and
checkpoints in accessing NK cell cytotoxicity. Immunology and cell biology 92,
245-255
Romee, R., Leong, J. W., and Fehniger, T. A. (2014) Utilizing cytokines to
function-enable human NK cells for the immunotherapy of cancer. Scientifica
2014, 205796
Liang, S., Wei, H., Sun, R., and Tian, Z. (2003) IFNalpha regulates NK cell
cytotoxicity through STAT1 pathway. Cytokine 23, 190-199
Imada, K., Bloom, E. T., Nakajima, H., Horvath-Arcidiacono, J. A., Udy, G. B.,
Davey, H. W., and Leonard, W. J. (1998) Stat5b is essential for natural killer cellmediated proliferation and cytolytic activity. The Journal of experimental
medicine 188, 2067-2074
Fortin, C., Huang, X., and Yang, Y. (2013) Both NK cell-intrinsic and -extrinsic
STAT1 signaling are required for NK cell response against vaccinia virus.
Journal of immunology 191, 363-368
174

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

175.
176.

Lee, C. K., Rao, D. T., Gertner, R., Gimeno, R., Frey, A. B., and Levy, D. E.
(2000) Distinct requirements for IFNs and STAT1 in NK cell function. Journal of
immunology 165, 3571-3577
Lesinski, G. B., Anghelina, M., Zimmerer, J., Bakalakos, T., Badgwell, B.,
Parihar, R., Hu, Y., Becknell, B., Abood, G., Chaudhury, A. R., Magro, C.,
Durbin, J., and Carson, W. E., 3rd. (2003) The antitumor effects of IFN-alpha are
abrogated in a STAT1-deficient mouse. The Journal of clinical investigation 112,
170-180
Vairo, D., Tassone, L., Tabellini, G., Tamassia, N., Gasperini, S., Bazzoni, F.,
Plebani, A., Porta, F., Notarangelo, L. D., Parolini, S., Giliani, S., and Badolato,
R. (2011) Severe impairment of IFN-gamma and IFN-alpha responses in cells of
a patient with a novel STAT1 splicing mutation. Blood 118, 1806-1817
Kaplan, M. H., Sun, Y. L., Hoey, T., and Grusby, M. J. (1996) Impaired IL-12
responses and enhanced development of Th2 cells in Stat4-deficient mice.
Nature 382, 174-177
Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S.
R., Carson, R. T., Sangster, M. Y., Vignali, D. A., Doherty, P. C., Grosveld, G.
C., and Ihle, J. N. (1996) Requirement for Stat4 in interleukin-12-mediated
responses of natural killer and T cells. Nature 382, 171-174
Frank, D. A., Robertson, M. J., Bonni, A., Ritz, J., and Greenberg, M. E. (1995)
Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proceedings
of the National Academy of Sciences of the United States of America 92, 77797783
Kim, T. J., Kim, N., Kang, H. J., Kim, E. O., Kim, S. T., Ahn, H. S., Bluestone, J.
A., and Lee, K. M. (2010) FK506 causes cellular and functional defects in human
natural killer cells. Journal of leukocyte biology 88, 1089-1097
Strengell, M., Matikainen, S., Siren, J., Lehtonen, A., Foster, D., Julkunen, I.,
and Sareneva, T. (2003) IL-21 in synergy with IL-15 or IL-18 enhances IFNgamma production in human NK and T cells. Journal of immunology 170, 54645469
Kalina, U., Kauschat, D., Koyama, N., Nuernberger, H., Ballas, K., Koschmieder,
S., Bug, G., Hofmann, W. K., Hoelzer, D., and Ottmann, O. G. (2000) IL-18
activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and
mediates IFN-gamma production by the stress kinase p38 and by the
extracellular regulated kinases p44erk-1 and p42erk-21. Journal of immunology
165, 1307-1313
Yu, C. R., Lin, J. X., Fink, D. W., Akira, S., Bloom, E. T., and Yamauchi, A.
(1996) Differential utilization of Janus kinase-signal transducer activator of
transcription signaling pathways in the stimulation of human natural killer cells by
IL-2, IL-12, and IFN-alpha. Journal of immunology 157, 126-137
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G.,
Albanese, C., and Darnell, J. E., Jr. (1999) Stat3 as an oncogene. Cell 98, 295303
Yue, P., and Turkson, J. (2009) Targeting STAT3 in cancer: how successful are
we? Expert opinion on investigational drugs 18, 45-56
Somanchi, S. S., Senyukov, V. V., Denman, C. J., and Lee, D. A. (2011)
Expansion, purification, and functional assessment of human peripheral blood
NK cells. Journal of visualized experiments : JoVE
175

177.

178.

179.
180.

181.

182.

183.

184.

185.

186.

187.

188.

189.

190.

Bryant, J., Day, R., Whiteside, T. L., and Herberman, R. B. (1992) Calculation of
lytic units for the expression of cell-mediated cytotoxicity. Journal of
immunological methods 146, 91-103
Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., and Madden, T.
L. (2012) Primer-BLAST: a tool to design target-specific primers for polymerase
chain reaction. BMC bioinformatics 13, 134
Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to
ImageJ: 25 years of image analysis. Nature methods 9, 671-675
Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25, 402-408
Liadi, I., Roszik, J., Romain, G., Cooper, L. J., and Varadarajan, N. (2013)
Quantitative high-throughput single-cell cytotoxicity assay for T cells. Journal of
visualized experiments : JoVE, e50058
Romain, G., Senyukov, V., Rey-Villamizar, N., Merouane, A., Kelton, W., Liadi,
I., Mahendra, A., Charab, W., Georgiou, G., Roysam, B., Lee, D. A., and
Varadarajan, N. (2014) Antibody Fc engineering improves frequency and
promotes kinetic boosting of serial killing mediated by NK cells. Blood 124,
3241-3249
Merouane, A., Rey-Villamizar, N., Lu, Y., Liadi, I., Romain, G., Lu, J., Singh, H.,
Cooper, L. J., Varadarajan, N., and Roysam, B. (2015) Automated profiling of
individual cell-cell interactions from high-throughput time-lapse imaging
microscopy in nanowell grids (TIMING). Bioinformatics
Banerjee, P. P., and Orange, J. S. (2010) Quantitative measurement of F-actin
accumulation at the NK cell immunological synapse. Journal of immunological
methods 355, 1-13
Banerjee, P. P., Pandey, R., Zheng, R., Suhoski, M. M., Monaco-Shawver, L.,
and Orange, J. S. (2007) Cdc42-interacting protein-4 functionally links actin and
microtubule networks at the cytolytic NK cell immunological synapse. The
Journal of experimental medicine 204, 2305-2320
Mentlik, A. N., Sanborn, K. B., Holzbaur, E. L., and Orange, J. S. (2010) Rapid
lytic granule convergence to the MTOC in natural killer cells is dependent on
dynein but not cytolytic commitment. Molecular biology of the cell 21, 2241-2256
Roger, R., Issaad, C., Pallardy, M., Leglise, M. C., Turhan, A. G., Bertoglio, J.,
and Breard, J. (1996) BCR-ABL does not prevent apoptotic death induced by
human natural killer or lymphokine-activated killer cells. Blood 87, 1113-1122
Park, Y. W., Kee, S. J., Cho, Y. N., Lee, E. H., Lee, H. Y., Kim, E. M., Shin, M.
H., Park, J. J., Kim, T. J., Lee, S. S., Yoo, D. H., and Kang, H. S. (2009)
Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus
erythematosus. Arthritis and rheumatism 60, 1753-1763
Voskens, C. J., Watanabe, R., Rollins, S., Campana, D., Hasumi, K., and Mann,
D. L. (2010) Ex-vivo expanded human NK cells express activating receptors that
mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct
recognition and antibody directed cellular cytotoxicity. Journal of experimental &
clinical cancer research : CR 29, 134
Bryceson, Y. T., Fauriat, C., Nunes, J. M., Wood, S. M., Bjorkstrom, N. K., Long,
E. O., and Ljunggren, H. G. (2010) Functional analysis of human NK cells by
flow cytometry. Methods in molecular biology 612, 335-352
176

191.

192.

193.
194.

195.

196.

197.

198.

199.
200.

201.

202.

203.

204.

Sierich, H., and Eiermann, T. (2013) Comparing individual NK cell activity in
vitro. Current protocols in immunology / edited by John E. Coligan ... [et al.]
Chapter 14, Unit 14 32
Thielens, A., Vivier, E., and Romagne, F. (2012) NK cell MHC class I specific
receptors (KIR): from biology to clinical intervention. Current opinion in
immunology 24, 239-245
Cooper, M. A., Fehniger, T. A., and Caligiuri, M. A. (2001) The biology of human
natural killer-cell subsets. Trends in immunology 22, 633-640
Nielsen, C. M., White, M. J., Goodier, M. R., and Riley, E. M. (2013) Functional
Significance of CD57 Expression on Human NK Cells and Relevance to
Disease. Frontiers in immunology 4, 422
Vossen, M. T., Matmati, M., Hertoghs, K. M., Baars, P. A., Gent, M. R., Leclercq,
G., Hamann, J., Kuijpers, T. W., and van Lier, R. A. (2008) CD27 defines
phenotypically and functionally different human NK cell subsets. Journal of
immunology 180, 3739-3745
Clausen, J., Vergeiner, B., Enk, M., Petzer, A. L., Gastl, G., and Gunsilius, E.
(2003) Functional significance of the activation-associated receptors CD25 and
CD69 on human NK-cells and NK-like T-cells. Immunobiology 207, 85-93
Dancker, P., Low, I., Hasselbach, W., and Wieland, T. (1975) Interaction of actin
with phalloidin: polymerization and stabilization of F-actin. Biochimica et
biophysica acta 400, 407-414
Lin, L., Amin, R., Gallicano, G. I., Glasgow, E., Jogunoori, W., Jessup, J. M.,
Zasloff, M., Marshall, J. L., Shetty, K., Johnson, L., Mishra, L., and He, A. R.
(2009) The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers
with disrupted TGF-beta signaling. Oncogene 28, 961-972
Liongue, C., and Ward, A. C. (2013) Evolution of the JAK-STAT pathway. JakStat 2, e22756
Tuli, A., Thiery, J., James, A. M., Michelet, X., Sharma, M., Garg, S., Sanborn,
K. B., Orange, J. S., Lieberman, J., and Brenner, M. B. (2013) Arf-like GTPase
Arl8b regulates lytic granule polarization and natural killer cell-mediated
cytotoxicity. Molecular biology of the cell 24, 3721-3735
Kanwar, N., and Wilkins, J. A. (2011) IQGAP1 involvement in MTOC and
granule polarization in NK-cell cytotoxicity. European journal of immunology 41,
2763-2773
Wang, X., Lee, D. A., Wang, Y., Wang, L., Yao, Y., Lin, Z., Cheng, J., and Zhu,
S. (2013) Membrane-bound interleukin-21 and CD137 ligand induce functional
human natural killer cells from peripheral blood mononuclear cells through
STAT-3 activation. Clinical and experimental immunology 172, 104-112
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B.,
Lawrence, H. R., Yip, M. L., Jove, R., McLaughlin, M. M., Lawrence, N. J., Sebti,
S. M., and Turkson, J. (2007) Selective chemical probe inhibitor of Stat3,
identified through structure-based virtual screening, induces antitumor activity.
Proceedings of the National Academy of Sciences of the United States of
America 104, 7391-7396
Rook, A. H., Hooks, J. J., Quinnan, G. V., Lane, H. C., Manischewitz, J. F.,
Macher, A. M., Masur, H., Fauci, A. S., and Djeu, J. Y. (1985) Interleukin 2
enhances the natural killer cell activity of acquired immunodeficiency syndrome
patients through a gamma-interferon-independent mechanism. Journal of
immunology 134, 1503-1507
177

205.

206.

207.

208.

209.

210.

211.

212.

213.

214.

215.

216.

Ogbomo, H., Michaelis, M., Kreuter, J., Doerr, H. W., and Cinatl, J., Jr. (2007)
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS
letters 581, 1317-1322
Chiossone, L., Vitale, C., Cottalasso, F., Moretti, S., Azzarone, B., Moretta, L.,
and Mingari, M. C. (2007) Molecular analysis of the methylprednisolonemediated inhibition of NK-cell function: evidence for different susceptibility of IL2- versus IL-15-activated NK cells. Blood 109, 3767-3775
Meazza, R., Azzarone, B., Orengo, A. M., and Ferrini, S. (2011) Role of
common-gamma chain cytokines in NK cell development and function:
perspectives for immunotherapy. Journal of biomedicine & biotechnology 2011,
861920
Eckelhart, E., Warsch, W., Zebedin, E., Simma, O., Stoiber, D., Kolbe, T.,
Rulicke, T., Mueller, M., Casanova, E., and Sexl, V. (2011) A novel Ncr1-Cre
mouse reveals the essential role of STAT5 for NK-cell survival and development.
Blood 117, 1565-1573
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon,
A., and Melero, I. (2011) Direct effects of type I interferons on cells of the
immune system. Clinical cancer research : an official journal of the American
Association for Cancer Research 17, 2619-2627
Robbins, S. H., Tessmer, M. S., Van Kaer, L., and Brossay, L. (2005) Direct
effects of T-bet and MHC class I expression, but not STAT1, on peripheral NK
cell maturation. European journal of immunology 35, 757-765
Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young,
D., Herrmann, S. H., and Ritz, J. (1992) Response of human natural killer (NK)
cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of
NK cells are differentially regulated by NKSF. The Journal of experimental
medicine 175, 779-788
Gately, M. K., Warrier, R. R., Honasoge, S., Carvajal, D. M., Faherty, D. A.,
Connaughton, S. E., Anderson, T. D., Sarmiento, U., Hubbard, B. R., and
Murphy, M. (1994) Administration of recombinant IL-12 to normal mice enhances
cytolytic lymphocyte activity and induces production of IFN-gamma in vivo.
International immunology 6, 157-167
Gately, M. K., Wolitzky, A. G., Quinn, P. M., and Chizzonite, R. (1992)
Regulation of human cytolytic lymphocyte responses by interleukin-12. Cellular
immunology 143, 127-142
Chehimi, J., Starr, S. E., Frank, I., Rengaraju, M., Jackson, S. J., Llanes, C.,
Kobayashi, M., Perussia, B., Young, D., Nickbarg, E., and et al. (1992) Natural
killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from
both healthy donors and human immunodeficiency virus-infected patients. The
Journal of experimental medicine 175, 789-796
Trzonkowski, P., Szmit, E., Mysliwska, J., Dobyszuk, A., and Mysliwski, A.
(2004) CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK
lymphocytes in the direct cell-to-cell interaction. Clinical immunology 112, 258267
Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig,
P. E., Novault, S., Escudier, B., Vivier, E., Lecesne, A., Robert, C., Blay, J. Y.,
Bernard, J., Caillat-Zucman, S., Freitas, A., Tursz, T., Wagner-Ballon, O.,
Capron, C., Vainchencker, W., Martin, F., and Zitvogel, L. (2005) CD4+CD25+
regulatory T cells inhibit natural killer cell functions in a transforming growth
178

217.

218.

219.

220.

221.
222.

223.

224.

225.

226.

227.

228.

factor-beta-dependent manner. The Journal of experimental medicine 202,
1075-1085
Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E., Cochran, K., Cameron,
C., Schow, P., Ross, M. E., Klumpp, T. R., Soiffer, R. J., and et al. (1993)
Selective modulation of human natural killer cells in vivo after prolonged infusion
of low dose recombinant interleukin 2. The Journal of clinical investigation 91,
123-132
Yu, T. K., Caudell, E. G., Smid, C., and Grimm, E. A. (2000) IL-2 activation of
NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. Journal of
immunology 164, 6244-6251
Vitale, M., Bassini, A., Secchiero, P., Mirandola, P., Ponti, C., Zamai, L., Mariani,
A. R., Falconi, M., and Azzali, G. (2002) NK-active cytokines IL-2, IL-12, and IL15 selectively modulate specific protein kinase C (PKC) isoforms in primary
human NK cells. The Anatomical record 266, 87-92
Yu, C. R., Young, H. A., and Ortaldo, J. R. (1998) Characterization of cytokine
differential induction of STAT complexes in primary human T and NK cells.
Journal of leukocyte biology 64, 245-258
Carow, B., and Rottenberg, M. E. (2014) SOCS3, a Major Regulator of Infection
and Inflammation. Frontiers in immunology 5, 58
Braunschweig, A., Poehlmann, T. G., Busch, S., Schleussner, E., and Markert,
U. R. (2011) Signal transducer and activator of transcription 3 (STAT3) and
Suppressor of Cytokine Signaling (SOCS3) balance controls cytotoxicity and IL10 expression in decidual-like natural killer cell line NK-92. American journal of
reproductive immunology 66, 329-335
Iannello, A., Boulassel, M. R., Samarani, S., Tremblay, C., Toma, E., Routy, J.
P., and Ahmad, A. (2010) IL-21 enhances NK cell functions and survival in
healthy and HIV-infected patients with minimal stimulation of viral replication.
Journal of leukocyte biology 87, 857-867
Fujita, M., Zhu, X., Sasaki, K., Ueda, R., Low, K. L., Pollack, I. F., and Okada, H.
(2008) Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy
using type-1 CTLs by modulation of the immunological microenvironment in a
murine intracranial glioma. Journal of immunology 180, 2089-2098
Dai, B., Meng, J., Peyton, M., Girard, L., Bornmann, W. G., Ji, L., Minna, J. D.,
Fang, B., and Roth, J. A. (2011) STAT3 mediates resistance to MEK inhibitor
through microRNA miR-17. Cancer research 71, 3658-3668
Blaskovich, M. A., Sun, J., Cantor, A., Turkson, J., Jove, R., and Sebti, S. M.
(2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal
transducer and activator of transcription 3 signaling pathway inhibitor with potent
antitumor activity against human and murine cancer cells in mice. Cancer
research 63, 1270-1279
Shi, X., Franko, B., Frantz, C., Amin, H. M., and Lai, R. (2006) JSI-124
(cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of
transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma
kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell
lymphoma cells. British journal of haematology 135, 26-32
Stankiewicz, T. R., Loucks, F. A., Schroeder, E. K., Nevalainen, M. T., Tyler, K.
L., Aktories, K., Bouchard, R. J., and Linseman, D. A. (2012) Signal transducer
and activator of transcription-5 mediates neuronal apoptosis induced by
179

229.

230.

231.
232.

233.

234.

235.

236.

237.

238.
239.

240.

241.

inhibition of Rac GTPase activity. The Journal of biological chemistry 287,
16835-16848
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S.,
Niu, G., Kay, H., Mule, J., Kerr, W. G., Jove, R., Pardoll, D., and Yu, H. (2005)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent
antitumor immunity. Nature medicine 11, 1314-1321
Gotthardt, D., Putz, E. M., Straka, E., Kudweis, P., Biaggio, M., Poli, V., Strobl,
B., Muller, M., and Sexl, V. (2014) Loss of STAT3 in murine NK cells enhances
NK cell-dependent tumor surveillance. Blood 124, 2370-2379
Mestas, J., and Hughes, C. C. (2004) Of mice and not men: differences between
mouse and human immunology. Journal of immunology 172, 2731-2738
Vaidya, S. V., and Mathew, P. A. (2006) Of mice and men: different functions of
the murine and human 2B4 (CD244) receptor on NK cells. Immunology letters
105, 180-184
Chen, X., Trivedi, P. P., Ge, B., Krzewski, K., and Strominger, J. L. (2007) Many
NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing
center and granule polarization and cytotoxicity. Proceedings of the National
Academy of Sciences of the United States of America 104, 6329-6334
Bae, D. S., Hwang, Y. K., and Lee, J. K. (2012) Importance of NKG2D-NKG2D
ligands interaction for cytolytic activity of natural killer cell. Cellular immunology
276, 122-127
Billadeau, D. D., Brumbaugh, K. M., Dick, C. J., Schoon, R. A., Bustelo, X. R.,
and Leibson, P. J. (1998) The Vav-Rac1 pathway in cytotoxic lymphocytes
regulates the generation of cell-mediated killing. The Journal of experimental
medicine 188, 549-559
Orange, J. S., Ramesh, N., Remold-O'Donnell, E., Sasahara, Y., Koopman, L.,
Byrne, M., Bonilla, F. A., Rosen, F. S., Geha, R. S., and Strominger, J. L. (2002)
Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and
colocalizes with actin to NK cell-activating immunologic synapses. Proceedings
of the National Academy of Sciences of the United States of America 99, 1135111356
Riteau, B., Barber, D. F., and Long, E. O. (2003) Vav1 phosphorylation is
induced by beta2 integrin engagement on natural killer cells upstream of actin
cytoskeleton and lipid raft reorganization. The Journal of experimental medicine
198, 469-474
Butler, B., and Cooper, J. A. (2009) Distinct roles for the actin nucleators Arp2/3
and hDia1 during NK-mediated cytotoxicity. Current biology : CB 19, 1886-1896
Orange, J. S., Roy-Ghanta, S., Mace, E. M., Maru, S., Rak, G. D., Sanborn, K.
B., Fasth, A., Saltzman, R., Paisley, A., Monaco-Shawver, L., Banerjee, P. P.,
and Pandey, R. (2011) IL-2 induces a WAVE2-dependent pathway for actin
reorganization that enables WASp-independent human NK cell function. The
Journal of clinical investigation 121, 1535-1548
James, A. M., Hsu, H. T., Dongre, P., Uzel, G., Mace, E. M., Banerjee, P. P.,
and Orange, J. S. (2013) Rapid activation receptor- or IL-2-induced lytic granule
convergence in human natural killer cells requires Src, but not downstream
signaling. Blood 121, 2627-2637
Li, C., Ge, B., Nicotra, M., Stern, J. N., Kopcow, H. D., Chen, X., and
Strominger, J. L. (2008) JNK MAP kinase activation is required for MTOC and
180

242.

243.

244.

245.

246.
247.

248.

249.

250.

251.

252.

253.

254.

granule polarization in NKG2D-mediated NK cell cytotoxicity. Proceedings of the
National Academy of Sciences of the United States of America 105, 3017-3022
Segovis, C. M., Schoon, R. A., Dick, C. J., Nacusi, L. P., Leibson, P. J., and
Billadeau, D. D. (2009) PI3K links NKG2D signaling to a CrkL pathway involved
in natural killer cell adhesion, polarity, and granule secretion. Journal of
immunology 182, 6933-6942
Liu, D., Bryceson, Y. T., Meckel, T., Vasiliver-Shamis, G., Dustin, M. L., and
Long, E. O. (2009) Integrin-dependent organization and bidirectional vesicular
traffic at cytotoxic immune synapses. Immunity 31, 99-109
Liu, D., Meckel, T., and Long, E. O. (2010) Distinct role of rab27a in granule
movement at the plasma membrane and in the cytosol of NK cells. PloS one 5,
e12870
Liu, D., Xu, L., Yang, F., Li, D., Gong, F., and Xu, T. (2005) Rapid biogenesis
and sensitization of secretory lysosomes in NK cells mediated by target-cell
recognition. Proceedings of the National Academy of Sciences of the United
States of America 102, 123-127
Waldhauer, I., and Steinle, A. (2008) NK cells and cancer immunosurveillance.
Oncogene 27, 5932-5943
Levy, E. M., Roberti, M. P., and Mordoh, J. (2011) Natural killer cells in human
cancer: from biological functions to clinical applications. Journal of biomedicine
& biotechnology 2011, 676198
Gorin, L. J., Jeha, S. C., Sullivan, M. P., Rosenblatt, H. M., and Shearer, W. T.
(1989) Burkitt's lymphoma developing in a 7-year-old boy with hyper-IgE
syndrome. The Journal of allergy and clinical immunology 83, 5-10
Nester, T. A., Wagnon, A. H., Reilly, W. F., Spitzer, G., Kjeldsberg, C. R., and
Hill, H. R. (1998) Effects of allogeneic peripheral stem cell transplantation in a
patient with job syndrome of hyperimmunoglobulinemia E and recurrent
infections. The American journal of medicine 105, 162-164
Belada, D., Smolej, L., Stepankova, P., Kralickova, P., and Freiberger, T. (2010)
Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful
treatment with risk-adapted rituximab-based immunochemotherapy. Leukemia
research 34, e232-234
Goussetis, E., Peristeri, I., Kitra, V., Traeger-Synodinos, J., Theodosaki, M.,
Psarra, K., Kanariou, M., Tzortzatou-Stathopoulou, F., Petrakou, E., Fylaktou, I.,
Kanavakis, E., and Graphakos, S. (2010) Successful long-term immunologic
reconstitution by allogeneic hematopoietic stem cell transplantation cures
patients with autosomal dominant hyper-IgE syndrome. The Journal of allergy
and clinical immunology 126, 392-394
Clark, T. J., Herod, J. J., Kehoe, S., and Luesley, D. M. (1998) The development
of invasive vulvar cancer in a patient with Job's syndrome, a rare
immunodeficient condition. British journal of obstetrics and gynaecology 105,
468-470
Oztop, I., Demirkan, B., Tarhan, O., Kayahan, H., Yilmaz, U., Kargi, A., and
Alakavuklar, M. (2004) The development of pulmonary adenocarcinoma in a
patient with Job's syndrome, a rare immunodeficiency condition. Tumori 90, 132135
Tursz, T., Dokhelar, M. C., Lipinski, M., and Amiel, J. L. (1982) Low natural killer
cell activity in patients with malignant lymphoma. Cancer 50, 2333-2335
181

255.

256.

257.

258.

259.

260.

261.

262.

263.

264.

265.

266.

267.

Konjevic, G., Jurisic, V., Banicevic, B., and Spuzic, I. (1999) The difference in
NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's
disease. British journal of haematology 104, 144-151
Reiners, K. S., Kessler, J., Sauer, M., Rothe, A., Hansen, H. P., Reusch, U.,
Hucke, C., Kohl, U., Durkop, H., Engert, A., and von Strandmann, E. P. (2013)
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific
antibodies in vitro and in patients. Molecular therapy : the journal of the
American Society of Gene Therapy 21, 895-903
Putz, E. M., Hoelzl, M. A., Baeck, J., Bago-Horvath, Z., Schuster, C., Reichholf,
B., Kern, D., Aberger, F., Sexl, V., and Hoelbl-Kovacic, A. (2014) Loss of STAT3
in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. Cancers 6, 193210
Roda, J. M., Parihar, R., Lehman, A., Mani, A., Tridandapani, S., and Carson,
W. E., 3rd. (2006) Interleukin-21 enhances NK cell activation in response to
antibody-coated targets. Journal of immunology 177, 120-129
Eriksen, K. W., Sondergaard, H., Woetmann, A., Krejsgaard, T., Skak, K.,
Geisler, C., Wasik, M. A., and Odum, N. (2009) The combination of IL-21 and
IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.
Molecular immunology 46, 812-820
Takaki, R., Hayakawa, Y., Nelson, A., Sivakumar, P. V., Hughes, S., Smyth, M.
J., and Lanier, L. L. (2005) IL-21 enhances tumor rejection through a NKG2Ddependent mechanism. Journal of immunology 175, 2167-2173
Jamieson, A. M., Isnard, P., Dorfman, J. R., Coles, M. C., and Raulet, D. H.
(2004) Turnover and proliferation of NK cells in steady state and lymphopenic
conditions. Journal of immunology 172, 864-870
Sun, J. C., Beilke, J. N., Bezman, N. A., and Lanier, L. L. (2011) Homeostatic
proliferation generates long-lived natural killer cells that respond against viral
infection. The Journal of experimental medicine 208, 357-368
Zhang, Y., Wallace, D. L., de Lara, C. M., Ghattas, H., Asquith, B., Worth, A.,
Griffin, G. E., Taylor, G. P., Tough, D. F., Beverley, P. C., and Macallan, D. C.
(2007) In vivo kinetics of human natural killer cells: the effects of ageing and
acute and chronic viral infection. Immunology 121, 258-265
Lutz, C. T., Karapetyan, A., Al-Attar, A., Shelton, B. J., Holt, K. J., Tucker, J. H.,
and Presnell, S. R. (2011) Human NK cells proliferate and die in vivo more
rapidly than T cells in healthy young and elderly adults. Journal of immunology
186, 4590-4598
Lee, S. H., Kim, K. S., Fodil-Cornu, N., Vidal, S. M., and Biron, C. A. (2009)
Activating receptors promote NK cell expansion for maintenance, IL-10
production, and CD8 T cell regulation during viral infection. The Journal of
experimental medicine 206, 2235-2251
Welsh, R. M., Brubaker, J. O., Vargas-Cortes, M., and O'Donnell, C. L. (1991)
Natural killer (NK) cell response to virus infections in mice with severe combined
immunodeficiency. The stimulation of NK cells and the NK cell-dependent
control of virus infections occur independently of T and B cell function. The
Journal of experimental medicine 173, 1053-1063
Guma, M., Angulo, A., Vilches, C., Gomez-Lozano, N., Malats, N., and LopezBotet, M. (2004) Imprint of human cytomegalovirus infection on the NK cell
receptor repertoire. Blood 104, 3664-3671
182

268.

269.

270.

271.

272.

273.

274.

275.

276.

277.

278.

279.

280.

Guma, M., Budt, M., Saez, A., Brckalo, T., Hengel, H., Angulo, A., and LopezBotet, M. (2006) Expansion of CD94/NKG2C+ NK cells in response to human
cytomegalovirus-infected fibroblasts. Blood 107, 3624-3631
Williams, H., McAulay, K., Macsween, K. F., Gallacher, N. J., Higgins, C. D.,
Harrison, N., Swerdlow, A. J., and Crawford, D. H. (2005) The immune response
to primary EBV infection: a role for natural killer cells. British journal of
haematology 129, 266-274
Mavilio, D., Lombardo, G., Benjamin, J., Kim, D., Follman, D., Marcenaro, E.,
O'Shea, M. A., Kinter, A., Kovacs, C., Moretta, A., and Fauci, A. S. (2005)
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional
NK subset expanded in HIV-infected viremic individuals. Proceedings of the
National Academy of Sciences of the United States of America 102, 2886-2891
De Maria, A., Fogli, M., Mazza, S., Basso, M., Picciotto, A., Costa, P., Congia,
S., Mingari, M. C., and Moretta, L. (2007) Increased natural cytotoxicity receptor
expression and relevant IL-10 production in NK cells from chronically infected
viremic HCV patients. European journal of immunology 37, 445-455
Lee, S. H., and Biron, C. A. (2010) Here today--not gone tomorrow: roles for
activating receptors in sustaining NK cells during viral infections. European
journal of immunology 40, 923-932
French, A. R., Sjolin, H., Kim, S., Koka, R., Yang, L., Young, D. A., Cerboni, C.,
Tomasello, E., Ma, A., Vivier, E., Karre, K., and Yokoyama, W. M. (2006) DAP12
signaling directly augments proproliferative cytokine stimulation of NK cells
during viral infections. Journal of immunology 177, 4981-4990
Geurs, T. L., Zhao, Y. M., Hill, E. B., and French, A. R. (2009) Ly49H
engagement compensates for the absence of type I interferon signaling in
stimulating NK cell proliferation during murine cytomegalovirus infection. Journal
of immunology 183, 5830-5836
Alter, G., Rihn, S., Walter, K., Nolting, A., Martin, M., Rosenberg, E. S., Miller, J.
S., Carrington, M., and Altfeld, M. (2009) HLA class I subtype-dependent
expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human
immunodeficiency virus type 1 infection. Journal of virology 83, 6798-6805
Andre, P., Castriconi, R., Espeli, M., Anfossi, N., Juarez, T., Hue, S., Conway,
H., Romagne, F., Dondero, A., Nanni, M., Caillat-Zucman, S., Raulet, D. H.,
Bottino, C., Vivier, E., Moretta, A., and Paul, P. (2004) Comparative analysis of
human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
European journal of immunology 34, 961-971
Wang, K. S., Ritz, J., and Frank, D. A. (1999) IL-2 induces STAT4 activation in
primary NK cells and NK cell lines, but not in T cells. Journal of immunology 162,
299-304
Pillet, A. H., Theze, J., and Rose, T. (2011) Interleukin (IL)-2 and IL-15 have
different effects on human natural killer lymphocytes. Human immunology 72,
1013-1017
Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y.,
Yamaguchi, T., Nakajima, K., and Hirano, T. (1996) Two signals are necessary
for cell proliferation induced by a cytokine receptor gp130: involvement of
STAT3 in anti-apoptosis. Immunity 5, 449-460
Bowman, T., Broome, M. A., Sinibaldi, D., Wharton, W., Pledger, W. J., Sedivy,
J. M., Irby, R., Yeatman, T., Courtneidge, S. A., and Jove, R. (2001) Stat3mediated Myc expression is required for Src transformation and PDGF-induced
183

281.

282.

283.

284.

285.

286.

287.

288.

289.

290.

291.

292.

mitogenesis. Proceedings of the National Academy of Sciences of the United
States of America 98, 7319-7324
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A.,
Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G.,
Dalton, W. S., and Jove, R. (1999) Constitutive activation of Stat3 signaling
confers resistance to apoptosis in human U266 myeloma cells. Immunity 10,
105-115
Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam,
S., Eweis, I., Diaz, N., Sullivan, D., Yoder, S., Enkemann, S., Eschrich, S., Lee,
J. H., Beam, C. A., Cheng, J., Minton, S., Muro-Cacho, C. A., and Jove, R.
(2006) Persistent activation of stat3 signaling induces survivin gene expression
and confers resistance to apoptosis in human breast cancer cells. Clinical
cancer research : an official journal of the American Association for Cancer
Research 12, 11-19
Quah, B. J., Warren, H. S., and Parish, C. R. (2007) Monitoring lymphocyte
proliferation in vitro and in vivo with the intracellular fluorescent dye
carboxyfluorescein diacetate succinimidyl ester. Nature protocols 2, 2049-2056
Parish, C. R., Glidden, M. H., Quah, B. J., and Warren, H. S. (2009) Use of the
intracellular fluorescent dye CFSE to monitor lymphocyte migration and
proliferation. Current protocols in immunology / edited by John E. Coligan ... [et
al.] Chapter 4, Unit4 9
Zhang, G., Gurtu, V., Kain, S. R., and Yan, G. (1997) Early detection of
apoptosis using a fluorescent conjugate of annexin V. BioTechniques 23, 525531
Pillet, A. H., Bugault, F., Theze, J., Chakrabarti, L. A., and Rose, T. (2009) A
programmed switch from IL-15- to IL-2-dependent activation in human NK cells.
Journal of immunology 182, 6267-6277
Dunne, J., Lynch, S., O'Farrelly, C., Todryk, S., Hegarty, J. E., Feighery, C., and
Doherty, D. G. (2001) Selective expansion and partial activation of human NK
cells and NK receptor-positive T cells by IL-2 and IL-15. Journal of immunology
167, 3129-3138
Huntington, N. D., Legrand, N., Alves, N. L., Jaron, B., Weijer, K., Plet, A.,
Corcuff, E., Mortier, E., Jacques, Y., Spits, H., and Di Santo, J. P. (2009) IL-15
trans-presentation promotes human NK cell development and differentiation in
vivo. The Journal of experimental medicine 206, 25-34
Leonard, W. J., and Spolski, R. (2005) Interleukin-21: a modulator of lymphoid
proliferation, apoptosis and differentiation. Nature reviews. Immunology 5, 688698
Toomey, J. A., Gays, F., Foster, D., and Brooks, C. G. (2003) Cytokine
requirements for the growth and development of mouse NK cells in vitro. Journal
of leukocyte biology 74, 233-242
Lee, J. K., Won, C., Yi, E. H., Seok, S. H., Kim, M. H., Kim, S. J., Chung, M. H.,
Lee, H. G., Ikuta, K., and Ye, S. K. (2013) Signal transducer and activator of
transcription 3 (Stat3) contributes to T-cell homeostasis by regulating prosurvival Bcl-2 family genes. Immunology 140, 288-300
Perdreau, H., Mortier, E., Bouchaud, G., Sole, V., Boublik, Y., Plet, A., and
Jacques, Y. (2010) Different dynamics of IL-15R activation following IL-15 cis- or
trans-presentation. European cytokine network 21, 297-307
184

293.
294.

295.

296.

297.

Huntington, N. D. (2014) The unconventional expression of IL-15 and its role in
NK cell homeostasis. Immunology and cell biology 92, 210-213
Kim, T. J., Kim, M., Kim, H. M., Lim, S. A., Kim, E. O., Kim, K., Song, K. H., Kim,
J., Kumar, V., Yee, C., Doh, J., and Lee, K. M. (2014) Homotypic NK cell-to-cell
communication controls cytokine responsiveness of innate immune NK cells.
Scientific reports 4, 7157
Zhao, W., Jaganathan, S., and Turkson, J. (2010) A cell-permeable Stat3 SH2
domain mimetic inhibits Stat3 activation and induces antitumor cell effects in
vitro. The Journal of biological chemistry 285, 35855-35865
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta,
S., Iwakura, Y., Yagita, H., and Okumura, K. (2001) Involvement of tumor
necrosis factor-related apoptosis-inducing ligand in surveillance of tumor
metastasis by liver natural killer cells. Nature medicine 7, 94-100
Steward-Tharp, S. M., Laurence, A., Kanno, Y., Kotlyar, A., Villarino, A. V.,
Sciume, G., Kuchen, S., Resch, W., Wohlfert, E. A., Jiang, K., Hirahara, K.,
Vahedi, G., Sun, H. W., Feigenbaum, L., Milner, J. D., Holland, S. M., Casellas,
R., Powrie, F., and O'Shea, J. J. (2014) A mouse model of HIES reveals proand anti-inflammatory functions of STAT3. Blood 123, 2978-2987

185

VITA
Prasad V. Phatarpekar was born in Savantwadi, Maharashtra. He is the son of Ms.
Padma Phatarpekar and Mr. Vijaykumar Phatarpekar. He completed his B.Sc. in
Zoology from Ruparel College, University of Mumbai, India in 1993. He thereafter
earned a M.Sc. degree in Marine Sciences from Goa University, India in 1995.He
worked at the National Institute of Oceanography (NIO) in Goa, India from 1995-2000
as a Marine Biologist.

In 2001, he moved to United States and joined the College of William & Mary, Virginia
to pursue a Ph.D. in Marine Sciences at the Virginia Institute of Marine Sciences
(VIMS). However, he decided to change his career from a Marine Biologist to a Cell
Biologist. In 2002, he joined the M.S. program in Biology at Texas State University-San
Marcos. After graduating from the program, he worked as a Research Assistant in the
Free Radical and Aging Biology department at the Oklahoma Medical Research
Foundation (OMRF), Oklahoma City, Oklahoma until 2005.

He joined the Graduate School of Biomedical Sciences at the University of Texas
Health Science Center in August 2005. He joined the laboratory of Dr. Dean Anthony
Lee in January 2010.

186

Copyright © 2015
Prasad Vijaykumar Phatarpekar
All Rights Reserved.

187

